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ABSTRACT 
Overall paediatric high grade glioma (pHGG) has a poor prognosis, in part due to the 
lack of understanding of the underlying biology. We therefore used high resolution 
244K oligo array comparative genomic hybridisation (oligo aCGH) (Agilent 
Technologies) to analyse DNA from 38 formalin-fixed paraffin embedded pHGG 
samples, including 13 DIPG. The pattern of gains and losses were distinct from those 
seen in HGG arising in adults. In particular we found 1q gain in 21% of our cohort 
compared to 9% in adults. Homozygous loss at 8p12 was seen in 6/38 (15%) of 
pHGG. This deletion has not been previously reported in adult or paediatric high 
grade gliomas. The minimal deleted region is of the gene ADAM3A and homozygous 
deletion of ADAM3A was confirmed by quantitative real time PCR (qPCR). This 
novel homozygous deletion of ADAM3A in pHGG merits further study. 
Amplification of the 4q11-13 region was detected in 8% of cases and included 
PDGFRA and KIT and subsequent qPCR analysis was consistent with amplification 
of PDGFRA. MYCN amplification was seen in 2/38 samples (5%) and was shown to 
be significantly associated with anaplastic astrocytomas (p=0.03). Loss of 
CDKN2A/B was seen in 4/38 (10%) samples by oligo a CGH, confirmed by FISH on 
TMAs, and was restricted to supratentorial tumours. ~50% of supratentorial tumours 
were positive for CDKN2B expression by IHC, whilst ~75% of brainstem gliomas 
were positive for CDKN2B expression (p = 0.03). Overall DIPG shared a similar 
spectrum of changes to supratentorial HGG with some notable differences including 
high frequency of 17p loss and 14q loss, low occurrence of 10q loss and lack of 
CDKN2A/B deletion. 
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1.1 Paediatric Brain Tumours 
1.1.1 Background  
Paediatric brain tumours are the most common solid tumours in children and have 
the highest mortality rate of all paediatric cancers (Wong, Tsang et al. 2006). 
Tumours of the brain and spinal cord account for up to 25% of all childhood cancers 
(Stiller 2004). Over the past 20 years the reported incidence of paediatric primary 
nervous system tumours has risen to 35%. During this time no obvious advances in 
treatment have been discovered (Packer 1999). Whilst research has led to knowledge 
of genetic alterations of other childhood cancers such as leukaemia, paediatric brain 
tumours still lag behind. As a result 80% of leukaemia incidences are successfully 
treated compared to a survival rate of around 60% for all paediatric brain tumours 
(Stiller 2004). However, over the past decade more attention has been directed 
towards brain tumour research in both adults and children with the hope that gaining 
information about the genetics of these tumours will facilitate new treatments, as in 
other cancers. Of those children that survive brain tumours around 60% will suffer 
long term deficits due to damage to the normal brain tissue caused by the tumour 
itself, surgery, intensive radiotherapy and some chemotherapeutic agents. 
Radiotherapy is preferably only given to children over three but damage can still be 
done in these children leading to decrease in IQ and other neurological problems 
(Mulhern, Merchant et al. 2004).  
Paediatric cancers, including brain tumours, vary at the histological level which 
makes tumour classification difficult and treating these tumours complex (Stiller 
2004). Increased knowledge of the genetics of paediatric brain tumours will 
hopefully lead to treatment based on an understanding of the underlying biology of 
the tumour rather than the treatment program currently used.  
 
 
 
 
 
3 
 
1.1.2 Neural Development 
During neural development cells have properties that are similar to that of cancer 
cells; the ability to divide, self-renew and migrate. Paediatric brain tumours are 
WHUPHGµHPEU\RQDOWXPRXUV¶DVWKH\DUHWKRXJKW to originate from immature tissues 
as the result of abnormal development due to defects in key developmental pathways 
(Scotting, Walker et al. 2005).  
The nervous system consists of the peripheral nervous system (PNS) and the central 
nervous system (CNS). The central nervous system is made up of the brain and 
spinal cord. Around 90% of cells in the CNS are glial cells. There are six major 
catagories of glial cell; astrocytes, oligodendrocytes, ependymal cells, Schwann 
cells, migroglia and satellite cells. The most abundant of these glial cells types are 
astrocytes. Astrocytes act as a scaffold which hold the neurons in the appropriate 
place and act as a guide during fetal brain development to migrating neurons. 
Astrocytes play an important role in the maintenance of the blood brain barrier 
(BBB) and the repair of damage to the brain. Oligodendrocytes are responsible for 
the formation of myelin sheaths around the axons of neurons in the CNS. Schwann 
cells are the myelin producing cells in the PNS. Ependymal cells form the lining of 
the ventricles of the brain and have a role in the production of cerebrospinal fluid.  
Glial cells, unlike neurons, do not lose the ability to divide and more than half of 
paediatric brain tumours are of glial origin (Packer 1999). The most common type of 
glioma is the astrocytoma. 7.7% of all childhood cancers are astrocytomas (Rickert, 
Strater et al. 2001). 
 
1.1.3 Cancer Stem Cells 
Stem cells are characterised by their ability to self renew and differentiate into a 
wide range of cell types. Embryonic stem cells are pluripotent meaning they are able 
to become any type of cell. In adult humans there are still stem cells present in 
certain areas of the body such as bone marrow, blood vessels, colon, and heart and in 
the brain.  
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Until recently it was thought that there was very rarely, if ever, cell division 
occurring in the brain. A series of studies in the early 90s showed that neurogenesis 
was present in the brains of birds, mice and eventually humans (Hemmati, Nakano et 
al. 2003; Vescovi, Galli et al. 2006). If neurogenesis is occurring in the mature brain 
then this indicates that there is a population of undifferentiated stem cells which are 
actively proliferating. If there are proliferating cells present in the brain capable of 
differentiating into a range of cell types then it is logical to hypothesise that these 
cells could undergo transformation into cancer causing stem cells. The sub 
ventricular zone has been identified as the area of the brain where most neurogenesis 
occurs (Vescovi, Galli et al. 2006). Cells from the sub ventricular zone which 
express Glial Fibrillary Acidic Protein (GFAP), an astrocytic marker, have been 
shown to be neural stem cells. Many gliomas develop in areas adjacent or close to 
the sub ventricular zone indicating that transformed neural stem cells may be the 
source of these tumours.  
Most tumour cells are differentiated cells that individually are incapable of 
tumorigenesis.  A number of groups have now shown that tumours, particularly 
GBM and medulloblastoma, contain a fraction of cells that can form neurospheres in 
culture and have the ability to differentiate into an array of different cell types. This 
stem cell ± like behaviour of a small fraction of cells was first seen in leukaemia and 
KDV OHG WR WKHµFDQFHUVWHPFHOO¶ WKHRUy (Singh and Dirks 2007). Small numbers of 
cells from leukaemia, and more recently multiple myeloma and breast cancer, have 
be shown to have the ability to self renew in the long term and to initiate tumours.  
Expression of CD133, Sox2, BMI1 and nestin is seen in both normal stem cells and 
the tumour derived progenitors with self renewal ability (Singh and Dirks 2007). 
7KH WHUP µFDQFHU VWHP FHOO¶ LPSOLHV WKDW WKHVH WXPRXU LQLWLDWLQJ FHOOV DUH GHULYHG
from normal stem cells, and whilst this may be the case it could also be that cancer 
stem cells are a results of de-differentiation of mature brain cells.  
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1.2 Classification of astrocytic tumours 
The vast majority of high grade gliomas in children are high grade astrocytomas. 
Gliomas that are either non-astrocytic or mixed are rare in children (Broniscer and 
Gajjar 2004). Astrocytomas fall into two major categories; low grade (World Health 
Organisation (WHO) grade I and II) and high grade (WHO grade III and IV) (Louis, 
Ohgaki et al. 2007).  
 
Astrocytic Tumours 
µ$VWURF\WLFWXPRXUV¶GHVFULEHVD range of tumours spanning all four WHO grades. 
1.2.1 Grade I Astrocytomas. 
Pilocytic astrocytomas are the most common gliomas of childhood, comprising 21% 
of CNS tumours between 0-14 years. They most commonly occur in the cerebellum 
but also arise in the brainstem, spinal cord and supratentorially.  Pilocytic tumours 
are usually slow growing tumours that appear well circumscribed on scans and rarely 
infiltrate surrounding tissues.  The histopathological characteristics of pilocytic 
astrocytomas are compacted bipolar cells, rare mitoses and Rosenthal fibres (See fig. 
1.1) (Louis, Ohgaki et al. 2007). 
It is rare for juvenile pilocytic astrocytomas to progress to a higher grade tumour and 
most tumours remain as grade I for many years. Prognosis is usually good for 
pilocytic tumours, although pilocytic tumours of the brainstem often result in death.  
Pilocytic astrocytomas are the tumours most associated with neurofibromatosis 1 
(NF1), and NF1 pilocytic tumours have a better prognosis than non-NF1 tumours 
(see section 1.3.1) (Rosenfeld, Listernick et al. 2009).  
1.2.2 Grade II Astrocytomas. 
Grade II astrocytomas describes a range of tumour types with varying histology. 
Diffuse astrocytomas are infiltrating tumours that most frequently occur 
supratentorially.  Whilst these tumours are slow growing, there is high cellular 
differentiation and the ability to progress into high grade tumours which distinguish 
GLIIXVH DVWURF\WRPDV IURP SLORF\WLF DVWURF\WRPDV 7KH WHUP µGLIIXVH DVWURF\WRPD¶
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actually covers three different tumours types according to the 2007 WHO CNS 
tumour classification book; fibrillary astrocytoma, gemistocytic astrocytoma and 
protoplasmic astrocytoma (Louis, Ohgaki et al. 2007). 
 Fibrillary astrocytomas are the most common grade II astrocytoma. 
Histologically, fibrillary tumours consist of fibrillary neoplastic astrocytes 
with nuclear aytpia. Cell density is higher than grade I tumours but still only 
PRGHUDWH DQG WKH QXFOHL FDQ DSSHDU µQDNHG¶ GXH WR WKH ODFN RI F\WRSODVP
GFAP is expressed but not in all cells. 
 Gemistocytic astrocytomas are characterised, as the name suggests, by the 
presence of gemistocytes. Gemistocytes are large astrocytes with abundant 
cytoplasm that highly express GFAP. For a grade II tumour to be classified 
as a gemistocytic astrocytoma more than 20% of cells should be 
gemistocytes.  
 Protoplasmic astrocytomas have a similar histological appearance to pilocytic 
astrocytomas with low cellularity, lack of mitoses and low GFAP. Formation 
of microcysts and mucoid degeneration are the defining features of this 
tumour sub-type. 
Diffuse astrocytomas with gemistocytes are likely to progress to higher grade 
tumours more rapidly than those without gemistocytes.  Survival of patients with 
diffuse astrocytomas varies widely, with the average survival time post- surgery of 
6-8 years. The variation in survival is dependent on many factors including extent of 
resection of the original tumour, tumour progression to a higher grade, size of the 
tumour and patient age (Louis, Ohgaki et al. 2007). 
Pleomorphic xanthoastrocytomas are also grade II tumours usually occurring in the 
cerebral hemispheres with a good prognosis.  Histologically varied, these tumours 
are characterised by large, neoplastic astrocytic cells with atypical nuclei. These 
tumours are GFAP positive (Louis, Ohgaki et al. 2007). 
 
1.2.3 High grade astrocytomas (WHO Grade III and IV) 
High grade astrocytomas are highly vascular and frequently rapidly advancing 
tumours with a poor prognosis in both children and adults. Very young children 
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(children under 3 at diagnosis) with high grade astrocytomas fare better than older 
children, which suggests different underlying genetic causes (Duffner, Krischer et al. 
1996). There are also thought to be differences in the genetic causes of adult and 
paediatric gliomas. 70% of adult gliomas occur supratentorially whilst up to 60% of 
paediatric glioma occur infratentorially. Whilst high grade astrocytomas are the most 
common type of brain tumour in adults only 6-12% of primary paediatric brain 
tumours are supratentorial high grade astrocytomas (Broniscer and Gajjar 2004). 
High grade astrocytomas are aggressive tumours that can invade adjacent tissues 
(Rutka, Murakami et al. 1997). Prognosis varies depending on the location of the 
tumour within the brain, the degree of resection and the treatment possibilities. The 
majority of astrocytomas develop in the frontal lobe, the area of the brain responsible 
for many functions including thought, behaviour, and judgement. 
 
Grade III astrocytomas 
Grade III astrocytomas are also called anaplastic astrocytomas (AA). AAs are 
malignant tumours with mitotic activity, infiltration of surrounding tissue, high 
cellularity and nuclear atypia (See fig. 1.1). AAs are most frequently seen in the 
cerebral hemispheres and can arise as a progression from a grade II diffuse 
astrocytoma in adults (Louis, Ohgaki et al. 2007). AAs are thought to arise from 
immature astrocytic cells although the mechanism has not been well characterised. 
AAs can, and often do, progress to grade IV (glioblastoma multiforme).   
 
Grade IV Astrocytoma 
Grade IV astrocytoma, also known as glioblastoma multiforme (GBM), is the most 
common primary brain tumour in adults but is relatively rare in children.  GBM is an 
aggressive tumour with high cellularity, high levels of mitoses, neovascularisation, 
nuclear atypia and necrosis (See fig. 1.1) (Louis, Ohgaki et al. 2007). Necrosis is 
caused by poor oxygen supply leading to cell lysis. It is a complex process that is not 
only associated with cell death but also cell proliferation and tumour growth (King 
2000). 
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GBMs are highly infiltrative and invade neighbouring tissues. Histopathology can 
vary between tumours and within a single tumour, leading to difficulty in diagnosis 
from small biopsies (Nalin Gupta 2004). 
 
1.2.4 GBM Sub-types 
Small cell GBMs are a subtype of GBM characterised by small, round, densely 
packed cells with high levels of mitosis and low GFAP. These tumours can look 
similar in appearance to anaplastic oligodendroglioma. 
Giant cell GBMs are GBMs with giant, multinuclear cells which make up 5% of 
GBM occurrences.  Giant cell GBM shares histopathological features with ordinary 
GBM but has variable expression of GFAP. Some studies have indicated that giant 
cell GBM may have a better prognosis than normal GBM, possibly due to the less 
infiltrative nature of giant cell GBM.  
Gliosarcoma describes a sub-type of GBM with a mixture of glial and sarcoma ±like 
areas of tumours in a biphasic pattern. It is thought that both parts of the tumour arise 
from neoplastic glial cells (Louis, Ohgaki et al. 2007). 
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Figure 1.1. Haematoxylin and eosin (H&E) stained sections of a brain tumour showing major features typical for 
a particular tumour. Haematoxylin stains nuclei purple and eosin stain cytoplasm pink: A. Pilocytic astrocytomas 
are slow growing tumours with rare mitoses and Rosenthal fibres. B. Diffuse astrocytomas are slow growing but 
have high cellular differentiation. C. Anaplastic astrocytomas have high cellularity, mitotic cells and nuclear 
atypia. D. Glioblastoma multiforme is a highly cellular tumour with mitoses, neovascularisation, nuclear atypia 
and necrosis. 
 
1.2.5 Oligodendrogliomas 
Oligodendrogliomas are thought to develop either from transformation of mature 
oligodendrocyte cells or from glial precursor cells, and are more common in adults 
although they do rarely occur in children (Louis, Ohgaki et al. 2007). Only 1% of 
paediatric brain tumours are oligodendrogliomas (Nalin Gupta 2004). 
Oligodendrogliomas are classified as either grade II or grade III tumours depending 
on the levels of cellularity and cell proliferation and the presence of features 
associated with other higher grade glioma tumours.  
 
 
A B 
C D 
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Grade II oligodendrogliomas are diffuse tumours with well differentiated cells 
resembling oligodendroglial cells. Histologically, these tumours are characterised by 
small, uniformly round nuclei surrRXQGHG E\ D µKDOR¶ RI F\WRSODVP (Nalin Gupta 
2004). Cellularity is moderate and there is infrequent mitosis. In adults, loss of 1p 
and 19q is seen in more than 80% of oligodendrogliomas and is associated with 
increased survival (Louis, Ohgaki et al. 2007). Grade II oligodendrogliomas can 
progress to grade III tumours, but this usually takes a number of years (Louis, 
Ohgaki et al. 2007). 
Anaplastic oligodendrogliomas are grade III tumours which share the diffuse, 
infiltrative ability of grade II oligodendrogliomas. However, the grade III tumours 
have additional features such as high levels of mitosis, increased cellularity, necrosis 
and neovascularisation that are associated with more malignant tumours (Louis, 
Ohgaki et al. 2007). 
Oligoastrocytomas are grade II glial tumours with components from two separate 
glial cell origins; oligodendroglial and astrocytic. These tumours usually occur in the 
cerebral hemispheres and share the histological features of grade II 
oligodendrogliomas and grade II astrocytomas. Anaplastic oligoastrocytomas are 
grade III tumours that have all the characteristics of grade II oligoastrocytomas with 
additional features associated with malignancy (Louis, Ohgaki et al. 2007). 
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1.2.6 Brainstem Glioma 
Brainstem gliomas account for up to 20% of paediatric CNS tumours, with a mean 
age of diagnosis of 7-9 years old (Jallo, Biser-Rohrbaugh et al. 2004). Brainstem 
gliomas are considered surgically inaccessible due to their anatomical location. The 
brainstem describes an area of the brain encompassing the midbrain, pons and 
medulla oblongata (see fig. 1.2) (Jallo, Biser-Rohrbaugh et al. 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. MRI Image of the brain in which the areas of the brain described as 
being part of the brainstem (midbrain, pons, medulla oblongata) are highlighted. 
Around 20% of brainstem gliomas are low grade astrocytomas and the remaining 
80% are diffuse tumours involving the pons (Hargrave, Bartels et al. 2006). Diffuse 
pontine gliomas differ from all other brainstem gliomas and are characterised by 
infiltration of the brainstem which in turn causes swelling. The majority are 
classified as high grade gliomas, at least in terms of behaviour but also frequently in 
terms of histology (Jallo, Biser-Rohrbaugh et al. 2004). Only 3-9% of all paediatric 
brain tumours are diffuse brainstem gliomas and more than 90% of children die 
within two years of diagnosis (Hargrave, Bartels et al. 2006). Due to the infiltrative 
Enlarged Pons 
Forebrain 
(cerebrum) 
Midbrain 
Medulla 
oblongata 
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nature of diffuse brainstem gliomas surgical resection is not an option. 
Neurofibromatosis-linked diffuse pontine gliomas have an improved prognosis 
compared to those diffuse pontine gliomas not linked to neurofibromatosis, as they 
are less aggressive tumours.  Further studies are required to determine the prognostic 
and genetic differences between these two subtypes of diffuse pontine glioma (Jallo, 
Biser-Rohrbaugh et al. 2004).  
Diffuse pontine gliomas are only one subtype of brainstem glioma. The first 
classification of brainstem glioma subtypes was by Epstein in 1985 which divided 
the tumours into three groups; intrinsic tumour, exophytic tumours and disseminated 
tumours (Epstein 1985). The most recent classification by Choux in 2000 divided 
brainstem gliomas into four subtypes; diffuse, focal, exophytic and cervicomedullary 
(Choux 2000).  
Table 1.1 Classification of brainstem gliomas. 
Brain Stem 
Tumour Type 
Approximate 
Frequency (%) 
Imaging 
Characteristics  
Pathology 
Diffuse Intrinsic 75-86 Pontine 
enlargement 
Astrocytoma 
(grade II-IV) 
Focal midbrain 5-10 Small, well defined Low grade 
astrocytoma. 
Dorsally exophytic 10-20 Arise from the 
floor of the fourth 
ventricle 
Pilocytic 
astrocytoma, grade 
II astrocytoma. 
Cervicomedullary 
 
5-10 Causes a 
characteristic bulge 
in the medulla 
towards the fourth 
ventricle 
Low grade 
astrocytoma. 
 
 
Focal tumours are small tumours with well-defined borders that most frequently 
occur in the midbrain and medulla. Focal tumours are low grade and so lack 
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infiltrative ability and can be treated with surgery (Mauffrey 2006). Exophytic 
tumours grow up from the floor of the fourth ventricle, often nearly filling the fourth 
ventricle. Exophytic tumours are usually low grade and so there is minimal invasion 
of the brainstem and surgery is often the preferred treatment (Freeman and Farmer 
1998). Cervicomedullary tumours arise either in the medulla or in the spinal cord and 
cause a characteristic bulge in the medulla towards the fourth ventricle. 
Cervicomedullary tumours are mostly low grade tumours and so can be treated with 
surgery as there is little infiltration of the brainstem. 
Symptoms of brainstem gliomas include diplopia, irregular eye movement, 
dysphagia, dysarthria and muscle weakness in the face. Other possible symptoms are 
ataxia, headache and vomiting and mood/behavioural changes. Radiotherapy is the 
most common treatment with up to 70% of children showing neurological 
improvement and a visible response to radiotherapy on the MRI, although this 
response is short lived. Diffuse pontine gliomas tend to be more resistant to 
radiotherapy than other brainstem tumours. No chemotherapy agents have so far 
been shown to significantly increase survival. Drug access to the brain is problematic 
due to the blood brain barrier (BBB) but many trials are ongoing. In this case drug 
resistance is problematic as drugs that can cross the BBB are ineffective.  
The location of brainstem gliomas means surgery is usually not an option making 
little tissue available for research, and if there is tissue available it is often from a 
needle biopsy and so is minimal. The ability to perform stereotactic biopsy on 
brainstem tumours has been around since 1978, but has always been controversial as 
WKHUH LVQRVLJQLILFDQW LPSURYHPHQW LQSURJQRVLV(SVWHLQ¶VSDSHUDUJXHGWKDW
biopsying brainstem tumours was a risk that gave no benefit to the patient, and this 
view was supported by Stroink in 1986 (Epstein 1985; Stroink, Hoffman et al. 1986). 
However, in recent years with the evolution of new biologically analysis techniques 
and genetically tailored treatments for cancers such as leukaemia, the question of 
biopsy has arisen again. In 2003 a meta-analysis of brainstem biopsies was carried 
out by Samadini et al and the need for biopsy stressed (Samadani and Judy 2003). 
Currently, brainstem gliomas are biopsied if there is an atypical MRI, the clinical 
presentation is unusual or to allow the patient to enter a clinical trial that requires 
biopsy. However, MRI predicts tumour grade correctly in only two thirds of cases 
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and recent studies have found none of the negative effects of biopsy which were 
previously reported. With recent advances in high throughput genetic techniques 
which can determine the genetic signatures of tumours and the success of tailored 
treatments based on these genetic findings it is important to have brainstem tissue 
available for research if the treatment of these tumours is to improve.  
Understanding the genetic causes and underlying biology of these tumours is the key 
to future treatments. Many adult brainstem gliomas have mutation or loss of 
heterozygosity of the well characterised tumour suppressor p53, over expression of 
the growth factor EGFR protein and loss of the tumour suppressor PTEN (TCGA 
2008). Further research will uncover more potential targets for therapy but the tissue 
available to carry out this research is still frustratingly scarce.  
 
1.2.7 Treatment of high grade glioma 
Low grade gliomas can often be completely resected and chemotherapy and 
radiotherapy are only used if the resection is incomplete (Wong, Tsang et al. 2006). 
Therefore these tumours have a high cure rate and low therapy related damage. 
Patients with high grade glioma have a much graver prognosis.  Surgery is often the 
first stage in the treatment of supratentorial high grade glioma. The extent of 
resection depHQGVRQDQXPEHURI IDFWRUV WKHSDWLHQW¶VDJH WKHSDWLHQW¶VFRQGLWLRQ
and most importantly the anatomical location of the tumour. For paediatric high 
grade glioma as extensive a surgical resection as is possible should be performed to 
give the best prognosis for the patient (Kramm, Wagner et al. 2006). By the time 
patients become symptomatic the tumour may have reached a considerable size and 
this in turn can limit the degree of surgical resection that can be achieved. Following 
surgery radiotherapy is given, with the dose depending on the location of the tumour 
and the age of the patient. Radiotherapy is predominantly used to stabilize the 
tumour and increase progression free survival in high grade glioma patients. 
Chemotherapy in children following radiation treatment has been shown in a number 
of studies to increase progression-free survival, especially in patients with GBM. 
However, chemotherapy only provides a slight improvement in survival time at 
present. A recent study in adult patients with GBM showed promising results with 
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the drug temozolomide in addition to radiotherapy but only by months (Martens, 
Laabs et al. 2008). 
Clinical trials of a number of chemotherapeutic agents have been carried out in adult 
GBM.  EGFR overexpression is associated with tumour growth, migration, invasion, 
progression and resistance to radiotherapy in vitro. EGFR inhibitors, such as 
Erlotinib and Gefitinib, have been trialled due to the frequent overexpression of 
EGFR in adult GBM (40%) (Halatsch, Schmidt et al. 2006). These low molecular 
weight tyrosine kinase inhibitors are particular attractive for brain tumours as they 
should be able to cross the blood brain barrier. In a trial by Halatsch et al there was 
no significant clinical response with Gefitinib or Erlotinib compared with standard 
chemotherapy treatment (Halatsch, Schmidt et al. 2006). 
Monoclonal antibodies, such as the EGFR inhibitor Cetuximab have a high 
molecular weight so crossing the blood brain barrier is an issue. However, 
Cetuximab has been shown to increase apoptosis and decrease rate of growth in a 
xenograft model of GBM (Martens, Laabs et al. 2008). 
A recent trial by the Canadian Paediatric Brain Tumour Consortium (CPBTC) 
looked at the effect of Imatinib which inhibits subclass III receptor tyrosine kinases 
including PDGFRA and B, KIT and VEGF (Baruchel, Sharp et al. 2009). PDGFRA, 
KIT and VEGF proteins are seen overexpressed in both adult and paediatric high 
grade gliomas. Patients were aged between 2-18 years with a tumour of the CNS. 
Unfortunately no clinical response was seen in the tumours with Imatinib, possibly 
due to the poor penetration of the blood brain barrier by Imatinib (Baruchel, Sharp et 
al. 2009). 
O6-methylguanine-DNA methyltransferase (MGMT) is a gene located on 10q26 that 
encodes a DNA repair protein (Hegi, Diserens et al. 2005). MGMT removes alkyl 
groups from the O6 position on guanine bases and so prevents the cross linking of 
double stranded DNA which can trigger apoptosis (Esteller, Garcia-Foncillas et al. 
2000). MGMT expression has been negatively linked with survival in high grade 
gliomas as MGMT is able to undo some of the damage done by alkylating agents 
used as chemotherapeutic drugs, such as temozolomide (Hegi, Diserens et al. 2005). 
In patients where the promoter region of MGMT is methylated, and so MGMT is not 
expressed, survival is increased as the tumours are more susceptible to temozolomide 
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treatment as there is reduced DNA repair activity (Esteller, Garcia-Foncillas et al. 
2000; Hegi, Diserens et al. 2005). MGMT is a possible drug target in pHGG as 
inhibiting the activity of MGMT in tumours with high levels of MGMT expression 
ZRXOGWKHRUHWLFDOO\LQFUHDVHWKHWXPRXU¶VVHQVLWLYLW\WRDON\ODWLQJFKHPRWKHUDSHXWic 
agents (Esteller, Garcia-Foncillas et al. 2000). 
The BBB is an obstacle to all therapeutic agents directed towards brain tumours 
(Schinkel 1999). An intracranial approach to drug delivery has been used in adults, 
e.g. Gliadel wafers following GBM resection. However, it is unknown how far the 
drug is distributed throughout the surrounding tissue especially with high molecular 
weight drugs (Perry, Chambers et al. 2007). 
 
1.3 Syndromes associated with High Grade Glioma 
1.3.1 Neurofibromatosis  
There are two major categories of neurofibromatosis; type 1 (NF1) and type 2 (NF2). 
Both NF1 and NF2 are nervous system disorders that involve the growth of nerve 
tumours.  
NF1 is more common than NF2, affecting around 1 in 3500 people (Boyd, Korf et al. 
2009). Approximately 50% of cases of NF1 are cause by sporadic mutations in the 
NF1 gene, with the other 50% caused by inherited mutation. NF1 is an autosomal 
dominant disease with penetrance reaching almost 100% by the age of 20. Even 
though the penetrance is high the severity of symptoms can vary dramatically even 
between family members. NF1 symptoms include nerve tumours, bone abnormalities 
and cafe-au-lait spots on the skin. It is common for a first degree relative to also be 
affected (Rosenfeld, Listernick et al. 2009). 
Mutations to NF1 that cause the NF1 disorder include deletions, insertions and stop 
mutations and in some cases the entire gene is deleted. NF1 produces the protein 
neurofibromin, a tumour suppressor.  Neurofibromin is normally expressed in 
neurons and glial and Schwann cells and is a cell cycle regulator that inhibits Ras 
signalling, which in turn inhibits the action of mTOR.  Deregulation of Ras leads to 
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uncontrolled cell proliferation (Boyd, Korf et al. 2009; McGillicuddy, Fromm et al. 
2009) . 
Sufferers of NF1 are susceptible to benign and malignant tumours, with dermal 
neurofibromas being the most common benign tumour occurring in 40% of children 
with NF1. 20% of children with NF1 will develop tumours of the CNS with optic 
pathways tumours being the most common (Rosenfeld, Listernick et al. 2009). 
Brainstem gliomas in individuals with NF1 are almost always low grade tumours 
that are slow growing and have a better prognosis than brainstem tumours in 
individuals without NF1 (Rosenfeld, Listernick et al. 2009). 
NF2 is an autosomal dominant disorder caused by mutations in the NF2 gene. The 
NF2 protein, merlin, is involved in cell-cell interactions and adhesion and has been 
implicated as a tumour suppressor. NF2 is characterised by the formation of 
schwannomas, meningiomas and ependymomas with neurofibromas actually rare. 
NF2 is particularly associated with bilateral vestibular schwannomas (Evans 2009). 
The incidence of NF2 may be as high as 1/25,000 with the majority of cases 
presenting with hearing loss caused by vestibular schwannomas (Evans 2009). 
 
1.3.2 Turcot Syndrome 
Turcot syndrome describes a disorder with multiple colon tumours and a primary 
brain tumour, and was first described by Turcot in 1959. Turcot syndrome is the 
overall name for two separate conditions caused by different genes but with very 
similar symptoms (Hamilton, Liu et al. 1995). 
Brain tumour polyposis 1 (BTP1) affects mainly children and young adults under the 
age of 20. Symptoms of BTP1 include astrocytomas, small numbers of intestinal 
polyps, and coffee coloured spots on the skin. It is thought BTP1 is linked to 
Hereditary Non-Polyposis Colorectal Carcinoma (HNPCC). HNPCC is caused by an 
inherited defect in the mismatch repair pathway (Chan, Yuen et al. 1999). 
Brain tumour polyposis 2 (BTP2) can affect any age group. BTP2 is characterised by 
large numbers of intestinal polyps and is associated with medulloblastoma.  There is 
often a family history of colorectal polyps and it is thought BTP2 is closely related to 
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Familial Adenomatous Polyposis (FAP). FAP is associated with mutations in the 
APC gene which acts as a tumour suppressor gene (Hamilton, Liu et al. 1995; Chan, 
Yuen et al. 1999). FAP is an autosomal dominant condition with an incidence of 1 in 
10000 people. 
 
1.3.3 Li-Fraumani Syndrome 
Li-Fraumeni syndrome is a rare, autosomal dominant disorder that is usually caused 
by a germ line TP53 gene mutation. TP53 is a well characterised tumour suppressor 
gene and deregulation of TP53 can lead to uncontrolled cell proliferation (King 
2000). Almost 400 different mutations have been described in Li-Fraumeni families 
and sufferers. People suffering from Li-Fraumeni syndrome have an increased risk of 
tumours such as sarcomas, breast cancer, brain tumours and leukaemia (Rieber, 
Remke et al. 2009). The overall lifetime cancer risk for sufferers of Li-Fraumeni is 
85%. 
 
1.3.4 Tuberous sclerosis  
Tuberous sclerosis (TS) is a rare genetic disorder which affects multiple systems. TS 
causes the growth of benign tumours predominantly in the CNS but also in other 
vital organs. TS gets its name from the characteristic tuberous growths in the brain. 
Common symptoms of TS include seizures, developmental problems, behavioural 
problems and kidney disease. The incidence of TS is approximately 1 in every 6000 
births and TS is found in all ethnic groups and both males and females.  
TS is caused by mutation of one of two possible genes; tuberous sclerosis 1 (TSC1) 
or tuberous sclerosis 2 (TSC2) (Napolioni and Curatolo 2008). Only one of these 
genes needs to be deregulated for TS to occur. TSC1 and TSC2 encode the proteins 
hamartin and tubulin respectively. Both these proteins are involved in a complex that 
acts to inhibit mTOR (Napolioni and Curatolo 2008). 
TS is an autosomal dominant disorder, although most cases are caused by sporadic 
mutations. Three types of brain tumour are associated with TS, including giant cell 
astrocytomas. Tumours are rarely malignant, but high grade tumours can occur.  
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1.4 Genetics of Cancer 
Cancer is a genetic disease of somatic cells. All cancers have some underlying 
genetic cause that affects the control of the cell cycle (Tamarin 2002). The two main 
categories of genes that play a major role in carcinogenesis are oncogenes and 
tumour suppressor genes. 
 
1.4.1 Oncogenes and Tumour Suppressors 
Oncogenes (cancer genes) are genes which are activated by mutation or gain of copy 
number and cause the over proliferation of cells seen in tumours. Oncogenes are 
present in a non-mutated form in normal cells and are here referred to as proto-
oncogenes to distinguish the non-mutated genes from the mutated form. Oncogenes 
are dominant at the cellular level (King 2000). 
There are three different mechanisms by which a proto-oncogene can be transformed 
into an oncogene.  
1. A mutation which causes a change in amino acid in the expressed protein can 
induce an oncogene. Mutations associated with cancer are usually missense 
mutations that disrupt the DNA binding domain. 
2.  Translocations which move a proto-oncogene into a region with a strong 
promoter can cause over expression of the gene, inducing oncogenic activity.  
3. Amplification of the area of the genome where the proto-oncogene is located 
causes an increase in copy number of the proto-oncogene, and therefore over-
expression of the gene (Tamarin 2002). Gene amplification is often seen in 
advanced, aggressive cancers possibly due to increased chromosome 
instability.  
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Tumour Suppressors 
$ELJVWHSLQXQGHUVWDQGLQJWKHJHQHWLFPHFKDQLVPRIFDQFHUFDPHZLWK.QXGVRQ¶V
two hit hypothesis. This hypothesis, formulated in 1971 by Alfred Knudson, was 
based on his observation of Retinoblastoma patients. Retinoblastoma can be 
unilateral or bilateral and Knudson observed that the bilateral form occurred most 
frequently in children under the age of two (90% cases).  Knudson hypothesised that 
the difference between the age of incidence could be explained by the number of 
hits, or mutations, that it takes for retinoblastoma to occur (King 2000). 
Normally cells have two wild type copies of the retinoblastoma gene (Rb). In 
ELODWHUDOUHWLQREODVWRPDWKHILUVWµKLW¶LVLQKHULWHGDQGVRRQO\RQHIXQFWLRQDORb allele 
UHPDLQV 7KLV PHDQV RQO\ RQH µKLW¶ LV UHTXLUHG IRU WKH IRUPDWLRQ RI D WXPRXU ,Q
sporadic cases, the individual has two copies of the wild type Rb allele to start with 
VRWZRµKLWV¶DUHUHTXLUHGWRPDNHERWKDOOHOHVQRQIXQFWLRQDO:KLOVWWKHSUREDELOLW\
of the first mutation is low, the first mutation leads to DNA instability meaning the 
probability of the second hit is much higher. This explains the earlier age at which 
bilateral retinoblastoma occurs as the carrier is already born with one mutated Rb 
allele. Rb was the first tumour suppressor gene to be described. In reality, most 
cancers are much more complex than this hypothesis suggests with multiple hits 
being required in both tumour suppressor genes and oncogenes to trigger 
carcinogenesis (King 2000). 
Tumour suppressor genes are genes that have inhibitory functions in cell cycle 
progression (Tamarin 2002). The loss of a tumour suppressor gene due to mutation 
or deletion leads to a deregulation of the cell cycle and unrestricted cell proliferation. 
Tumour suppressor genes are recessive at the cellular level and so both copies of the 
gene must carry an inactivating mutation or be deleted for carcinogenesis to occur in 
reality.  
Variation in copy number of regions of the human genome has been highlighted 
recently as being important in the study of human disease. Around 12% of the 
human genome is covered by copy number variable regions (CNVRs), although 
changes to copy number often occur preferentially away from genes (Redon, 
Ishikawa et al. 2006). Genes that have been identified as containing copy number 
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variation include genes involved in cell-cell adhesion and response to intercellular 
chemical signals (Redon, Ishikawa et al. 2006). 
Mutation of genes is a common event in cancer. There are various types of mutation, 
with missense mutations being the most common in cancer. Dominant negative 
mutations are mutations where the mutated gene product in some way inhibits the 
wild type product, most frequently by dimerisation. 
 
1.4.2 Loss of Heterozygosity 
Loss of heterozygosity (LOH) describes an event where one allele at a particular 
locus is lost leaving one allele present. If the remaining allele contains a recessive 
mutation then the mutant phenotype will now be seen. LOH can occur via a number 
of mechanisms; deletion, gene conversion, mitotic recombination, chromosome loss 
(fig. 1.3 and fig. 1.4)  (Tamarin 2002). 
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Figure 1.3: Gene Conversion and Mitotic Recombination leading to loss of 
heterozygosity (LOH). 
  
 
Figure 1.4: Double strand break on a single chromosome leading to a deletion of a 
region of the chromosome and hence LOH of the deleted region. 
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1.4.3 Epigenetics 
Epigenetics describes changes to the DNA that do not involve alteration of the bases 
that make up the DNA but can affect the expression of genes. Methylation is the 
most frequent epigenetic alteration in humans. Around 80% of cytosines in CpG 
islands in the human genome are methylated.  Methylation is associated with the 
silencing of genes. If the promoter region of a gene is methylated the DNA 
transcriptases cannot bind and so the gene is not expressed. The methylation of 
tumour suppressor genes halts expression and can lead to uncontrolled cell 
proliferation, e.g. aberrant methylation of the APC gene in colorectal carcinoma and 
BRCA1 in breast cancer (Magdinier, Ribieras et al. 1998; Catteau, Harris et al. 1999; 
Iwama 2001). 
Genes can be methylated at certain stages of development and so not expressed, but 
then de-methylated at other stages of development and so expressed (Jones and 
Takai 2001). Loss of methylation (hypomethylation) is thought to play an important 
role in cancer. Hypomethylation can allow the aberrant expression of oncogenes that 
promote cell division. It is thought abnormal methylation of genes may play a key 
role in cancer (Garinis, Patrinos et al. 2002). 
Imprinting is inherited methylation where alleles of certain genes from each parent 
are silenced by methylation. Loss of imprinting leads to aberrant gene expression 
and has been shown to play a role in carcinogenesis. The first example of loss of 
LPSULQWLQJ LQ FDQFHU ZDV LQ :LOPV¶ WXPRXUV 7KH JHQH IGF-2 (11p15) is usually 
imprinted so that the maternally inherited IGF-2 allele is methylated whilst the 
paternal allele is un-PHWK\ODWHGDQGVRH[SUHVVHG ,QPDQ\:LOPV¶WXPRXUVORVVRI
imprinting leads to expression of the maternal IGF-2 allele in addition to the 
paternal, leading to overexpression of IGF-2. As IGF-2 is a growth factor, over-
expression may give cells a growth advantage (Brown, Power et al. 2008). 
 
Uniparental disomy (UPD) describes a situation where both alleles of a gene are 
from the same parent. There are several known disorders in human caused by UPD 
where there is a recessive mutation in the affected genomic region or imprinting 
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patterns are disrupted. There are a number of mechanism by which UPD can occur 
(see fig. 1.5). 
 
Figure 1.5: Mechanisms of uniparental disomy (UPD). 
 
1.4.4 Genetics of paediatric high grade glioma 
A small number of single nucleotide polymorphism (SNP) and CGH studies have 
been carried out on paediatric high grade gliomas. Wong et al carried out a study of 
28 paediatric  gliomas (14 high grade and 14 low grade) which were analysed by 
Affymetrix 10K SNP array (Wong, Tsang et al. 2006). A major difference between 
the high grade and low grade tumours was the lack of LOH in the low grade gliomas 
compared to wide spread LOH in the high grade gliomas.  There is very little 
detectable LOH in low grade gliomas, and if LOH does occur in low grade tumours 
it is often only one arm of the chromosome that is affected. In contrast high grade 
gliomas are characterised by multiple copy number aberrations and LOH is a 
common event. It is most common on chromosome arms 4q, 6q, 9p, 10q, 11p, 12, 
13q, 14q, 17, 18p and 19q.  
 Amplification of epidermal growth factor receptor (EGFR) and platelet derived 
growth factor receptor type alpha (PDGFRA) were seen in a small number of the 
high grade tumours (4/13). EGFR is the most commonly amplified gene in primary 
glioblastoma in adults but amplification of EGFR is rarely seen in paediatric 
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glioblastoma (Maher, Furnari et al. 2001). EGFR amplification is associated with a 
loss of chromosome 10 in glioblastoma and with a loss of the p14ARF locus on 
chromosome arm 9p (Godard, Getz et al. 2003; Ohgaki 2005). 
In some cases, the amplification of EGFR was shown to have occurred even though 
the EGFR locus was located in a chromosomal region affected by loss of 
heterozygosity. This means the amplification of EGFR was of the one remaining 
EGFR allele only. This mechanism of allele-specific amplification where LOH has 
occurred had not been previously reported.  In a study by Niskizaki et al 
amplification of 7p12 (EGFR) occurred exclusively in tumours with loss of 10q. The 
well characterised tumour suppressor PTEN, located on 10q is frequently lost in 
anaplastic astrocytomas (Maher, Furnari et al. 2001). Loss of the 10q 23-25 locus is 
more common in primary astrocytoma than secondary astrocytoma which correlates 
with the observed loss of PTEN (Rickert, Strater et al. 2001). 
The same mechanism of loss of one allele and then amplification of the remaining 
allele was also seen at the PDGFRA locus (Wong, Tsang et al. 2006). PDGFRA is 
located on chromosome arm 4q, a region frequently lost in paediatric high grade 
glioma. PDGFRA is highly expressed in glial cell progenitors but expression is 
down-regulated in infancy, and so may play a role in the differentiation and 
migration of neurons (Maher, Furnari et al. 2001).  
Chromosome arm 12q has been shown to be gained in glioblastoma in a number of 
studies and appears to be associated with glioblastoma tumourigenesis. 12q is the 
location of MDM2, an oncogene which negatively regulates the activity of tumour 
suppressor p53 through binding with p14 ARF. 12q is also the site of CDK4, a cyclin-
dependent kinase important for cell cycle progression. MDM2 and CDK4 are 
frequently seen amplified together, although the amplifications are thought to be 
independent events (Suzuki, Maruno et al. 2004). 
Loss of chromosome arm 17p is frequently seen in both paediatric and adult 
glioblastoma, specifically loss of heterozygosity at 17p13.1 (Rickert, Strater et al. 
2001). This locus is the position of the tumour suppressor gene TP53. There is a 
significantly higher occurrence of TP53 mutation in secondary glioblastoma 
compared with primary glioblastoma (Ohgaki 2005). Loss of 17p has been observed 
in low grade gliomas as well as high grade gliomas, although less frequently.  
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Many other gains and losses of chromosomal regions have been reported in 
paediatric high grade glioma although few studies have been done and not all the 
results correlate between studies. This is lack of correlation is probably due to poor 
histological review of the samples involved in these studies. A frequent loss that has 
been reported in a number of papers is loss of chromosome arm 9p. The 9p21 locus 
is the site of three candidate genes for glioblastoma neogenesis; CDKN2B, CDKN2A 
and ELAVL2 (Hu, Pang et al. 2002; Wong, Tsang et al. 2006). CDKN2A is an 
important tumour suppressor gene and has been implicated in tumourigenesis in a 
variety of cancers. CDKN2B lies adjacent to CDKN2A and is involved in the control 
of cell growth and proliferation by the inhibition of cyclin dependant kinases 
(Simon, Koster et al. 1999). ELAVL2 has recently been shown to be lost in some 
glioblastoma multiforme samples (Wong, Tsang et al. 2006). ELAVL2 has a role in 
the post-transcriptional regulation of p21 mRNA and therefore is involved in 
controlling neural differentiation. p21 is a tumour suppressor gene encoding a 
protein that is expressed at very low levels in normal glial cells but found over 
expressed in a high number of glioma. The p21 gene is located at 6p21.2, but no 
copy number variation at this locus or at any other region of 6p has been reported so 
far. High grade tumours with expression of p21 have a shorter disease-free survival 
than those without (Korkolopoulou, Kouzelis et al. 1998). 
The CCND3 gene, located adjacent to the p21 gene at 6p21, is a member of the 
cyclin family which regulates cyclin dependent kinase activity. CCND3 forms a 
complex with CDK4 and CDK6, a process required for cell cycle progression from 
G1 to S phase. CCND3 is involved in the phosphorylation of pRb. The gene RB1 is 
located at 13q14.2 and encodes pRb, a well known regulator of the cell cycle. 
Chromosome arm 13q is a common region of loss of heterozygosity in paediatric 
high grade glioma and is associated with malignant transformation from low grade to 
high grade glioma in adults (Wong, Tsang et al. 2006). Disruption of the pRb 
pathway is thought to be associated with the dramatic increase in cell proliferation 
seen in the transformation from low grade to high grade glioma (Ohgaki 2005).  
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1.4.5 Adult vs Paediatric High Grade Glioma 
Primary GBM is the most common glioma in adult patients and arises de novo from 
the glial cells, whilst in paediatrics low grade gliomas are much more common than 
high grade tumours. Paediatric low grade gliomas (grade II) can progress to high 
grade tumours although this is uncommon. A number of studies have looked at the 
genetics of adult GBM with disruption of the RB, p53 and Ras/PI3K pathways seen 
in most tumours.  
Rickert et al performed metaphase CGH on 23 paediatric high grade astrocytomas 
(Rickert, Strater et al. 2001). There were wide spread chromosome imbalances with 
high level gains on 1q, 2q, 7q, 3q, 9, 17q, 4q, 8q, 18 and 20q.  The findings were 
compared with adult high grade glioma data. Gain of 1p, 2q and 21q and loss of 6q, 
11q and 16q seem to be more common in the paediatric tumours compared with the 
adult (Rickert, Strater et al. 2001). 
Paediatric high grade gliomas have had much less research attention compared with 
adult tumours. Mutations in p53 and loss of the INK4A/ARF locus have been shown 
in adult and paediatric high grade glioma. EGFR amplification, the most common 
amplification in adult GBM, is much less common in children (Sung, Miller et al. 
2000).  PDGFRA is the most common focal amplification in paediatric tumours but 
is seen much less frequently in adult tumours (Wong, Tsang et al. 2006).  
In paediatric tumours gain of 1q has been identified as the most common whole arm 
gain whereas in adults gain of 1q is much less frequent. Chromosome arms 10q, 13q 
and 14q are lost in both adult and childhood tumours (Wong, Tsang et al. 2006). The 
level of loss of 13q and 14q is similar in adults and paediatrics but gain of 10q is less 
common in paediatric tumours.  
Age seems to be an important factor in survival with children under three having a 
better survival rate than children over three. TP53 mutation is much less frequent in 
children under three than children over three and adults, indicating a distinct tumour 
mechanism in very young children (Pollack, Finkelstein et al. 2001).  
Oligodendrogliomas in adults frequently have loss of 1p and 19q, and this is 
associated with increased survival compared to other high grade glial tumours 
(Cairncross, Ueki et al. 1998; Kreiger, Okada et al. 2005). Paediatric 
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oligodendrogliomas do not tend to have the characteristic loss of 1p and 19q and 
survival does not seem to be affected.  Whilst adult and paediatric high grade glioma 
clearly share similar aberrations it is the frequency of these aberrations which 
separates adult and paediatric high grade gliomas into two separate entities.  
Similarities between the genetic profiles of secondary adult high grade gliomas and 
paediatric high grade gliomas have been noticed. For example, amplification and 
subsequent overexpression of PDGFRA is seen in adult secondary GBM and 
paediatric GBM, but not in adult primary GBM. EGFR amplification is seen in adult 
primary GBM, but not in adult primary GBM or paediatric GBM (Faury, Nantel et 
al. 2007).  Other focal aberrations found in paediatric GBM, e.g. MYCN 
amplification, are also seen in adult secondary GBM.  
Microsatellite instability is seen in 25% of pHGG but is rarely seen in adult tumours. 
Microsatellite instability is caused by defects in the mismatch repair pathways, often 
due to mutations in mismatch repair genes, e.g. MLH1, MSH6, PMS1, PMS2 (Abdel-
Rahman 2008)). Microsatellites are small repeating sequences that are prone to 
replication errors by DNA polymerase. If there are defects in the mismatch repair 
pathway then these errors are not fixed resulting in mutations (Boland and Goel 
2010).  
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Table 1.2: Summary of genetic aberrations found in adult and paediatric high grade 
glioma 
Adult high grade glioma Paediatric high grade glioma 
Amplification of EGFR is the most 
common genetic aberration. 
Overexpression of EGFR is common but 
gene amplification is rare.  
 
Loss of p53 is common in adult tumours. Loss of p53 is common in children 
diagnosed over the age of 4, rarer in 
children diagnosed under the age of 4.  
 
Rb pathway commonly disrupted. 
 
Rb pathway in children is not well 
characterised. 
 
Deletion of p16 seen in 50-70% patients 
 
Deletion of p16 only in 9% of patients. 
Microsatellite instabilty rarely seen in 
adults. 
 
Microsatellite instability found in around 
25% of paediatric tumours. (caused by a 
disruption in the MMR pathway) 
 
PTEN mutations common in primary 
adult glioblastomas. 
PTEN mutations rarely seen in paediatric 
secondary glioblastomas. 
(Pollack, Finkelstein et al. 2001; Rickert, Strater et al. 2001; Broniscer and Gajjar 
2004; TCGA 2008) 
 
1.4.6 Mouse Models 
Mouse models of tumours are vital tools in studying the behaviour and progression 
of tumours and the effect of genetic alterations to tumours. Mouse models are also 
important in the development of therapies to treat human tumours. Mouse models of 
gliomas have had limited successful with tumours demonstrating low penetrance and 
minimal progression (Reilly, Loisel et al. 2000).  Whilst single gene knockouts of 
gene such as Cdkn2a, Nf1 and Trp53 have resulted in the formation of low grade 
tumours, no high grade tumours are seen.  Reilly et al demonstrated that a double 
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knockout of one copy of Nf1 and Trp53 enabled the development of low and high 
grade gliomas (Reilly, Loisel et al. 2000). 
Further studies have shown that overexpression of activated EGFR in Cdkn2a 
deficient mice can give rise to low and high grade tumours if targeted to specific 
nestin expressing cells in the developing brain.  High and low grade tumours also 
arise when ras and activated Akt1 are targeted to nestin positive cells highlighting 
the importance of the disruption of specific pathways in the development of high 
grade gliomas (Holland, Hively et al. 1998). More recently, it has been shown that 
inactivation of tumour suppressor genes, e.g. Nf1, Trp53, Pten, in nestin-expressing 
neural stem cells can result in high grade astrocytoma formation (Alcantara Llaguno, 
Chen et al. 2009). 
 
1.5 Signalling Pathways 
1.5.1 Growth Factors 
Growth factors are thought to have an important role in primary and secondary 
GBM. EGF and PDGF are two growth factors that have been widely implicated in 
GBM development. PDGF is expressed by neuron and astrocytes during neural 
development. Glial progenitors and neurons express PDGFRA during development, 
but expression is down regulated as the glial progenitors differentiate. PDGF 
expression is still present in the adult brain in neurons and astrocytes, whilst 
PDGFRA expression is only seen in the sub-ventricular zone. This suggests it is the 
neural stem cells that are expressing PDGFRA, and so PDGFRA may have a vital 
role in neural stem cell differentiation and migration.  
A study by Toepoel et al has suggested that expression levels of PDGFRA, as 
determined by promoter haplotype, may pre-dispose individuals to gliomas 
(Toepoel, Joosten et al. 2008). Five distinct promoter haplotypes have been 
identified for PDGFRA. Haplotype H1, associated with lower PDGFRA expression, 
is found at high frequencies in patients with neural tube defects whilst patients with 
GBMs have a lower frequency of the H1 haplotype (Toepoel, Joosten et al. 2008). 
This suggests high PDGFRA expression pre-disposes patients to gliomagenesis. 
PDGFRA is an interesting target for drug development. Imatinib, a tyrosine kinase 
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inhibitor, targets the tyrosine kinase site of PDGFRA, decreasing the function of 
PDGFRA. Imatinib is commonly used in the treatment of chronic myeloid leukaemia 
and gastrointestinal tumours (Waller 2010). 
The most common gene amplification in adult GBM is the amplification of EGFR.  
EGFR is the activator of the EGFR/PTEN/Akt/mTOR pathway that is thought to be 
key in the development of primary GBM in adults (Ohgaki and Kleihues 2007).  
 
1.5.2 RTK/Ras/PI3K pathway 
A recent study by The Cancer Genome Atlas (TGCA) identified three key pathways 
frequently disrupted in adult GBM; the RTK/Ras/PI3K pathway, the p53 pathway 
and the RB pathway (TCGA 2008).  
The Ras family of proteins are key cell cycle regulators.  Ras proteins are activated 
when growth factor ligands, e.g. EGF, bind to extra-cellular membrane bound 
growth factor receptors, e.g. EGFR. This binding leads to activation of downstream 
target such as Raf and PI3K. When Ras binds with GTP it recruits Raf to the cell 
membrane where Raf becomes active either by phosphorylation or another process. 
When Raf is active it phosphorylates MEK, which in turn phosphorylates ERK1 and 
ERK2. When ERK1 and 2 are phosphorylated they become active and phosphorylate 
a variety of targets. Some of these targets are transcription factors and so are 
involved in cell proliferation.  
Loss of control of cell proliferation in many cancers is thought to be down to 
deregulation of the Ras/Raf/MEK/ERK signalling pathway. Although mutation of 
Ras in brain tumours is rare, around 30% of adult high grade gliomas have 
overexpression of EGFR, which is known to activate the Ras pathway (Fanton, 
McMahon et al. 2001). 
Ras activation of PI3K leads to the activation of Akt which then phosphorylates the 
pro-apoptotic protein Bad. The phosphorylation of Bad means that Bad can no 
longer bind to Bcl2, an anti-apoptotic protein. When Bad is phosphorylated, Bcl2 is 
released in an active form and apoptosis is inhibited (King 2000). Another 
downstream target of Akt is mTOR, a kinase that mediates cell response to stress. 
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mTOR controls expression of p21 which halts the cell cycle in response to damage.  
,QKLELWLRQ RI P725 OHDGV WR GHFUHDVHG H[SUHVVLRQ RI S DQG LQFUHDVHV WKH FHOO¶V
suscHSWLELOLW\WR'1$GDPDJHDQGVRWKHFHOO¶VVXVFHSWLELOLW\WRFKHPRWKHUDSHXWLFV
that use a DNA damage mechanism.  mTOR also promotes angiogenesis by 
promoting the expression of hypoxia-inducible factor (HIF) which controls the 
expression of a variety of genes involved in angiogenesis.  
The NF1 protein neurofibromin converts Ras from its active form to an inactive form 
and so stops cell proliferation. When NF1 function is lost the Ras mechanism of cell 
cycle control is lost (Boyd, Korf et al. 2009). 
 
Figure 1.6: RTK/Ras/PI3K signalling pathway, adapted from TCGA (TCGA 2008). 
 
Loss of 10q is the most common chromosome arm loss in high grade glioma. PTEN, 
located at 10q23, dephosphorylates PIP3 and PIP2 which blocks PI3K activity and 
so negatively regulates the cell cycle at G1. If PTEN is lost, then PI3K activates Akt 
which in turn can activate downstream targets including BCL2 (via Bad) and mTOR. 
PTEN is mutated in up to 40% of adult GBM but mutations are rarely seen in 
secondary GBM.  
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1.5.3 RB Pathway and p53 Pathway 
RB1 is a tumour suppressor gene that controls the cell cycle at the point of transition 
from G1 to S phase by inhibiting E2F1 (see fig. 1.7). A complex composed of CDK4 
and CCND1 phosphorylates RB1 which leads to the release of E2F1. E2F1 then 
activates genes required for the transition from G1 to S phase.  If the CDK4/CCND1 
complex is inhibited by p16INK4A binding to CDK4 then the complex cannot 
phosphorylate RB1 and so the cell cycle is stopped.  Mutations in RB1 that cause 
inactivation can lead to uncontrolled cell proliferation. Disruption of the RB pathway 
is seen in the majority of adult GBM.  Disruption is usually due to loss of RB1, loss 
of p16INK4A, or amplification of CDK4.  
p53 is the most commonly aberrant gene in human cancer. Around half of grade II 
astrocytomas and anaplastic astrocytomas have no wild type p53 allele. p53 is a 
transcription factor which halts the cell cycle in response to stress, eg. DNA double 
strand breaks, to allow DNA repair enzymes to work or to induce apoptosis.  
p14ARF binds to and stabilizes p53. p53 is degraded by the MDM2, a gene which is 
amplified in around 10% of adult GBM.   
p16INK4A and p14ARF are both produced from the INK4a/ARF locus at 9p21 due 
to alternative splicing so if this locus is lost both the RB1 and p53 pathways are 
deregulated. In adult GBM, even if the INK4a/ARF locus is intact tumours usually 
have disruption of the RB1 and p53 pathways by some other mechanism (Kanu et 
al). 
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Figure 1.7: RB/p53 signalling pathway (Soni, King et al. 2005). 
 
 
1.6 Research Methods 
1.6.1 Formalin-Fixed Paraffin Embedded and Fresh Frozen Tissue Samples 
Formalin-fixation has been the most common soft tissue preservation method for 
clinical studies for decades. Tissue is fixed in formalin and then embedded in a 
paraffin block for storage and for histopathological review. Paraffin sections are used 
in the histopathological diagnosis of tumours. Unfortunately DNA from formalin-
fixed paraffin embedded tissue (FFPE tissue) shows some degradation due to the 
extensive cross-links formed between nucleic acids and proteins within cells by the 
formalin-fixation method. The crosslinks formed in the fixation process can be 
broken by treatment of the fixed tissue with protease, although it is likely that some 
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crosslinks will remain. DNA isolated from FFPE samples tends to have a broad 
range of fragment sizes and so will appear as a smear on an electrophoresis gel. Only 
a few studies have looked at the possibility of using DNA isolated from FFPE tissue 
for whole genome molecular analysis and the results have been varied, although 
some success has been reported where the isolated DNA has been of a reasonable 
integrity. The variation in success when using FFPE tissue for molecular analysis is 
probably due to a number of factors including the age of the sample, the time taken 
to fix the sample when originally extracted from the patient, and whether buffered 
formalin was used in the fixation process. Array CGH can be used with FFPE tissue 
with good results although the quality of the aCGH does depend on the integrity of 
the test DNA. The lack of quality of DNA extracted from FFPE tissue presents a real 
problem for genomic analysis of these samples, especially as FFPE tissue is often the 
only available material for research.  
The gold standard is flash frozen tissue where the tissue is frozen in liquid nitrogen 
immediately following surgery. This preserves the DNA and RNA and does not 
cause any chemical alteration of nucleic acid. Therefore, DNA and RNA isolated 
from frozen material is usually of a high quality unlike DNA isolated from formalin 
fixed tissue.  
 
 
1.6.2 Comparative Genomic Hybridisation 
Comparative Genomic Hybridization (CGH) is a technique that was developed to 
detect gains and losses in copy number in DNA. Traditional CGH uses fluorescent 
dyes to label the genomic DNA; test DNA samples are labeled red and control DNA 
samples labeled green (Figure 1.8). Control DNA can be DNA isolated from an 
unaffected tissue in the case of a tumour or a DNA pool from healthy individuals. 
The ratio of red to green signals is measured on metaphase chromosomes with 
deleted regions appearing red and amplified regions green. Regions of the 
chromosome with no difference in copy number between the test and the control 
DNA appear yellow. This method of labeling metaphase chromosomes only provides 
limited resolution of the areas of copy number change (Inazawa, Inoue et al. 2004). 
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It is assumed that any reference sample will have a diploid genome although there 
may be some local areas of gain or loss due to variation within the population.  
 
Figure 1.8: Metaphase CGH. 
Array CGH (aCGH) uses a series of genomic clones, spotted onto a glass slide, that 
span the genome. The clones are bacterial artificial chromosomes (BACs), P1-
derived artificial chromosomes (PACs) or yeast artificial chromosomes (YACs) and 
each BAC or PAC contains an insert between 100-300bp in size (Cowell, Matsui et 
al. 2004). The clones spotted on the slide are termed the probes and are therefore the 
hybridization target for the sample DNA. The test and reference DNA compete for 
binding to the probes on the array and therefore the ratio of red to green dye 
represents the differences in copy number between the two samples (Warr, Ward et 
al. 2001). The resolution of aCGH is determined by three factors; the size of the 
probes, the distance between the probes and the number of probes on the slide 
(Johnson, Hamoudi et al. 2006). Arrays contain on average around 6000 BACs and 
can have a resolution of up to 1Mb (Cowell, Matsui et al. 2004). 
Array CGH allows for the screening of chromosomal gains and losses and so can 
indicate changes in copy number when there is a change in the net amount of 
chromosomal material. However, because aCGH works by detecting gains and losses 
in copy number, changes in the DNA where there is no overall loss or gain of 
chromosomal material cannot be detected. In the same way, when loss of 
heterozygosity (LOH) occurs without a net loss of genomic material or in an area 
with no probe coverage, no change will be detected by aCGH. This may occur due to 
a duplication of the corresponding area of the intact chromosome (Cowell, Matsui et 
al. 2004). 
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Array CGH can be used with formalin-fixed paraffin embedded (FFPE) tissue with 
good results although the quality of the aCGH does depend on the integrity of the 
sample DNA (Johnson, Hamoudi et al. 2006). 
The newest advance in comparative genomic hybridization is oligo array CGH (oligo 
aCGH). Oligo aCGH uses short DNA sequences called oligonucleotides as probes 
rather than BAC or PAC clones. Oligo arrays have several advantages over BAC 
arrays; oligonucleotides are easier to design and create and their production is less 
time consuming and cheaper than BAC clone production. Oligo aCGH can have a 
resolution as high as 6.4 Kb. As a result of the increased resolution, oligo aCGH is 
able to detect single copy number amplifications and deletions and gives a more 
informative genomic profile than aCGH (Carvalho, Ouwerkerk et al. 2004). 
There are three main stages to the oligo aCGH protocol; digestion, labelling and 
hybridization. The digestion stage involves the addition of restriction enzymes to the 
DNA sample to produce DNA fragments of an appropriate length for labeling and 
hybridization. Labeling involves the binding of fluorescent dyes to the digested 
DNA, either cyanine 3 (Cy-3) or cyanine 5 (Cy-5). The test sample is labelled with 
Cy-3 and the control sample with Cy-5, or vice versa. Hybridisation is the process of 
applying the labelled test DNA and control DNA to the oligo aCGH microarray slide 
and incubating the array at a certain temperature for a specific amount of time (see 
fig. 1.9). After incubation the microarray slides are washed and scanned to generate 
an image that can be transferred into an analytical program for analysis.  
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Figure 1.9: Combination of Cy-3 and Cy-5 labeled samples for hybridization to 
aCGH microarray. 
Copy number aberrations are extremely common in cancer cells and aCGH is 
helping not only to identify the numerical abnormalities but also to associate these 
variations with diagnostic factors. Copy number aberrations leading to diseases are 
often the result of recombination between regions rich in low copy number repeats 
(Mendrzyk, Korshunov et al. 2006). This is a potential problem for aCGH because 
these regions of low copy number repeats have a tendency to cross hybridize. This 
will therefore lead to a misrepresentation of copy number as probes will not be able 
to bind to cross hybridized DNA (Fellermann, Stange et al. 2006). 
1.6.3 Single Nucleotide Polymorphism (SNP) arrays 
Array CGH and oligo array CGH allow for the identification of areas of 
chromosomal gain and loss but do not have a high enough resolution to identify 
single base pair changes within the genomic material (Herr, Grutzmann et al. 2005). 
Having the resolution to detect single base pair changes means that genotyping 
arrays such as SNP arrays have the ability to detect copy neutral events e.g. mitotic 
recombination, gene conversion, uniparental disomy (Zhao, Li et al. 2004).  Single 
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nucleotide polymorphisms (SNPs) are the most common form of genetic variation in 
the human genome with more than 106 SNP loci thought to be present (Dong, Wang 
et al. 2001). SNP arrays or oligonucleotide arrays consist of a series of 
oligonucleotides arranged on a glass chip. The oligonucleotides, which are the 
probes on the array, are approximately 25bp in length and contain known SNPs. The 
high resolution of SNP arrays has made them a standard method for detecting 
complex genetic aberrations within DNA samples in cancer research. There are a 
number of biotech companies that produce SNP chips commercially including 
NimbleGen and Affymetrix. Affymetrix, the market leader in SNP array 
manufacturing, produces SNP arrays called GeneChips which use pairs of perfect 
match (PM) probes and mismatch (MM) probes (Affymetrix 2006). The mismatch 
probes act as an internal control by detecting levels of non-specific hybridization that 
may occur. High density arrays contain thousands of oligonucleotides with 
Affymetrix GeneChips containing up to 500,000 probes (Affymetrix 2006).  
 
Figure 1.10: Affymetrix GeneChip. 
The first step in SNP analysis is the extraction of DNA from the cells of the sample 
tissue. The DNA is then amplified, ligated and labeled with fluorescent dye before it 
is hybridized to the oligonucleotide probes on the surface of the chip array (fig. 1.11) 
(Primrose 2001). Any test DNA displaying variation at a SNP site cannot hybridize 
to the complementary oligonucleotide probe on the chip, as just one base difference 
is enough to prevent annealing. The reagents used in the SNP chip protocol make 
non-specific binding very unlikely but if it were to occur then this hybridization 
would be detected by the MM probes and the non-specific binding compensated for.  
Affymetrix GeneChip 
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Figure 1.11: Hybridisation of DNA to SNP array (Affymetrix 2006).  
         
When hybridization is complete the chip is washed to remove any un-hybridized 
material before the chip is scanned and the data produced is interpreted by a 
computer. There is a range of computer software available to aid the analysis of the 
vast amounts of data generated from SNP chip array analyses. The DNA required for 
analysis on a SNP chip has to be of a good quality to generate data with the 
minimum amount of background noise.  
The problem when designing SNP chip arrays is that the vast majority of SNPs fall 
outside genes due to selective pressure away from coding regions of the genome. 
This poses the question of whether to select for SNPs within genes or distribute the 
SNPs throughout the genome. 
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1.7 Hypotheses and Aims 
 
The objective of this study is to use high through-put genetic techniques to facilitate 
the identification of diagnostic and prognostic markers in paediatric high grade 
glioma using FFPE samples, and hence identify novel therapy targets. 
Having conducted the literature review the hypotheses of this study were: 
 Paediatric and adult high grade glioma have different genetic causes. 
 High grade glioma occurring in the brainstem are genetically distinct from 
high grade glioma in the cerebrum. 
 High grade glioma occurring in children over 3 years old are genetically 
distinct from those tumours occurring in children under 3 years old. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
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The aim of this study was to use high through-put genetic techniques to analyse 
FFPE pHGG samples. The following techniques and methods were used during this 
study. 
2.1 DNA Isolation 
2.1.1 DNA isolation from FFPE tissue 
All the samples for this oligo aCGH project are fixed in formalin and embedded in 
paraffin blocks. 10 cores or scrolls were taken from each tumour sample to be used 
for DNA isolation. 10 cores should correspond to approximately 30 mg of tissue. 
The cores were placed in an Eppendorf tube on dry ice and then crushed into a very 
fine powder. Throughout the crushing process the cores were kept on dry ice so they 
remained frozen and were easier to crush. Once the cores were reduced to a powder, 
1 ml of 100% xylene was added to break down the paraffin and the tube was 
LQFXEDWHG DW Û& IRU  PLQ ,W LV YHU\ LPSRUWDQW WKDW WKH FRUHV were  been 
sufficiently crushed to allow as large a surface area as possible to be exposed to the 
xylene.  
 
 After incubation, each tube was centrifuged for 2 min to produce a tissue pellet and 
the xylene carefully removed and discarded. 1 ml of 100% ethanol was added at 
room temperature and the tube was vortexed then centrifuged for 2 min. The ethanol 
was carefully removed and discarded to leave a pellet. This wash with ethanol was 
then repeated before the tube was quickly centrifuged again to remove as much 
ethanol as possible. The tube was left with the lid open to air dry for 10-15 min until 
there was no visible liquid remaining in the tube.  
 
RecoverAll Total Nucleic Acid Kit for FFPE (Ambion, Applied Biosystems, 
Warrington) was used for DNA extraction. 400 µl of digestion buffer plus 4 µ l of 
protease was added to each tube to allow protease digestion of tissue. The protease 
was added to remove the cross-links between primary amino groups in proteins with 
other nearby nitrogen atoms in protein or DNA through a -CH2- linkage formed 
during the formalin fixation process. The tube was  gently agitated to ensure all the 
44 
 
tissue is immersed. The tubes weUH WKHQ SODFHG DW  Û& IRU  K WR DOORZ WKH
digestion process to occur. 
 
After the 48 h incubation 480 µl of isolation additive was added to each tube and the 
tube vortexed. The resulting solution has a milky white appearance. 1.1 ml 100% 
ethanol was added to each sample making sure the sample solution was well mixed 
by pipetting up and down. A collection tube was prepared for each sample by 
placing a filter in the top of the collection tube. 700 µl of each sample was then 
applied to the filters in the corresponding tubes and the lids firmly shut. The 
collection tubes were centrifuged at 10,000 xg for 1 min to allow the sample solution 
to pass through the filter cartridge. The flow through was discarded and the filter 
replaced into the same collection tube. This centrifuge step was repeated until all the 
sample had passed through the filter. 700 µl of wash 1 was applied to the centre of 
the filter and the collection tubes centrifuged at 10,000 xg for 30 s. The flow-through 
was discarded and the filter replaced into the same collection tube. 500 µl of wash 
2/3 from the RecoverAll kit was applied to the centre of the filter and the collection 
tube centrifuged at 10,000 xg for 30 s. Again, the flow-through was discarded and 
the filter replaced into the same collection. 
The final stage in the DNA isolation process was nuclease digestion and final 
purification. An RNase mix was prepared; 
 per sample 
RNase A 10 µl 
Nuclease free 
water 50 µl 
 
60 µl of RNase mix was added to the centre of each filter and the tube incubated at 
Û&IRUPLQ$IWHr incubation, 700 µl of wash 1 was added to the centre of the 
filter cartridge. The tubes were then left for 1 min at room temperature before 
centrifuging at 10,000 xg for 30 s. The flow-through was discarded and the filter 
cartridge replaced into the correct collection tube. 500µl of wash 2/3 from the 
RecoverAll kit was applied to each filter and the collection tubes centrifuged at 
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10,000 xg for 30 s.  The flow-through was discarded and the wash 2/3 step repeated. 
The collection tubes were centrifuged at 10,000 xg for one min to remove as much 
liquid as possible for the filter.  
 
The filter was then removed from the collection tube and placed into a new 
collection tube. 30 µl of nuclease-free water or elution solution, which had been 
hHDWHGWRÛ&ZDV applied to each filter and left to rest at room temperature for one 
min. The tubes were then spun at maximum xg for one min. An additional 30 µl of 
nuclease-free water or elution solution was added to each filter and the following 
steps repeated. This produced a final volume of approximately 60 µl in each tube.  
 
The DNA samples were then stored at -Û& 
 
2.1.2 Multiplex PCR Quality Control Step 
It has been shown that DNA concentration alone is not a definitive predictor of 
success of oligo aCGH. Multiplex PCR is a quality control method which better 
illustrates the integrity of the DNA. Multiple sets of primers are used in a single PCR 
reaction to generate products of differing length. The multiplex PCR used in this 
study is taken from van Beers 2005 paper and was designed for the purpose of 
measuring the integrity of DNA isolated from FFPE tissue.(van Beers, Joosse et al. 
2006) This reaction involves four sets of primers that produce a 100 base pair (bp), 
200 bp, 300 bp and 400 bp product from the GAPDH gene.  
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Table 2.1. Primer sequences used for multiplex PCR (van Beers, et al 2006). 
Primer Primer Sequence 
100 F GTTCCAATATGATTCCACCC 
100 R CTCCTGGAAGATGGTGATGG 
200 F AGGTGGAGCGAGGCTAGC 
200 R TTTTGCGGTGGAAATGTCCT 
300 F AGGTGAGACATTCTTGCTGG 
300 R TCCACTAACCAGTCAGCGTC 
400 F ACAGTCCATGCCATCACTGC 
400 R GCTTGACAAAGTGGTCGTTG 
 
PCR Mastermix 
Reagent Volume 
BioMix 
Red 7.5 µl 
H2O 3.5 µl 
Primers 
(x8) 1.5 µl 
 
100 ng of sample DNA was added to 23 µl of PCR mastermix in a PCR tube. Tubes 
were placed into PCR machine and the following programme run: 
Cycles Temperature (oC) 
Time 
(min) 
1 94 4 
35 94 1 
  56 1 
  72 3 
1 72 7 
Hold 15   
 
PCR products were run on a 1.5% agarose gel (1.5 g agarose in 100 ml TAE buffer) 
stained with ethidium bromide alongside 100 bp ladder. 
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Figure 2.1: Products from multiplex PCR run on an agarose gel. 
The high quality samples produced all four bands as the DNA is less fragmented 
than the poor quality samples which produce no bands. DNA samples which 
produced a 200 bp band or longer were used for oligo aCGH. 
 
2.2 Oligo array Comparative Genomic Hybridisation (aCGH) 
2.2.1 Agilent Oligo aCGH Protocol Overview (Agilent Technologies, Berkshire) 
$JLOHQW¶VROLJRQXFOHRWLGHDUUD\EDVHGFRPSDUDWLYHJHQRPLFK\EULGLVDWLRQLVGHVLJQHG
to detect copy number aberrations using 60-mer oligonucleotides in a microarray 
format.  
There are two methods of sample preparation depending on the quantity of sample 
'1$ DYDLODEOH ,I  J RU PRUH RI VDPSOH '1$ LV DYDLODEOH WKHQ WKH µGLUHFW
PHWKRG¶ RI SUHSDUDWLRQ FDQ EH IROORZHG ,I OHVV WKDQ  J RI VDPSOH '1$ LV
available for analysis, whole genome amplification must be carried out to create 
enough template DNA for the digestion and labelling stages. 
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Figure 2.2: Oligo aCGH protocol (Agilent Technologies). 
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Figure 2.3: Oligo aCGH protocol for amplified DNA (Agilent Technologies). 
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Agilent aCGH Protocol (Agilent Technologies) 
2.2.2 DNA digestion 
For 244K Agilent oligo arrays only 0.5 µg of input DNA is required, however 1 µg 
of DNA was used due to the poor quality of DNA isolated from formalin fixed tissue 
to ensure there are enough long fragments of DNA in the solution. Nuclease-free 
water was added to the input DNA to give a volume of 20.2 µl. The DNA was 
digested by two restriction enzymes; Alu1 and Rsa1.  
 
Digestion Master Mix 
Component per reaction (µl) 
nuclease-free water 2.0 
10X Buffer C 2.6 
Acetylated BSA 
(10µg/µl) 0.2 
Alu I (10U/µl) 0.5 
Rsa I (10U/µl) 0.5 
Final Volume 5.8 
 
 
5.8 µl of digestion mix was added to each genomic DNA sample to make a total 
volume of 26 µl. The samples weUHLQFXEDWHGDWÛ&WKHRSWLPDOWHPSHUDWXUHIRU
enzyme activity, IRUKDQGWKHQPRYHGWR&ÛIRUPLQWRGHQDWXUHWKHHQ]\PHV
and deactivate them. At this point 2 µl of each sample can be run on a gel to ensure 
the digestion has been successful. Fragments should ideally be between 200-500bp 
in length, although when using DNA isolated from FFPE tissue the fragments may 
be shorter due to degradation. 
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2.2.3 DNA labelling 
Oligo array CGH uses the principle of a competitive binding process between two 
samples; the test sample and the control sample. Each sample was labelled with one 
of two dyes, Cy-3 or Cy-5. The experimental sample was labelled with one dye and 
the control DNA is labelled with the other.  
 
5 µl of random primers were added to each DNA sample, and samples were 
LQFXEDWHGDWÛ&IRUPLQWKHQSODFHGRQLce for 5 min. 
 
Labelling Master Mix 
Component per reaction (µl) 
nuclease-free water 2.0 
5X buffer 10.0 
10XdNTP 5.0 
cyanine-3-dUTP 
or 
cyanine-5-dUTP 3.0             
Exo-klenow fragment 1.0 
Final Volume 21.0 
 
21 µl of master mix was added to each sample, and then the samples were incubated 
IRUKDWÛ&IROORZHGE\PLQDWÛ&WRGHQDWXUHWKHHQ]\PH 
After labelling, a series of steps were performed to clean up the labelled DNA before 
hybridisation of the samples to the arrays. 430 ml of 1xTE buffer was added to each 
sample before the sample was loaded into a Microcon YM-30 filter (Millipore, 
Watford) and spun at 8000 xg for ten min. After discarding the flow-through, a 
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further 480 µl of 1xTE was added to each filter and each sample was again spun at 
8000xg for ten min. After discarding the flow through the filters are inverted into 
fresh tubes and spun at 8000 xg for one min to collect the purified DNA from the 
filter into the tube.  
 
Samples are analysed on the Nanodrop photospectrometer (Thermo Fisher Scientific, 
Leicestershire) to determine the DNA yield and the amount of dye activity. The 
specific activity of the labelled DNA can be determined by using the following 
equation: 
Specific activity =      (pmol per µl dye)   
                             (µg per µl genomic DNA)  
(specific activity is measured in pmol dyes per µg genomic DNA) 
 
Table 2.2: Recommended specific activity values for labelled DNA 
Input 
DNA (µg) 
Yield 
(µg) 
Specific activity of cyanine-3 
labelled sample (pmol/µg) 
Specific activity of cyanine-5 
labelled sample (pmol/µg) 
0.5 5 to 7 25 to 40 20 to 35 
 
 
At this point if the DNA has labelled appropriately (see Table 2.2) the correct Cy-3 
and Cy-5 labelled samples should be combined to give a final volume of 79 µl. 
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2.2.4 Hybridisation 
The labelled samples are prepared for hybridisation to the arrays by the addition of 
Human Cot-1 DNA (Invitrogen, Paisley, UK), blocking agent and hybridisation 
buffer.  
 
Component Volume (µl) per hybridisation 
Cy-3 and Cy-5 labelled gDNA mixture 79 
Cot-1 DNA (1.0 mg/µl) 25 
Agilent 10X Blocking Agent 26 
Agilent 2X Hybridisation Buffer 130 
Final Hybridisation Sample Volume 260 
 
After being briefly spun down the samples weUH LQFXEDWHG IRUPLQDW  Û&DQG
WKHQIRUPLQDWÛ&$IWHULQFXEDWLRQ the samples are spun at 79000 xg for one 
min. The samples are now prepared for hybridisation to the arrays. 
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Agilent oligo aCGH microarrays 
 
 
Figure 2.4: Agilent microarray slides. 
For the 244K Agilent arrays there is one array on the active side of the slide (Figure 
2.4). The hybridisation sample was not applied directly to the array slide but instead 
to a gasket slide. 
 
 
Figure 2.5: Agilent gasket slide. 
A gasket slide was placed into an Agilent SureHyb chamber with the Agilent 
barcode facing upwards (Figure 2.5). 490 µl of sample was dispensed into the well 
on the gasket slide. 
The microarray slide was placed on top of the gasket slide with the numerical 
barcode facing upwards and the active side in contact with the gasket slide. The top 
of the hybridisation chamber waVSODFHGFDUHIXOO\RQWRSRIWKHVOLGHµVDQGZLFK¶DQG
clamped into place by sliding on the clamp and tightening the screw. 
The microarray slides have a barcode 
on either side. The side with the 
numerical barcode is the back of the 
slide and the side with the Agilent 
barcode is the side with the array on 
(the active side).  
The gasket slide has a defined region 
(well) with rubber boundaries which 
correspond to the position of the array 
on the active side of the array slide. 
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Assembled SureHyb Chamber 
 
Figure 2.6: Diagram of Agilent SureHyb chamber. 
After the chamber is assembled (Figure 2.6), it is important to rotate the chamber to 
wet the surface of the arrays and to make sure there are no stationary bubbles which 
could cause a mark on the array. The assembled chambers were placed into the 
K\EULGLVDWLRQRYHQDQGK\EULGLVHGDWÛ&IRUK 
 
2.2.5 Washing and Scanning 
Table 2.3: Summary of washes used for oligo aCGH 
 Dish Wash Buffer Temperature Time 
Disassembly 1 Oligo aCGH Wash Buffer 1 
Room 
temperature  
1st Wash 2 Oligo aCGH Wash Buffer 1 
Room 
temperature 5 min 
2nd Wash 3 Oligo aCGH Wash Buffer 2 Û& 1 min 
Acetonitrile 
Wash 4 Acetonitrile 
Room 
temperature 1 min 
3rd Wash 5 
Stabilization and Drying 
Solution 
Room 
temperature 30 s 
 
A hybridisation chamber was removed from the hybridisation oven and rotated to 
check there were no stationary bubbles that could cause anomalies on the array 
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images. The chamber was placed on a flat surface, and the clamp screw loosened and 
the clamp removed. The slide sandwich was carefully taken out and both slides 
immersed into dish 1 filled with wash buffer 1. One of the flat ends of the plastic 
tweezers was carefully slid between the slides and twisted to break the slides apart. 
Leaving the gasket slide in the container the array slide was removed, being careful 
not to touch the active surface, and placed into the slide holder in dish 2. The slide is 
now ready for the washing process.  
 
When all hybridised slides have been released from their gasket slides and are in dish 
2 containing wash buffer 1, the magnetic stirrer was activated and left for 5 min. The 
slides weUHWKHQWUDQVIHUUHGWRGLVKFRQWDLQLQJZDVKEXIIHUDWÛ&DQGOHIWIRU
min with a magnetic stirrer. The slides were next placed in acetonitrile for 1 min 
with a magnetic stirrer and finally into Stabilisation and Drying solution (Agilent 
Technologies) for 30 s. The slides should be removed from the Stabilisation and 
Drying solution slowly and carefully to prevent drops on the slides which could 
mark the arrays. The array slides are now prepared for scanning and should be 
scanned immediately to prevent oxidation of the dyes which will affect signal 
intensities. 
 
Scanning arrays 
 
To scan the arrays in an Agilent scanner, the arrays slides were placed into slide 
holders with the active side of the slide protected by the lid of the slide holder and 
the back of the array slide exposed (Figure 2.7).  
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Figure 2.7: Slide holder for scanning of microarrays. 
The slide carousel was removed from the scanner and slides loaded into the 
DSSURSULDWHVORWVEHLQJFDUHIXO WR OHDYH WKHµ+RPH¶SRVLWLRQ LQ WKHFDURXVHOHPSW\
The lid was placed onto the carousel making sure it clicks into place. The carousel 
was replaced inside the scanner and the scanner lid closed. 
 
The Agilent scanner used the software program Agilent Scanner Control software 
v7.0. When the Agilent Scanner Control Program was opened the lid of the scanner  
automatically locked.  
 
 
Table 2.4: Default settings for scanning 244K Agilent oligo aCGH microarrays; 
Scan Region Scan Area (61x21.6 mm) 
Scan Resolution (µm) 5 
Dye Channel Red & Green 
Green PMT 100% 
Red PMT  100% 
 
The slide holder lid lifts up to 
allow the slide to be put into 
and removed from the holder. 
Agilent barcode facing 
upwards, so active side is 
protected by the lid of the 
slide holder. 
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If any changes were made to the settings (Table 2.4) µVHW YDOXHV¶ was clicked to 
apply the changes. When the scanner had warmed up and was ready to scan a green 
light was displayed and Scanner Control displayed WKHRSWLRQWRVFDQHJµVFDQVORW
WR¶7REHJLQWKHVFDQWKHµVFDQVORWDWRE¶RSWLRQ was clicked. Each 244K array 
slide took about 15 min to scan at a resolution of 5 µm.  
2.2.6 Processing of oligo aCGH data 
The Agilent Scanner Control Program creates Tif images of the scanned arrays 
These Tif images require processing before they can be imported into a program for 
data analysis. The Agilent Feature Extraction Software version 9.1 was used in the 
study to process the array Tif files. 
 
Feature Extraction 
The Tif files were LPSRUWHGLQWR)HDWXUH([WUDFWLRQE\FOLFNLQJµ$GGQHZH[WUDFWLRQ
VHWV¶LFRQRQWKHWRROEDUDWWKHWRSRIWKHVFUHHQ:KHQWKHILOHs were imported they 
were automatically assigned a grid template, which was an .xml design file. If the 
correct grid template was not already incorporated into the program it was 
downloaded from the Agilent website. 
Once the Tif files had been successfully LPSRUWHG WKH WDE ODEHOOHG µ3URMHFW
3URSHUWLHV¶ was clicked. The majority of the default settings were appropriate in this 
study with the following exceptions: The outputs MAGE and JPEG were set to 
µ1RQH¶ DQG WKH 7(;7 RXWSXW SDFNDJH ZDV VHW WR µ&RPSDFW¶ Ds instructed in the 
Agilent oligo aCGH protocol.  
 The µ([WUDFWLRQ6HW&RQILJXUDWLRQ¶ WDE was selected and each file was checked to 
make sure there was a grid template, and that the Protocol Name column was 
displaying the correct protocol. For this study the protocol was CGH-v4_91. If the 
correct protocol was not available in the software it was downloaded from the 
Agilent website. 
The project was saved in an appropriate location (File>Save As) and then the 
extraction process was started by selecting µ3URMHFW¶ WKHQ µ6WDUW ([WUDFWLQJ¶  7KH
extraction proceeded automatically and generated QC summary reports for each 
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separate array. The QC report allows you to determine if the hybridisation has been 
uniform across the array, to look at the level of background noise on the array, and to 
make sure that Feature Extraction correctly aligned the grid template onto the Tif 
image of the scanned array.  
Feature Extraction generated .txt files from the processing of the Tif images which 
were LPSRUWHG LQWR $JLOHQW¶s data analysis software. In this study CGH Analytics 
version 3.4.1 was used for the majority of data analysis. Updated versions of the 
CGH Analytic program, DNA Analytics and Genomics Workbench were also used 
to produce figures.  
 
 
CGH Analytics 
To import WKHW[WILOHVSURGXFHGE\)HDWXUH([WUDFWLRQLQWR&*+$QDO\WLFVµ'DWD¶LQ
the toolbar at the top of the screen was clicked on DQGµ,PSRUW!)()LOHV¶ selected. 
The files to be imported were located and selected. CGH Analytics then gave the 
RSWLRQ WR µIOLS¶ a file which is important when dye swaps have been performed. In 
WKLV VWXG\ DOO G\H VZDS DUUD\V ZHUH µIOLSSHG¶ VR WKDW WKH G\H VZDSV DQG WKHLU
corresponding array could be combined to give one single profile.  
CGH Analytics recognised the type of Agilent array that has produced the txt file 
and automatically assigned a design file. The design files are GEML files that 
contain information on probe location, sequence and identification and are vital to 
the data analysis. If the appropriate design file is not already present in the software 
then it was GRZQORDGHGIURP$JLOHQW¶VH$UUD\$JHQRPHEXLOGwas automatically 
assigned to each array. Genome build Hg17 was used for the initial analysis in this 
study, with Hg18 being used in the updated versions of CGH Analytics used for later 
analysis and to create figures. 
7RYLVXDOLVHGDWDLQ&*+$QDO\WLFVWKHDUUD\ILOHVKDYHWREHSXWLQWRµH[SHULPHQWV¶
To create an experiment right click on the experiments folder in the left task pane 
DQGVHOHFWµQHZH[SHULPHQW¶7KHQHZH[SHULPHQWwas renamed accordingly. Array 
files from the data node were selected and dragged into the desired experiment. To 
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activate an experiment, the experiment was selected by right clicking on the 
experiment node and then µVHOHFWH[SHULPHQW¶ clicked. 
In this study every array that was hybridised with DNA isolated from FFPE tissue 
had a corresponding dye swap. In order for every dye swap pair to be viewed as a 
VLQJOHSURILOHµ,QWUD$UUD\¶was VHOHFWHGLQWKHµ&RPELQH¶VHFWLRQRIWKHWDVNEDUDW
the top of the screen before the experiment is selected. This causes the 2 array files 
to be combined and an average log2ratio for every probe on the array is calculated 
from the values of the 2 arrays. By creating an average profile from 2 separate arrays 
the noise seen on each individual array and any dye bias is reduced giving a cleaner 
combined profile.  
 
Centralization 
The centralization algorithm shifts the data so that the zero point reflects the most 
common copy number seen across the data. Centralization is active as a default in 
CGH Analytics and is very important when analysing noisy data as in this study. If 
centralization is for any reason turned off it can be turned on again by selecting 
µ7RROV!8VHU 3UHIHUHQFHV¶ DQG WKHQ VHOHFWLQJ WKH µ0LVFHOODQHRXV¶ WDE ,Q WKH
Centralization section of the tab clLFNµ$SSO\¶WRWXUQRQ&HQWUDOL]DWLRQ 
 
QC Metrics 
The QC Metrics were YLHZHGLQDWDEOHE\VHOHFWLQJµ7RROV!4&0HWULFV¶7KH4&
Metrics include values for signal intensity of the dyes used and the derivative log 
ration spread (DLR Spread) which is a measure of noise. DLR spread estimates the 
log ratio noise by calculating the spread of log ratio differences between consecutive 
probes along all chromosomes. The values are grouped into excellent, good and poor 
determined by the QC thresholds. The QC metrics give an indication of the quality 
of the array and can also show why a particular array has given an unexpected result, 
e.g. if the signal intensity of the dyes is significantly lower than the other. 
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Algorithms 
ADM-1 and ADM-2 
The ADM algorithms work by identifying all aberrant regions within a sample with 
higher or lower aberrant regions based on statistical scores.  ADM-1 and 2 are very 
similar with ADM-s including quality information on each probe value for a more 
stringent aberration calculation. 
Z-score 
Z-score assesses genomic regions with higher or lower numbers of probes with 
log2ratios that deviate significantly from zero. There are two stages to the z score 
calculation. Firstly, the number of probes with log ratios that are significantly 
different from a normal sample, where log ratios are zero, is calculated. Secondly, 
regions within the sample with higher or lower proportions of significantly aberrant 
probes than in the sample overall are identified as aberrant. The z score algorithm 
uses a sliding window of fixed size making it good for µnoisy¶ data. The Z score 
threshold can be adjusted to the correct level based on a visual analysis of gains and 
losses within a data set. Therefore, z-score was used as the algorithm during the data 
analysis in the study. Visual analysis of the data combined with initial qPCR results 
helped to determine the Z-score threshold. A Z-score threshold of 3.5 was used for 
the majority of samples, with a threshold of 4.0 being used for the noisiest samples. 
Data Analysis in CGH Analytics 
CGH Analytics has three panels showing three different views of the data (Figure 
2.8). The first panel is the genome view which gives an overall indication of 
aberrations across all chromosomes.  By clicking on a particular chromosome, you 
can then view that chromosome in greater detail in the second panel, the 
chromosome view.  
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Figure 2.8: Screenshot of CGH Analytics. 
 
The chromosome view shows one chromosome at a time and aberrations can be 
viewed more clearly. There are several viewing options in the chromosome view. 
The moving average line shows the average log2ratio of the probes along the 
chromosome displayed as a continuous line. Aberrant regions were highlighted in a 
number of ways including shading the aberrant area, which was the preferred method 
in this analysis. The distribution of the probes along the chromosome can be viewed, 
with each probe represented by a dot. This is a quick way of visually determining the 
noise level as the more  scattered the probes are away from the zero line, the noisier 
the chromosome. The data display options can be changed by right clicking in the 
DSSURSULDWHYLHZSDQHODQGVHOHFWLQJµ3URSHUWLHV¶ZKLFKWKHQGLVSOD\VWKHSUHIHUHQFH
window (Figure 2.9). 
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Figure 2.9: Preferences for visualising data in CGH Analytics. 
By highlighting a particular region of the chromosome in the chromosome view 
panel, particular regions were looked at in greater detail in the third view panel, the 
gene view. The gene view allowed the viewing of individual probes, again 
represented by coloured dots, and each probe was labelled with the gene that it is 
located in. The smaller the highlighted region in the chromosome view, the greater 
the detail seen in the gene view. These three views make a visual analysis of the data 
simple to carry out. 
Aberration Filters 
The aberration filters allow the user to reduce the number of regions that the program 
FDOOV DV µDEHUUDQW¶ E\ VHWWLQJ FHUWDLQ SDUDPHWHUV IRU DEHUUDWLRQV 7KH µ0LQLPXP
1XPEHU RI 3UREHV¶ YDOXH GHILQHV WKH PLQLPXP QXmber of probes that must be 
present in an aberrant region before that region is called as aberrant. 7KHµ0LQLPXP
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1XPEHURI3UREHV¶YDOXHZDVGHWHUPLQHGE\DYLVXDODQDO\VLVRIWKHGDWDFRPELQHG
with initial qPCR results to try and filter out false aberrations due to noise but 
maintain the true aberrations. 7KH µ0LQLPXP 1XPEHU RI $EHUUDQW 5HJLRQV¶
determines how many aberrant regions the program will show across the genome, 
and will remove the least significant aberrant regions. This is important in noisy 
data, as in this study, as it with display only the most significant aberrations and 
remove false aberrations.  
Reports 
CGH analytics produced a variety of lists and reports from the data.  There are two 
types of aberration summary displayed in a graphical manner; the graphical 
aberration summary and the graphical common aberration summary. The graphical 
aberration summary (Figure 2.10) displays the aberrations for one chromosome and 
can be used for multiple samples to give a heat map ±like figure.  
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Figure 2.10: Graphical aberration summary. 
The graphical penetrance summary (Figure 2.11) combines the data from all selected 
arrays to give a representation of the areas with the most common aberrations. All 
chromosomes can be viewed at once, or smaller groups of chromosomes can be 
selected. 
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Figure 2.11: Graphical penetrance summary. 
Text aberration summaries were generated and were based on probe values or 
intervals or a combination of probe values and intervals. The reports were exported 
from CGH Analytics and were view in Microsoft Excel.  
Gene lists for aberrant regions were created by right clicking on an aberrant region in 
WKHJHQHYLHZSDQHODQGVHOHFWLQJµ&UHDWHJHQHOLVW¶7KHXVHUFDQWKHQVSHFLI\LIWKH
gene list should include all genes in the current gene view or just the genes in the 
aberrant region below the cursor. The gene list was then saved as a node in the task 
pane on the left side of the screen and viewed when required. The gene lists were 
also exported to Microsoft Excel. The creation of gene lists of aberrant regions was 
important in this study. 
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2.3 Immunohistochemistry 
Immunohistochemistry was performed on 5 µm paraffin sections on glass slides 
using Real Envision Detection System with Peroxidase/DAB+ (Dako, 
Cambridgeshire).  
 
2.3.1 De-paraffinisation 
Slides were placed in a metal rack and submerged in xylene for 15 min. The slides 
were removed from xylene, drained briefly, then placed in 100% ethanol for 5 min. 
Finally the slides were washed in 95% ethanol for 5 min then washed in running 
water. If the water runs clear then the process has been successful and if not the de-
paraffinisation process can be repeated. 
 
2.3.2 Antigen Retrieval 
A pressure cooker was filled approximately half full with sodium citrate buffer 
(10.5g citric acid monohydrate added to 5 l of distilled water, adjusted to pH6 with 
approx 65 ml 2 M NaOH). The rack of slides was placed into the pressure cooker, 
submerged in sodium citrate buffer, and left for 1 min at full pressure. The cooker is 
then de-pressurised and the whole cooker cooled in cold water for 20 min, with the 
slides remaining in the citrate buffer. After 20 min the slides were removed from the 
citrate buffer and placed into a coplin jar with PBS (phosphate buffered saline) 
buffer for 5 min. 
 
After 5 min slides were removed from PBS and dried briefly. 100ul of peroxidise 
blocking solution (Dako) is applied to each section for 5 min. Slides are then washed 
in PBS for 5 min. After the slides were dried briefly, 100 µl of primary antibody was 
applied to the sections. Antibodies used in this study were MYCN monoclonal 
mouse (NCM II 100) antibody (Abcam, Cambridgeshire; 1:100) and 
CDKN2B/p15INK4b mouse monoclonal antibody (ab4068, Abcam; 1:50). FFPE 
sections from an sPNET with a validated amplification of MYCN were used as a 
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positive control for MYCN IHC. FFPE tonsil sections were used as a positive 
control for CDKN2B IHC. 
Slides were incubated overnight at 4oC.  
 
Slides washed in PBS for 5 min then dried briefly. 100ul secondary antibody applied 
to sections and slides incubated at room temperature for 30 min. Slides washed in 
PBS for 5 min then briefly dried. 100 µl 3,3'-Diaminobenzidine (DAB)  (20 µl DAB 
in 1 ml substrate buffer) (Dako) applied to each section for 5 min. Slides washed in 
PBS for 5 min. 
 
2.3.3 Counterstain 
Slides placed in rack and washed in Harris Haematoxylin (Surgipath, 
Cambridgeshire) for 10 s, then briefly in running water until the water run clear. 
Slides placed in lithium carbonate for 10 s then in running water. Slides drained well 
then washed briefly in 95% ethanol followed by 100% ethanol and xylene.  
 
2.3.4 Mounting 
Slides removed from xylene and left briefly for any remaining xylene to evaporate. 
A small amount of Dibutyl Phthalate; Xylene (DePeX) mounting medium 
(Surigipath) was placed onto a coverslip and the slide placed gently on top, allowing 
the coverslip to attach to the slide by capillary action. Slides were allowed to dry 
before viewing on an Olympus BX41 light microscope with an Olympus DP25 
camera and CellB Imaging Software (Olympus) at x40 magnification.  
 
 
 
 
69 
 
2.4 PDGFRA Immunohistochemistry 
PDGFRA IHC was performed at the Institute of Cancer Research, Surrey. 
De-paraffinisation 
Slides incubated at 60oC for 30 min. Slides then deparaffinised in xylene (2 x 5 min) 
and washed in 100% ethanol (5 min), 90% ethanol (5 min) and 70% ethanol (5 min). 
Slides then rinsed for 5 min in running tap water. Peroxidase (DAKO) applied to 
sections for 5 min and slides then washed in TBST (5 min). 
 
Antigen retrieval 
Slides placed in pressure cooker with 10 mM citrate buffer for 15 min and then 
allowed to cool for 20 min. Slides washed in TBST and Protein block (Dako) applied 
for 10 min. Primary antibody diluted in TBST and applied to section for 1 h. The 
primary antibody used was PDGFRA rabbit monoclonal antibody (D1E7E, Cell 
Signalling) at a dilution of 1:4000). Slides washed in TBST (4 x 3 min) then 
secondary antibody (Dako) applied for 30 min. Slides washed in TBST (4 x 3 min). 
ABC Elite Reagent (Vectastain) applied for 30 min then slides washed in TBST (4 x 
3 min).  DAB (1 drop chromogen in 1 ml buffer) applied to sections for 5 min then 
slides washed in TBST (2 x 3 min) then rinsed in running tap water.   
 
Counterstain 
6OLGHV VWDLQHG LQ 0D\HU¶V KDHPDWR[\OLQ IRU DSSUR[LPDWHO\  PLQ WKHQ ZDVKHG LQ
running tap water. Sections dehydrated by washing in 70% ethanol (3 min), 90% 
ethanol (3 min), 100% ethanol (2 x 3 min) and xylene (2 x 5 min). Slides then 
mounted, as previously described in section 2.4.4. 
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2.5 Sigma GenomePlex Whole Genome Amplification 
To perform whole genome amplification a Sigma GenomePlex Kit was used (Sigma-
Aldrich, Dorset). 1 µl of 10 X fragmentation buffer added to 10 ng template DNA (1 
ng/ul) in a PCR tube. Tubes placed in thermal cycler at 95oC for 4 min. Tubes cooled 
on ice. 1 µl 1 X library preparation buffer added to each tube followed by 1 µl 
library stabilisation solution. Tubes vortexed and placed in thermal cycler for 2 min 
at 95oC. Tubes cooled on ice. 1 µl library preparation enzyme added to each sample 
and tubes vortexed and briefly spun down. Tubes incubated in thermal cycler with 
the following programme; 
16oC of 20 min 
24oC for 20 min 
37oC for 20 min 
75oC for 5 min 
4oC hold 
 
Tubes briefly centrifuged and the following master mix was prepared and added to 
each sample; 7.5 µl 10X amplification master mix 
47.5 µl Nuclease-free water 
5 µl WGA DNA polymerase 
Tubes vortexed, briefly centrifuged and then placed in a thermal cycler with the 
following programme; 
Initial denaturation: 95oC for 3 min 
14 cycles of; 
Denature:                94oC for 15 s 
Anneal/extend:       65oC for 5 min 
 
Samples were stored at -20oC. DNA quality was checked by loading ~5 µl of 
amplified DNA on a 1.5% agarose gel. Mean DNA fragment size was  ~400 bp.  
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2.6 Fluorescence In Situ Hybridisation (FISH) 
FISH was performed on 3 µm paraffin sections on glass slides. Slides were baked in 
an oven overnight at 60oC. Tonsil sections were used as positive controls for all 
FISH experiments performed. 
Day 1 
Slides were placed in a rack then put in xylene for 3 x 5 min then 3 x 5 min in 100% 
ethanol. Slides were then put in a coplin jar with formalin fixative (10% phosphate 
buffered formalin, Sigma) for 1 h to fix the tissue. Whilst the slides were in formalin, 
the steamer was filled with distilled water and the slide container with citrate buffer 
and switched on to heat the citrate buffer.  
After an hour the slides were removed from the formalin fixative and washed in 
warm running water for 5 min. Slides were placed into the citrate buffer in the 
steamer for 1 h. After an hour the slides were removed and washed in warm running 
tap water for 5 minutes. Slides were placed into a coplin with Pepsin (Dako 8 mg/ml, 
320 mg in 40 ml 0.1 HCl) for 30 min then washed slides in cold running tap water 
for 5 min. Slides were rinsed in distilled water then air dried. 
Slides were placed in a coplin with Carnoy mild fixative (3 parts 100% methanol to 
1 part glacial acetic acid) for 30 min then air dried.  10ul of commercial FISH probe 
applied and covered with a coverslip. FISH probes used in this study; Vysis 1q25 
SpectrumGreen probe and 1p36 SpectrumOrange control probe (Abbott Molecular, 
Maidenhead, UK), Kreatech MYCN (2p24) specific PlatinumBright550 probe plus 
LAF (2q11) PlatinumBright495 control probe (Stretton Scientific, Stretton, UK), 
Kreatech p16 (9p21) PlatinumBright550 probe and 9q21 PlatinumBright495 control 
probe (Stretton Scientific). Slides placed in StatSpin Hybridiser (Dako) at 90oC for 
12 min then 37oC overnight.  
Day 2 
Slides placed in coplin with 2 x SSC for 30 min. Coverslips were removed gently 
taking care not to disturb the tissue. Slides placed into a coplin jar containing 4 M 
urea (4 M urea in 2 x SSC) for 2 min then returned to 2 x SSC for 1 min. Slides 
washed in distilled water for 1 min then air dried.  1 drop of DAPI mounting medium 
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(Vector Laboratories, Peterborough, UK) applied to a coverslip and the slide placed 
on top gently. Paint around coverslip with nail varnish to seal in DAPI mounting 
agent. Slides viewed and photographed on a Leica DMRB microscope with a Nikon 
camera using NIS Elements (Nikon) software at x100 magnification.  
Advice on scoring FISH, particularly in relation to 1q FISH, was given by the 
Cytogenetics Department at Nottingham City Hospital. 
 
2.7 Quantitative Real Time PCR 
Primers for quantitative real time PCR (qPCR) designed using Primer-BLAST, a 
tool developed by NCBI which uses Primer3 to design primers and then performs a 
BLAST search to avoid primer set that produce more than just the intended product.  
2.7.1 Primer optimisation 
A temperature gradient PCR was performed to determine the optimal annealing 
temperature for primers. A control DNA was used in the PCR with the following 
master mix: 
Reagent Volume (µl) 
Stratagene Brilliant SYBR Green qPCR Master 
Mix (Agilent Technologies) 12.5 
Forward Primer (1 µM) 2.5 
Reverse Primer (1 µM) 2.5 
H2O 6.125 
DNA (10ng) 1 
Reference Dye (1:500) (Agilent Technologies) 0.385 
 
Master mix placed in a PCR tube then put into thermal cycler with the following 
PCR programme: 
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Number of Cycles Time Temperature (oC) 
1 10 min 95 
40 30 s 95 
  1 min 56-62 
1 1 min 72 
 
 
PCR results were visualised on a 2% agarose gel. The annealing temperature which 
gives the brightest band on the gel, and therefore the most product, is the optimal 
temperature for the primers. 
Quantitative PCR uses a control gene with a normal copy number (2) in all the 
tumour samples in the study which is used as a normal to compare the gene of 
interest to. A normal control DNA is always run alongside tumour DNA to 
normalise the real time reaction. 
 
2.7.2 Primer Efficiencies 
The efficiencies of the primer sets need to be known as two sets of primers, one set 
for the control gene and one set for the gene of interest, are used in each experiment. 
To calculate primer efficiency, a serial dilution was set up for each primer set using a 
range of control DNA concentrations. All experiments were performed in triplicate 
and the average taken. The same master mix was used as for the temperature 
gradient PCR. 
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Table 2.5: Tube set up for qPCR. 
  1 2 3 
A 10 ng 10 ng 10 ng 
B 5 ng 5 ng 5 ng 
C 2.5 ng 2.5 ng 2.5 ng 
D 1.25 ng 1.25 ng 1.25 ng 
E 0.625 ng 0.625 ng 0.625 ng 
F negative Negative negative 
 
With each cycle of PCR SYBR green dye is incorporated into the DNA product and 
therefore fluorescence can be used to determine the amount of product generated in 
the reaction.  
The results of the efficiency PCR were viewed as an amplification plot (below). Ct 
values for each dilution were taken from the amplification graph at the point where 
the amplification curve crossed the fluorescent threshold of 250 Dr.  
The average Ct values for each dilution were plotted on an efficiency graph in the 
program and an efficiency value was calculated (Efficiency=10(-1/gradient of 
slope)-1).  
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 Efficiency Graph 
Figure 2.12: qPCR primer efficiency graph. 
2.7.3 The Pfaffl equation 
The efficiency values are used to calculate fold change of copy number in tumour 
samples using the Pfaffl equation. The Pfaffl equation is used rather than the more 
commonly used deltaCt equation as it takes into account primer efficiencies, so 
primer sets with different efficiencies can be used in the same reaction. For primer 
efficiencies to be used in the Pfaffl equation, add 1 to the efficiency value.  
Pfaffl Equation  
Fold Change = Efficiency target gene (( Ct target gene, control DNA) - (Ct target gene, tumour DNA)) 
                            Efficiency control gene ((Ct control gene, control DNA) - (Ct control gene, tumour DNA)) 
 
The value for fold change was multiplied by two to give a derived copy number for 
the target gene. 
  
 
 
 
 
 
 
 
 
 
CHAPTER 3 
PILOT STUDIES 
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3.1 SNP array analysis of FFPE DNA 
Affymetrix SNP array analysis was carried out on DNA isolated from an FFPE 
sample. There are many samples in this study that only have formalin-fixed tissue 
available for molecular analysis. SNP arrays provide the highest resolution 
molecular analysis and are routinely used with high quality DNA from frozen tissue. 
To determine if DNA isolated from FFPE tissue would be of sufficient quality for 
SNP analysis, DNA was isolated from an ))3(&1631(7VDPSOHXVLQJ$PELRQ¶V
RecoverAll Total Nucleic Acid Kit for FFPE. The DNA was hybridised to an 
Affymetrix 100K SNP chip (Affymetrix, Buckinghamshire, UK). 
The Affymetrix SNP array protocol involves digestion and ligation of the sample 
DNA followed by a PCR step. Following the PCR step the DNA concentration is 
measured using a spectrophotometer. The DNA concentration after the PCR step 
needs to be 900 ng/µl.  
 
The DNA concentrations after PCR for the DNA isolated from the FFPE sample 
were; 
 
 FFPE Xba1 sample = 376.43 ng/µl 
 FFPE HindIII sample = 355.4 ng/µl 
 
This is well below the required concentration. Two further PCR reactions were 
needed to reach the required concentration which used up expensive reagents and 
took a substantial amount of time. 
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The DNA is then purified and fragmented and then can be run on a gel to check that 
the fragmentation has been successful. 
 
 
 
Figure 3.1: Fragmentation gels of FFPE and frozen DNA. 
Although the FFPE DNA sample was not passing the QC steps the decision was 
made to complete the hybridisation and get a final result. The DNA was hybridised 
to a 100K Affymetrix SNP chip and scanned. The results of the hybridisation were; 
 
1. FFPE HindIII sample = 24.69% SNP call rate. 
2. FFPE Xba1 sample = 24.53% SNP call rate. 
 
The SNP call rate (the number of probes with intensity values that can be detected) 
should be 92% or higher and so no useful information could be determined about the 
FFPE result 
No clean result and 1st 
sample has not fragmented 
Expected result 
Clean fragmented 
products, no DNA of high 
molecular weight, average 
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sample from this result. It was therefore concluded that DNA isolated from FFPE 
samples was too degraded to be successfully analysed by SNP arrays. 
 
 
3.2  Pre-Pilot Study 
The pre-pilot study was designed to test the quality of results from Agilent¶V oligo 
aCGH platform when using DNA isolated from FFPE samples compared to DNA 
isolated from frozen samples.  The purpose of this pre-pilot study was purely to 
confirm that DNA isolated from a 10 year old FFPE sample would be of sufficient 
integrity to use for oligo aCGH. The pre-pilot study used four Agilent 44K oligo 
arrays with the following sample combinations; 
 
Array Cy3  Cy5 
1 Frozen Test Sample DNA vs. FFPE Test Sample DNA 
2 FFPE Test Sample DNA vs. Frozen Test Sample DNA 
3 :LOPV¶WXPRXUSRROHGEORRG vs. CNS PNET pooled blood  
4 CNS PNET pooled blood  vs. Wilm's tumour pooled blood 
 
The test sample is a CNS PNET tumour that had been hybridised to Affymetrix SNP 
arrays in a previous study. Using this sample meant that it would be possible to 
compare the oligo aCGH results with the SNP array results and check that the data 
corresponded. On arrays 1 and 2 frozen DNA is hybridised against FFPE DNA. 
There should be no differences between the both samples as DNA was isolated from 
the same tumour. Therefore any differences can be assumed to be caused by 
degradation of the DNA isolated from thH))3(VDPSOH:LOPV¶WXPRXUEORRGDQG
CNS PNET pooled blood control samples were hybridised on arrays 3 and 4 because 
many of the HGG samples do not have matched blood and so a pooled blood control 
ZRXOG EH XVHG 7KH EORRG IURP :LOPV¶ WXPRXU SDWLHQWV DQG CNS PNET patients 
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should both be normal (diploid) and so there should be no significant differences 
between the two blood samples.  
On each array there should be no differences between the two samples being 
hybridised. This means there should be equal binding of each sample to the probes 
on the array and therefore equal Cy3 and Cy5 signals detected by the scanner. When 
put into Agilent CGH Analytics Software the visual representation of aberrations 
should therefore be a straight line. 
The figure below shows WKHROLJRD&*+SURILOHRIµIUR]HQYVIL[HG'1$¶OHIWDQG
µEORRGYVEORRG¶ULJKW%RWKSURILOHVDUHWKHFRPELQHGUHVXOWVRIG\HVZDSV 
 
Figure 3.2D&*+SURILOHVRIIUR]HQ'1$YV))3('1$DQG:LOPV¶EORRGSRROHG
DNA vs CNS PNET pooled blood DNA. 
7KHSURILOHIRUWKHµIUR]HQYVIL[HG'1$¶LVVOLJKWO\OHVVVWUDLJKWWKDQWKHµEORRGYV
EORRG SURILOH¶ DQG WKis is probably due to DNA degradation of the DNA from the 
FFPE sample. However, the profile does not vary considerably from the zero line 
:LOPV¶EORRG'1$SRROHG 
vs.  
    CNS PNET blood pooled 
control 
Frozen CNS PNET DNA     
vs.  
FFPE CNS PNET DNA 
81 
 
which represents a diploid genome and so it was concluded that the FFPE DNA had 
worked sufficiently well to go ahead with a trial study. 
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3.3 The Pilot Study 
The pilot study was designed to answer a number of questions; 
 $UHWKHROLJRD&*+UHVXOWVZLWKµ)UR]HQ'1$YV&1631(7SRROHGEORRG¶
FRPSDUDEOHZLWKµ))3('1$YV&1631(7SRROHGEORRG¶" 
 Will whole genome amplification of DNA isolated from FFPE samples affect 
the oligo aCGH results? 
 If whole genome amplification is carried out on the sample DNA should it 
also be performed on the blood control DNA? 
 Are the results of oligo aCGH reproducible when using FFPE samples? 
 Are the results from oligo aCGH with FFPE tissue comparable with the 
results from SNP chip analysis with frozen tissue from the same tumour? 
 
To answer these questions the pilot study was designed as below; 
Array Cy3  Cy5 
1 Frozen CNS PNET DNA vs. CNS PNET pooled blood  
2 CNS PNET pooled blood  vs. Frozen CNS PNET DNA 
3 FFPE CNS PNET DNA vs. CNS PNET pooled blood  
4 CNS PNET pooled blood  vs. FFPE CNS PNET DNA 
5 WGA FFPE CNS PNET DNA vs. CNS PNET pooled blood  
6 CNS PNET pooled blood  vs. WGA FFPE CNS PNET DNA 
7 WGA FFPE CNS PNET DNA vs. WGA CNS PNET pooled blood  
8 WGA CNS PNET pooled blood  vs. WGA FFPE CNS PNET DNA 
9 WGA FFPE CNS PNET DNA vs. WGA CNS PNET pooled blood  
10 WGA CNS PNET pooled blood  vs. WGA FFPE CNS PNET DNA 
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The pilot study was performed on Agilent 105K oligo aCGH arrays, which have a 
lower resolution (15 Kb) than the 244K arrays that were used in the actual HGG 
study (6.4 Kb), but a higher resolution than the 44K arrays used in the pre-pilot study 
(35 Kb). Arrays 1, 2, 3 and 4 addressed the question as to whether profiles produced 
using FFPE DNA are of a reasonable quality when compared to profiles produced 
using frozen DNA. Array 5 and 6 showed the affect of whole genome amplification 
of the sample DNA on the oligo aCGH results. Arrays 7, 8, 9 and 10 showed the 
effect on the oligo aCGH results of carrying out whole genome amplification on the 
sample DNA and the control DNA, and also showed how reproducible the results are 
when using FFPE samples.  
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Results and Discussion 
$UH WKH ROLJR D&*+ UHVXOWV ZLWK µ)UR]HQ '1$ YV V 31(7 SRROHG EORRG¶
FRPSDUDEOH ZLWK µ))3( '1$ YV V31(7 SRROHG EORRG¶"
 
Figure 3.3: Comparison between frozen DNA and FFPE DNA profiles. 
These two oligo aCGH profiles illustrate the increased noise introduced when using 
FFPE DNA. However, there are no significant false aberrations on the FFPE DNA 
profile and so the data are still useful and informative.  
Frozen DNA  
vs   
Pooled Blood Control 
FFPE DNA  
vs  
Pooled Blood Control 
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FFPE DNA vs. 
Pooled blood control 
WGA FFPE DNA 
vs. Pooled blood 
control 
Will whole genome amplification of DNA isolated from FFPE samples affect the 
oligo aCGH results? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: The effect of DNA amplification on aCGH profiles. 
The profile on the left is non-amplified FFPE DNA and the profile on the right is 
amplified FFPE DNA. There is hardly any visible difference between the 2 profiles 
although the noise on the WGA arrays was higher than the non-amplified. However, 
the 2 profiles are of a comparable quality so where WGA is necessary due to 
insufficient DNA, oligo aCGH will still generate useful results. 
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If whole genome amplification is carried out on the sample DNA should it also 
be performed on the blood control DNA? 
 
Figure 3.5: The effect of DNA amplification on noise in aCGH. 
The array profile on the left had no amplification, the centre array had amplification 
of the sample DNA, and the array on the right had amplification of both the sample 
'1$DQGWKHFRQWURO'1$7KHµ:*$))3('1$YV:*$SRROHGEORRGFRQWURO¶
array is visibly noisier than the other 2 profiles, which is the expected outcome as the 
PRUHDPSOLILFDWLRQWKHPRUHQRLVHZRXOGEHSUHGLFWHG7KHDUUD\SURILOHVIRUµ))3(
'1$YV3RROHG%ORRG&RQWURO¶DQGµ:*$))3('1$YV3RROHG%ORRG&RQWURO¶
are very similar whilst WKHµ:*$))3('1$YV:*$SRROHGEORRGFRQWURO¶DUUD\
profile is considerably noisier. Therefore, if there is insufficient sample DNA then 
FFPE DNA  
vs.  
Pooled Blood Control 
WGA FFPE DNA  
Vs. 
 WGA Pooled Blood Control 
WGA FFPE DNA   
vs.       
Pooled Blood Control 
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whole genome amplification will be carried out on the sample DNA but not on the 
blood control DNA to keep noise to a minimum. 
Are the results of oligo aCGH reproducible when using FFPE samples? 
 
Figure 3.6: The reproducibility of aCGH using FFPE DNA. 
The array profiles above show small aberrations on chromosome 1q which have been 
accurately reproduced on each array run in the pilot study. WGA DNA was used as 
there was an abundance of WGA DNA available to run on three arrays. Although 
there is clearly more noise in the FFPE arrays than the frozen array, this figure shows 
that results of oligo aCGH when using FFPE are highly reproducible.  
Frozen DNA 
   vs 
Pooled Blood 
Control 
FFPE DNA 
vs 
Pooled Blood 
Control 
WGA FFPE DNA 
 vs 
WGA Pooled 
Blood Control 
WGA FFPE 
DNA  
vs 
WGA Pooled 
Blood Control 
WGA FFPE 
DNA 
 vs 
  Pooled Blood 
Control 
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Are the results from oligo aCGH with FFPE tissue comparable with the results 
from SNP chip analysis with frozen tissue from the same tumour? 
The reasons for completing the pilot study were to establish that DNA isolated from 
FFPE of considerable age, e.g. 10 years old, would be of sufficient quality for oligo 
aCGH on Agilent 105K arrays, but also to optimise the oligo aCGH protocol. The 
results of the pilot study were compared with a list of aberrations generated by SNP 
array analysis of DNA from a frozen sample from the same tumour. Overall the two 
methods had identified similar aberrations even though some aberrations seen in the 
SNP array analysis were not seen in the oligo aCGH analysis. This is to be expected, 
however, as the resolution of oligo aCGH on 105K arrays is less than SNP 100K 
arrays and of course poorer quality DNA isolated from FFPE tissue was used as 
opposed to DNA isolated from frozen tissue. 
 
Conclusion 
The pilot study has shown that DNA isolated from FFPE tissue can be of sufficient 
quality to be used for Agilent oligo array CGH and the results obtained from FFPE 
DNA are comparable with the ones generated using DNA isolated from frozen 
material.  
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 4 
SAMPLES 
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4.1 FFPE samples for oligo aCGH 
Primary and recurrent paediatric brain tumour samples were identified for entry into 
this VWXG\ IURP WKH &KLOGUHQ¶V &DQFHU DQG /HXNDHPLD *URXS &&/* DQG WKH
SDWKRORJ\ DUFKLYHV DW %LUPLQJKDP &KLOGUHQ¶V +RVSLWDO DQG WKH 4XHHQ¶V 0HGLFDO
Centre, Nottingham. All cases were centrally reviewed to determine histological 
diagnosis according to the 2000 WHO classification. Only cases of WHO grade III 
and IV gliomas were included in this study. 
DNA was isolated from ~80 FFPE high grade glioma samples. Those samples which 
produced enough DNA for aCGH underwent multiplex PCR, with only those 
samples producing at least the 200 bp band deemed high enough quality for aCGH. 
Several brainstem glioma samples were including despite failing the multiplex PCR 
QC step due to the rarity of these tumours. 38 FFPE samples were analysed by 
aCGH (Table 4.1). 
 
Table 4.1: 38 FFPE high grade glioma samples were run on Agilent 244K oligo 
arrays. 
Sample Sex 
Age at 
Diagnosis 
(yrs) Location 
Resection 
Status 
Sample 
taken 
pre/post 
treatment 
Reviewed 
Diagnosis Treatment 
Survival 
(Months) 
HGG1 M 5.8 Cerebral Complete 
Pre-
treatment GBM CT+RT 5 
HGG2 M 7.3 Cerebral Complete 
Post-
treatment GBM RT 6 
HGG3 M 4 Cerebral Subtotal 
Pre-
treatment GBM CT 3 
HGG4 M 6 Cerebral Complete 
Post-
treatment GBM RT+CT 12 
HGG5 M 1 Cerebral Biopsy 
Pre-
treatment GBM CT 27 
HGG6 F 1.2 
Posterior 
fossa Subtotal 
Pre-
treatment GBM CT >168 
HGG7 M 14.1 DIPG Biopsy 
Pre-
treatment GBM - - 
HGG8 F 6.7 Cerebral Subtotal 
Post-
treatment GBM RT 24 
HGG9 M 17.3 DIPG Biopsy 
Pre-
treatment LGA - 127 
HGG10 M - Cerebral Subtotal 
Post-
treatment GBM CT - 
HGG11 F 7.8 DIPG 
Post 
mortem 
Post-
treatment GBM CT+RT 5 
HGG12 M 8.8 Cerebral Complete 
Pre-
treatment AA RT >108 
HGG13 M 8.1 DIPG Biopsy Pre- GBM RT 9 
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treatment 
HGG14 M 16.1 DIPG Biopsy 
Pre-
treatment GBM - 35 
HGG15 M - Cerebral Subtotal 
Pre-
treatment AA CT+RT - 
HGG16 M 3.1  - - 
Post-
treatment AO - 21 
HGG17 M 18.9 Frontal lobe Subtotal 
Pre-
treatment GBM CT+RT 21 
HGG18 M 12 
 Parietal 
lobe Subtotal 
Pre-
treatment GBM CT+RT >78 
HGG19 F 3.8 DIPG Biopsy 
Pre-
treatment GBM RT 15 
HGG20 M 12.5 DIPG Biopsy 
Pre-
treatment GBM - 1 
HGG21 M 12.6 DIPG Biopsy 
Pre-
treatment GBM CT+RT 16 
HGG22 M - Frontal Biopsy 
Pre-
treatment GBM CT 1 
HGG23 F 5.8 Chiasm Subtotal 
Pre-
treatment GBM CT >70 
HGG24 F 2.4 Frontal lobe Subtotal 
Pre-
treatment AA CT >88 
HGG25 M 16.7 Parietal lobe Complete 
Pre-
treatment GBM RT >34 
HGG26 M 2.7 Frontal lobe Subtotal 
Pre-
treatment AO CT+RT >46 
HGG27 F 7.3 
Posterior 
Fossa Biopsy 
Pre-
treatment AO - - 
HGG28 M 7.3 DIPG Biopsy 
Pre-
treatment GBM CT+RT 10 
HGG29 M 0.1 Cerebral  Subtotal 
Pre-
treatment GBM - 4 
HGG30 M 12.8 Thalamus Subtotal 
Pre-
treatment GBM CT+RT 48 
HGG31 F 4.5 Frontal lobe Complete 
Pre-
treatment GBM CT+RT 20 
HGG32 F 4.5 Frontal lobe Complete 
Post-
treatment GBM CT+RT  20 
HGG33 M 2.9 Frontal lobe Complete 
Post-
treatment GBM RT 15 
HGG34 M 10.1 Cerebral  Subtotal 
Pre-
treatment GBM CT+RT 11 
HGG35 F 5.6 DIPG Biopsy 
Pre-
treatment GBM CT 11 
HGG36 M 12.3 DIPG Biopsy 
Pre-
treatment GBM RT 8 
HGG37 M 4.5 DIPG 
Post 
mortem 
Post-
treatment GBM CT+RT 5 
HGG38 M 13.3 DIPG 
Post 
mortem 
Post-
treatment GBM CT+RT 7 
  
GBM= glioblastoma, AA= anaplastic astrocytoma, AO= anaplastic oligodendroglioma, 
LGA=low grade astrocytoma, DIPG = diffuse intrinsic pontine glioma. 
The samples used for the aCGH study were 19 GBMs, three AO, three AA and 13 
brainstem gliomas. aCGH data for the 38 FFPE samples is publically available from 
1&%,¶V*HQ%DQNGDWDEDVHDFFHVVLRQQXPEHUGSE21420 
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The results were analysed using Agilent CGH Analytics Software version 3.1.14 
(Agilent Technologies). As expected DNA isolated from FFPE samples was of 
poorer quality than freshly extracted DNA due to the extensive cross-links formed 
between nucleic acids and proteins within cells by the formalin-fixation method. 
Pilot studies have shown that DNA isolated from FFPE tissue can be of sufficient 
quality to produce reliable, reproducible data that is comparable with results 
generated using DNA isolated from frozen tissue, using Agilent Oligo Array CGH. 
A multiplex PCR was used as a quality control (QC) step to make sure DNA samples 
were of sufficient quality for oligo array comparative genomic hybridisation 
(aCGH). 
The majority of the samples analysed by aCGH had passed the QC PCR step and so 
had produced a PCR product of 200bp or greater. However, a number of samples 
that were brainstem tumours were analysed by aCGH without having passed this QC 
step because of the rarity of these samples.  
CGH Analytics has a number of in-built QC measures. The most important QC 
measure for low quality DNA is the Derivative Log Ratio spread (DLR spread). The 
DLR spread calculates the differences between the log2 ratio values of adjacent 
probes, and so gives a measure of noise. The DLR spreads for the combined dye 
swaps of all the FFPE samples run are displayed in the table below. 
Table 4.2: Multiplex PCR results and DLR Spreads of 38 HGG Samples. 
Sample Multiplex PCR DLR Spread 
HGG1 400bp 0.61 
HGG2 200bp 0.56 
HGG3 400bp 0.37 
HGG4 400bp 0.30 
HGG5 200bp 0.82 
HGG6 200bp 0.63 
HGG7 400bp 0.32 
HGG8 300bp 0.39 
HGG9 300bp 0.50 
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HGG10 400bp 0.36 
HGG11 400bp 0.70 
HGG12 300bp 0.57 
HGG13 no pcr 0.90 
HGG14 no pcr 0.91 
HGG15 no pcr 1.03 
HGG16 400bp 0.54 
HGG17 400bp 0.47 
HGG18 400bp 0.70 
HGG19 no bands 0.61 
HGG20 300bp 0.51 
HGG21 300bp 0.43 
HGG22 200bp 0.39 
HGG23 200bp 0.35 
HGG24 400bp 0.33 
HGG25 200bp 0.41 
HGG26 400bp 0.43 
HGG27 300bp 0.62 
HGG28 400bp 0.34 
HGG29 200bp 0.71 
HGG30 200bp 0.46 
HGG31 400bp 0.47 
HGG32 300bp 0.38 
HGG33 400bp 0.63 
HGG34 400bp 0.40 
HGG35 200bp 0.61 
HGG36 no pcr 1.02 
HGG37 no pcr 0.54 
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HGG38 no pcr 0.80 
 
As expected, the DLR spread values vary widely between samples. The samples 
which, on average, gave the best results in the QC PCR step have the lower DLR 
spreads, i.e. have the lowest level of noise.  Agilent guidelines suggest that good 
quality FFPE samples should give a DLR spread of <0.4. Most of the samples fall 
within or just outside the acceptable DLR spread range according to the Agilent 
protocol, however a number of samples do not. These very noisy samples were 
carefully analysed to determine whether there was any usable data. CGH Analytics 
XVHVYDULRXVILOWHUVDQGDOJRULWKPVWRILOWHURXWµQRLVH¶LQDYDULHW\RIZD\V)RUQRLV\
data, such as the data in the study from degraded DNA samples, the z-score 
algorithm is the most appropriate.  
Due to the wide range in DLR spread across the samples in this study, the samples 
were divided into three groups depending of their DLR spread value with group 1 
being the cleanest and group 3 being the noisiest. The settings for the noise filters 
and z-score algorithm were altered slightly for each group meaning the noisiest 
samples could have more stringent noise filtering than the good quality samples. 
This also meant that small aberrations in the clean samples were not lost by applying 
overly stringent filters to those samples. 
Table 4.3: Groups based on DLR spread 
Group Z-score Threshold Minimum number 
of aberrant probes 
Minimum number 
of aberrant regions 
1 3.5 3 100 
2 3.5 4 100 
3 4.0 4 100 
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4.2: Tissue MicroArrays (TMAs) 
The high grade glioma TMAs were constructed from 152 FFPE samples.  Areas of 
viable and representative tumour following review of paraffin blocks were marked 
by the reviewing pathologist before inclusion into the TMA. 3 x 0.6mm cores were 
included for each tumour. TMAs are an efficient way to screen large numbers of 
FFPE tumour samples for specific aberrations in copy number and expression levels. 
The TMAs were used in this study for FISH and IHC experiments.  
 
Table 4.4 TMA samples clinical information 
Sample Sex 
Age at 
Diagnosis 
(yrs) 
Tumour Site Resection Partial/Complete 
Reviewed 
diagnosis 
Primary/ 
Recurrence Treatment 
Survival 
Time 
(Months) 
1 M 2.3 Parietal Lobe Subtotal GBM  Primary CT 3 
2  - 
-  
-  -  GBM Primary   - 
-  
3 F 8.1 Frontal Lobe Subtotal SC GBM Post ALL  - 3 
4 F 14.3 Parietal Lobe Subtotal GBM Primary CT+RT 20 
5 F 4.3 Temporal Lobe Complete GBM Primary CT+RT 24 
6 F 
9.2 
Frontal lobe Biopsy GBM 
Post ALL 
(post 
radiation) 
CT+RT 
29 
7 F 4.3 Parietal Lobe Subtotal GBM Primary RT 30 
8 M 1.1 Parietal Lobe Subtotal GBM Primary -    
9 M 4.7 Occipital Lobe Subtotal GBM Primary CT+RT 4 
10 M 9.3 Frontal lobe Complete GBM Primary CT+RT 29 
11 M 
 - 
 - Subtotal GBM 1st 
recurrence 
 - 
- 
12 M 10.2 Temporal Lobe Complete GBM Primary CT+RT 7 
13 M 2.9 Frontal lobe Total GBM Primary CT 15 
14 F 3.6 Frontal lobe Subtotal GC GBM Primary CT  - 
15 M 7.3 Thalamus Subtotal GBM Primary RT  - 
16 M 9.8 Frontal lobe Subtotal GBM Primary CT+RT 12 
17 M 6.7 Frontal lobe Subtotal AA Primary RT 7 
18 M 8.4 Brain Stem/Pons Biopsy GBM Primary   2 
19 M 10.9 Frontal lobe Complete GBM Primary CT+RT 4 
20 M 
 - 
Frontal lobe Subtotal AA Primary   3 
21 M 4.8 Brain Stem/Pons Biopsy GBM Primary RT 6 
22 M 10.1 Cerebral Subtotal GBM Primary CT+RT  - 
23 M 
 - 
-  -  GBM -   - 
-  
24 M 
 - 
 -  - GBM  -  - 
 - 
25 F 8.5 Thalamus Biopsy AA Primary CT+RT 15 
26 F 4.5 Frontal lobe Complete GBM Primary CT+RT 20 
27 F 
 - 
Frontal lobe Complete GBM 1st 
recurrence 
-  
-  
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28 F 3.3 Temporal Lobe Subtotal HGG Primary  - 3 
29 M 12.3 Brain Stem/Pons Biopsy GBM Primary RT 8 
30 F 7.6 Thalamus -  AA Primary  - 0 
31 F 
 - 
Parietal Lobe  - GBM Primary  - 0 
32 F 4.3 Temporal Lobe Complete GBM Primary CT+RT 24 
33 M 7.7 Pineal Gland Biopsy GBM Primary CT 5 
34 M 
  
Pineal Gland Subtotal GBM 1st 
recurrence 
-  
-  
35 M 12.8 Thalamus Subtotal GBM Primary CT+RT  - 
36 M 
 - 
 -  - GBM 1st 
recurrence 
-  
 - 
37 M 7.3 Brain Stem/Pons Biopsy GBM Primary CT+RT 10 
38 M 
 - 
Frontal lobe Complete GBM 1st 
recurrence 
RT 
-  
39 M 
 - 
Frontal lobe  - GBM  - -  
-  
40 F 
-  
Frontal lobe Subtotal GC GBM Primary 
second op -   - 
41 M 9.0 Temporal Lobe  - AA Primary  -  - 
42 M 
 - 
Temporal Lobe Complete AA 1st 
recurrence 
CT 
-  
43 M 0.1 Cerebral Subtotal GBM Primary  - 4 
44 F 5.6 Brain Stem/Pons Biopsy GBM Primary CT 11 
45 F 5.7 Brain Stem/Pons Subtotal GBM Primary  - 5 
46 M 14.1 Cerebral Subtotal GBM Primary RT -  
47  - 
 - 
Cerebral Subtotal  GBM 1st 
recurrence 
CT 
-  
48 M 1.0 Cerebral Biopsy GBM Primary CT 27 
49 M 2.4 Cerebral Complete GBM 
1st 
recurrence 
CT 10 
50 M 2.5 Cerebral Complete GBM -  CT 9 
51 M 2.8 Cerebral Complete AA Primary CT  - 
52 F 2.0 Cerebral Subtotal AA Primary CT  - 
53 M 5.8 Cerebral Complete GBM Primary CT+RT 5 
54 M 5.8 Cerebral Complete GBM Primary CT+RT 5 
55 M 
7.3 
Cerebrum Complete GBM 
post ALL 
(post 
radiation) 
CT+RT 
6 
56 M 3.8 Cerebral Biopsy GBM Primary CT 5 
57 M 4.3 Brain Biopsy 
Gliomatosis 
cerebri grade III Primary CT 16 
58 F 8.1 Cerebral  - GBM  - -  -  
59 M 13.1 Cerebral  - 
Gliomatosis 
cerebri grade III  -  -  - 
60 M 1.8 Brain Biopsy GBM Primary CT 3 
61 M 4.0 Cerebral Subtotal GBM Primary CT 3 
62 M 0.5 Cerebral Biopsy GBM Primary  -  - 
63 M 6.5 Cerebral Complete GBM 
1st 
recurrence 
CT+RT 12 
64 F 12.3 Brain Biopsy AA Primary CT+RT -  
65 F 16.3 Brain Biopsy GBM Primary CT+RT 15 
66 F 14.1 Cerebral Complete GBM Primary CT+RT 8 
67 F 0.7 Brain stem Biopsy AA Primary CT+RT 89 
68 F 1.2 Posterior fossa Subtotal GBM Primary CT  - 
69 F 10.6 Brain stem Biopsy AA Primary CT+RT 18 
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70 F 15.3 -  -  GBM  - -  -  
71 F 4.6  - Biopsy small cell GBM Primary  -  - 
72 M 10.1 Brain Biopsy AA Primary CT+RT 10 
73 M 4.3 Spine Complete GBM Primary CT+RT  - 
74 F 18.8 Cerebral Subtotal AA Primary  -  - 
75 M 0.0 Brain Biopsy AA Primary CT -  
76 F 6.7 Cerebral Subtotal GBM 
1st 
recurrence 
RT 24 
77 M 
- 
right occipital 
lobe Subtotal GBM  - CT  - 
78 M  - right parietal Complete small cell GBM Primary RT  - 
79 F -  
temporal parietal 
lobe Biopsy GBM 
Post C. 
ALL (1986) RT  - 
80 M 16.6 cerebellum Complete GBM Primary CT  - 
81 
  0.0  - Complete GBM Primary  -  - 
82 F  - hypothalamic Subtotal GBM Primary CT  - 
83 M  - brainstem Complete GBM Primary RT  - 
84 M 
 - 
Temporal Lobe Complete AA 1st 
recurrence 
CT 
 - 
85 M 6.7 Frontal lobe Subtotal GBM Primary RT 7 
86 M  - cerebellum Biopsy AA Primary RT  - 
87 F  - 
right 
thalamus/midbrain Biopsy AA Primary RT  - 
88 M  - spinal cord Complete GBM Primary RT  - 
89 M 10.7 left parietal Complete AA Primary CT+RT  - 
90 M  - Brain stem Biopsy LGA Primary -  - 
91 F  - Brainstem Biopsy BSG Primary CT+RT  - 
92 M  - brainstem Biopsy AO Primary -  - 
93 M  - Brain stem Subtotal BSG Primary At LRI  - 
94 M 
 - 
Cerebral Subtotal AA Primary CT+RT 
 - 
95 F  - Brain stem Biopsy BSG Primary  -  - 
96 M  - cerebellum Complete BSG Primary -  - 
97 F  - Brain stem Biopsy BSG Primary RT  - 
98 M  -  - Subtotal BSG Primary -  - 
99 M  - cerebral Complete AA Primary RT  - 
100 F -  Brain stem Biopsy LGA Primary -  - 
101 M 0.7 Brain stem  - BSG Primary CT -  
102 F  - Brain stem Biopsy LGA Primary CT+RT -  
103 F  - cerebral Complete AO Primary CT  - 
104 
 - -   - Complete LGA Recurrence -  - 
105 
M 7.0 Cerebral Complete 
Anaplastic 
pleomorphic 
xantroastrocytoma Primary RT  - 
106 F 14.0 
R Parieto-
occipital Subtotal AO Primary CT+RT  - 
107 M 17.1 L Basal Ganglia Biopsy AA Primary CT  - 
108 M 18.9 R Frontal lobe Subtotal GBM Primary CT+RT  - 
109 M 12.0 L Parietal lobe Subtotal GBM Primary CT+RT  - 
110 M 12.5 Brain stem Biopsy BSG   -  - 
111 M 13.0 Brain stem Biopsy BSG Primary RT  - 
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112 M 19.6 Brain stem Biopsy BSG Primary CT+RT -  
113 M 12.6 
Brain 
stem/cerebellum Biopsy BSG Primary CT+RT  - 
114 F 3.8 Brain stem Biopsy BSG Primary RT  - 
115 M 3.3 Brain stem Subtotal BSG Primary RT  - 
116 F 5.8 Chiasm Subtotal GBM primary CT >70 
117  - 0.0  -  - GBM  -  -  - 
118 M 2.7 Frontal Subtotal AO primary CT+RT >46 
119 M 0.6 Frontal Biopsy GBM primary CT 1 
120  - 0.0  - -  
Gliomatosis 
cerebri III  - -  -  
121 F 2.4 Frontal Subtotal AA primary CT >88 
122  - 0.0 -   - AO -  -  -  
123 M 16.7 Parietal Complete GBM primary RT >34 
124 M 5.2 Suprasellar Biopsy AA Primary  -  - 
125 F 5.5 Suprasellar Complete  AA Primary -   - 
126 M 10.3 Frontal lobe Biopsy GBM Recurrence  - -  
127 M 17.3 Frontal lobe Biopsy AO Primary  - -  
128 F 7.3 Posterior Fossa Biopsy AO Primary -  -  
129 M 8.4 Brain Stem/Pons Biopsy GBM Primary  - 2 
130 F 5.7 Brain Stem/Pons Subtotal GBM Primary  - 5 
131 M 7.3 Brain Stem/Pons Biopsy GBM Primary CT+RT 10 
132 M 
9.8 
Suprasellar 
(corpus callosum) Biopsy AA Primary CT 
-  
133 F 
15.7 
Diffuse right 
frontal lobe Biopsy AA Primary CT 
-  
134  - 0.0  -  - GBM  -  -  - 
135  - 0.0  -  - GBM Primary  -  - 
136  - 0.0  -  - AO  -  -  - 
137 M 
1.6 
right fronto-
temporal lobe 
 - AO Primary  - 
 - 
138  - 2.6  -  - AO 
1st 
recurrence 
 - 
 - 
139  - 3.1  -  - AO  -  -  - 
140 
 -    -  - 
DIPG 
 -  -  - 
GBM=glioblastoma, AA=anaplastic astrocytoma, AO=anaplastic oligodendroglioma, DIPG=diffuse 
intrinsic pontine glioma, BSG=brainstem glioma, LGA=low grade astrocytoma, -  = information 
unknown.  
 
 
The majority of samples used for the aCGH analysis were included in the TMA 
(35/38). The table below lists the FFPE samples included in the aCGH study 
alongside the corresponding location of the samples on the TMA. 
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Table 4.5: Location of aCGH Samples on the TMAs. 
FFPE Sample for aCGH Location on TMA 
HGG1 TMA 53 
HGG2 TMA 55 
HGG3 TMA 61 
HGG4 TMA 63 
HGG5 TMA 48 
HGG6 TMA 68 
HGG7 TMA 96 
HGG8 TMA 76 
HGG9 TMA 90 
HGG10 TMA 47 
HGG11 TMA 140 
HGG12 TMA 99 
HGG13 not on TMA 
HGG14 TMA 93 
HGG15 TMA 94 
HGG16 TMA 139 
HGG17 TMA 108 
HGG18 TMA 109 
HGG19 TMA 114 
HGG20 TMA 110 
HGG21 TMA 113 
HGG22 TMA 119 
HGG23 TMA 116 
HGG24 TMA 121 
HGG25 TMA 123 
HGG26 TMA 118 
HGG27 TMA 128 
HGG28 TMA 131 
HGG29 TMA 43 
HGG30 TMA 35 
HGG31 TMA 26 
HGG32 TMA 27 
HGG33 TMA 38 
HGG34 TMA 22 
HGG35 TMA 44 
HGG36 TMA 29 
HGG37 not on TMA 
HGG38 not on TMA 
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5.1 Excel analysis of chromosome arm aberrations 
A summary of chromosome arm gains and losses was compiled using the original 
WH[WILOHVJHQHUDWHGE\WKH$JLOHQWVRIWZDUHµ)HDWXUH([WUDFWLRQ¶YHUVLRQ7H[W
files were modified in Microsoft Excel and then split into separate chromosome files.  
Each probe on the array is given a log2 ratio value by the Feature Extraction 
software.  A gain of one copy of a gene has a log2 ratio of 0.58 (3/2 ratio), a gain of 
two copies has a log2 ratio of 1 (4/2 ratio), etc. Because the data are from FFPE DNA 
there is a level of noise which has to be taken into account. The samples are split into 
3 groups depended on the DLR spread, which is basically a measure of noise. Group 
1 samples are the least noisy samples and group 3 the noisiest. 
 
Table 5.1: Cut Off Levels for Probe Gains and Losses; 
  Loss cut off 
(log2ratio) 
Gain cut off 
(log2ratio) 
Group 1 < -0.51 > 0.3 
Group 2 & 3  < -0.6 > 0.25 
 
Excel work-flow 
 Values in original txt file generated by Feature Extraction are log10. 
 
Convert log10 to log2;     log10 to linear:      10x 
                           In excel:       =POWER(10,REF) 
 
        Linear to log2:        ln(n) 
       ln2 = log2 
        In excel:       =LOG(REF,2) 
 Dye swap txt files (log2 ratios) combined: =((REF1+(-REF2))/2) 
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To summarise arm gains and losses; 
 Log2 ratios copied into an excel worksheet matched with probes and 
chromosomal location. 
 
FORMULAS; (using group1 values) 
 
Probes on whole chromosome: COUNTA(REF1:REFEND) 
Probes on p arm:                       COUNTA(REF1:REFp) 
Probes on q arm:                       COUNTA(REFq:REFEND) 
       
% Probes lost on whole chromosome: 
&2817,)5()5()(1'´´whole*100       
 
3UREHVORVWRQSDUP&2817,)5()5()S´´p*100 
 
% Probes lost on q arm: &2817,)5()T5()(1'´´q*100 
 
% Probes gained on whole chromosome: 
&2817,)5()5()(1'!´´whole*100 
 
3UREHVJDLQHGRQSDUP&2817,)5()5()S!´´p*100 
3UREHVJDLQHGRQTDUP&2817,)5()T5()(1'!´´q*100 
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A cut-off level of 50% was used to determine arm gain or loss, i.e. 50% or more of 
the probes on a chromosome arm would have to show gain for the whole arm to be 
classed as gained. Chromosome arm gain and loss in the 38 FFPE samples is 
displayed in table 5.2. 
 
Table 5.2: Chromosome arm gain and losses from Excel analysis. 
Chromosome Arm Gain (%) Loss (%) 
1p 0 8 
1q 21 0 
2p 3 0 
2q 3 0 
3p 0 3 
3q 3 3 
4p 0 3 
4q 3 8 
5p 8 3 
5q 3 5 
6p 0 3 
6q 3 5 
7p 3 0 
7q 3 0 
8p 0 3 
8q 3 3 
9p 5 5 
9q 5 0 
10p 0 5 
10q 0 10 
11p 0 0 
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11q 0 0 
12p 5 3 
12q 5 0 
13q 3 10 
14q 0 5 
15q 3 0 
16p 3 5 
16q 0 8 
17p 8 3 
17q 8 0 
18p 0 8 
18q 3 3 
19p 15 0 
19q 8 0 
20p 0 3 
20q 3 0 
21p 10 8 
21q 0 5 
22q 3 3 
 
 
Chromosome 1q is gained in 21% of samples, and has been shown to be gained in 
other paediatric brain tumours. Other noticeable gains are 19p (15%), 17p and q 
(8%), 21p (10%). Noticeable losses are 1p (8%), 10q (10%), 13q (10%). It is worth 
noting that chromosomes 19, 20, 21 and 22 have higher noise levels in the array 
CGH data compared to the other chromosomes, which may account for the high 
values for these chromosome arm gains and losses. Noise levels can vary from 
chromosome to chromosome due to the location of the probes within the 
chromosomes and the probe design. 
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5.2 CGH Analytics analysis of chromosome arm aberrations 
Calculating arm gain/loss in Microsoft Excel had the advantage of having definite 
numerical cut off values for gain or loss of individual probes and so for chromosome 
arms. However, in excel there are no noise filters and no way of centralising the data 
as in CGH Analytics. Because of this a visual analysis of chromosome arm gain and 
loss was looked at in CGH Analytics. 
The samples were separated into three groups based on their DLR spread and 
appropriate probe filters and z-score level applied (previously described). Every 
chromosome for each sample was looked at individually and if it appeared that over 
half the arm was lost or gained then it was noted as a whole arm loss or gain.  
There are various ways of viewing chromosome arms in CGH Analytics. The 
µFKURPRVRPH YLHZ¶ VKRZV DQ LQGLYLGXDO FKURPRVRPH IRU RQH RU D QXPEHU RI
samples.  
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Figure 5.1: Chromosome view showing normal and aberrant chromosome 1.  
7KHFRQWLQXRXVZDY\OLQHUHSUHVHQWVWKHµPRYLQJDYHUDJH¶RIWKHORJUDWLRYDOXHVRI
the probes on the array. On the chromosome view showing the normal, balanced 
FKURPRVRPH FRS\QXPEHU WKHPRYLQJDYHUDJH IROORZV WKH µ¶ OLQH meaning 
that there is no difference between the tumour sample and the control sample. On the 
right hand chromosome view, the moving average line moves away from the 0 line 
into the negative values on 1p and then into positive values on 1q. This represents a 
loss of 1p and gain of 1q. The shaded areas beneath the moving average line and the 
solid straight lines alongside the moving average line show the aberrant regions, as 
defined by the filters applied by the user.   
CGH analytics can generate heat maps of individual chromosomes for a selected 
group of samples, e.g. chromosome 1 below: (red is gain, green is loss) 
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Figure 5.2: Heatmap of chromosome 1. 
 
Having the ability to look at the data visually is useful for noisy data as it is often 
obvious where an DEHUUDWLRQ LV µUHDO¶ RU LV GXH WR D KDQGIXO RI SUREHV LQ D QRLV\
region.  
Using both the chromosome view and heat maps generated by CGH Analytics a 
summary of chromosome arm gain/loss in the 38 FFPE samples was generated.  
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Table 5.3: Chromosome arm gains and losses from CGH Analytics analysis. 
Chromosome Arm  Gain (%) Loss (%) 
1p   8 
1q 22   
2p 3   
2q 3 3 
3p 3   
3q   3 
4p   3 
4q   8 
5p 11 3 
5q 3 5 
6p 8 3 
6q 5 11 
7p 5   
7q 8   
8p   5 
8q 3   
9p 8   
9q 5   
10p   5 
10q   18 
11p   3 
11q   3 
12p 5 3 
12q 3 3 
13p     
13q   11 
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14q   13 
15q 3 8 
16p 5 11 
16q   13 
17p 8 13 
17q 11 5 
18p   8 
18q   3 
19p 3 11 
19q 3 11 
20p 5 3 
20q 5 3 
21p     
21q   3 
22p     
22q 5 13 
 
 
5.3 Excel vs CGH Analytics 
Overall, both methods of determining chromosome arm gain/loss have given very 
similar results for the majority of chromosome arms. Gain of 1q is the most common 
chromosome aberration in both cases, with loss of 10q being the second most 
common. Where there are discrepancies between the two methods, they are minor 
for most chromosomes. However, results for 6p, 19p, 19q, 21p and 22q are different 
for the two methods.  
By CGH Analytics analysis, three samples had gain of 6p but by the Excel 
calculation no samples had gain of 6p. The gains of 6p seen in CGH Analytics were 
not of the whole arm, but the majority of the arm. As 50% of the probes had to be 
gained in the excel calculations to call the arm as µJDLQHG¶HYHQWKRXJKPRUHWKDQ
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half the arm was shown to be gained in CGH Analytics the noise in the data  may 
have led to less than 50% of the probes on the arm having log2ratio values above the 
µJDLQ¶FXWRII 
Chromosome 19 was the noisiest chromosome in this study. This was predicted by 
Agilent, the company who produce the oligo arrays used in this study, as designing 
probes for chromosome 19 is notoriously difficult.  The discrepancy between the 
results for chromosome 19 arm gains/losses by CGH Analytics and Excel can be 
explained by the noise on this chromosome. The same is true for chromosome arm 
21p, but to a lesser extent. The excel calculations showed 10% samples having gain 
of 21p and 8% having loss, whilst CGH Analytics showed no gain or loss for 21p. 
The noise filters and centralisation algorithms that can be applied to the data in CGH 
Analytics can remove noise that may lead to false gains/losses, as shown on 21p. 
Loss of 22q was seen in 13% samples in CGH Analytics, but only 3% samples in 
Excel. In many cases, the majority but not all of 22q was lost and as with 6p and so 
the cut off for chromosome arm loss in Excel may have been too stringent to call the 
arm as lost. 
The CGH Analytics analysis gives a more accurate representation of chromosome 
arm gain/loss as it is able to take into account noise and more importantly, can 
centralise the data by finding the most common log2ratio and so remove the false 
chromosome loss seen in the Excel analysis. Therefore, the CGH Analytics data will 
be used in further discussion and analyses. 
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Chromosome arm gains and loss were seen across the genome (Figure 5.3). Some 
samples had numerous whole arm aberrations whilst other samples showed none 
(Table 5.4). 
Table 5.4: Chromosome arm gain and loss in 38 HGG samples. 
Sample Gain Loss 
HGG1 17p, 17q   
HGG2 1q, 12p 13q 
HGG3     
HGG4 17p, 17q 9p, 10p, 10q, 22q 
HGG5     
HGG6     
HGG7 5p, 5q, 6p, 6q, 7p, 7q, 20p, 20q   
HGG8     
HGG9     
HGG10 1q  9p  
HGG11 17p  14q 
HGG12     
HGG13 1q 14q, 16p, 16q, 17p 
HGG14     
HGG15     
HGG16 1q, 17q 10q, 16q 
HGG17 1q, 9q 4q, 9p, 3q, 10q 
HGG18 22q   
HGG19     
HGG20 1q 1p, 4q, 6q, 10q, 13q 
HGG21     
HGG22 5p, 7q 1p, 6q, 10q 
HGG23     
HGG24 16p, 16q   
HGG25 2p, 2q, 3p, 5p, 6p, 7p, 7q, 8q, 12p, 
12q, 15q, 16p, 16q, 17q, 19p, 19q, 
20p, 20q 
6q, 8p, 
HGG26 6p, 6q 22q 
HGG27 1q   
HGG28   6p, 6q, 14q, 16p, 16q, 17p, 19p, 19q, 22q 
HGG29 22q   
HGG30 5p 4p, 4q, 5q, 8p, 10p, 10q, 11p, 11q, 12p, 12q, 13q, 
14q, 15q, 16p, 17p, 17q, 18p, 19p, 19q, 21q, 22q 
HGG31     
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HGG32     
HGG33     
HGG34     
HGG35 1q 1p 
HGG36   16p, 16q, 17p, 17q, 19p, 19q, 20q, 22q 
HGG37   5p, 5q, 13q, 14q, 15q, 16q, 17p, 18p, 18q, 19p, 
19q, 20p 
HGG38 9q 5q, 18p 
p = the short arm of the chromosome, q = the long arm of the chromosome. 
Overall, loss was more common than gain with 82 chromosome arms lost compared 
to 52 gained.15/38 samples showed no chromosome arm gains or losses, whilst three 
samples showed 10 or more chromosome arm aberrations. It has been previously 
reported that tumours occurring in younger children have less genomic copy number 
aberrations than those in older children. 12/15 samples with no chromosome arm 
DEHUUDWLRQV KDG µDJH DW GLDJQRVLV¶ GDWD DYDLODEOH DQG   VDPSOHV ZHUH LQ
children under five years. Of the 23 samples with chromosome arm aberrations 22 
KDG µDJH DW GLDJQRVLV¶ GDWD DYDLODEOH DQG   VDmples were from children 
under five.   
There is one primary/recurrent pair within the data set; samples HGG31 (primary) 
and HGG32 (recurrence). Both the primary and recurrent tumour had no 
chromosome arm aberrations. 
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5.4 Chromosome arm aberrations in brainstem gliomas 
Chromosome arm aberrations in brainstem gliomas are displayed in Table 5.5. 
Table 5.5: Chromosome arm gain and loss in 13 brainstem tumours. 
Sample Gain  Loss 
HGG7 5p,5q,6p,6q,7p,7q,20p,20q   
HGG9     
HGG11 17p  14q 
HGG13 1q 14q,16p,16q,17p 
HGG14     
HGG19     
HGG20 1q 1p,4q,6q,10q,13q 
HGG21     
HGG28   6p,6q,14q,16p,16q,17p,19p,19q,22q 
HGG35 1q 1p 
HGG36   16p,16q,17p,17q,19p,19q,20q,22q 
HGG37   5p,5q,13q,14q,15q,16q,17p,18p,18q,19p,19q,20p 
HGG38 9q 5q,18p 
p = the short arm of the chromosome, q = the long arm of the chromosome. 
As with the other high grade gliomas, there is a wide variety in frequency of 
chromosome arm gain/loss in the brainstem tumours. Four of the 13 brainstem 
tumours show no chromosome arm aberrations whilst one sample shows more than 
ten arm aberrations. There a number of notable differences between the frequencies 
of chromosome arm aberrations in brainstem gliomas and non-brainstem high grade 
gliomas. 10q, which is frequently lost in adult high grade gliomas, is lost in 18% of 
all high grade tumours but only 1/13 (8%) brainstem gliomas. Across all the samples 
in this study there are five losses of 17p with four of those losses occurring in 
brainstem gliomas. Therefore, 4/13 (31%) of the brainstem gliomas samples have 
loss of 17p compared to 1/25 (4%) in the rest of the high grade glioma cohort (see 
115 
 
Figure 5.4). 14q is lost in four of the 13 brainstem gliomas (31%) but only one of the 
non-brainstem tumours. 
 
 
Figure 5.4: Ideogram showing all areas of gain and loss on chromosomes 1, 4, 14 and 17 in 
25 high grade glioma samples and 13 DIPG. Red indicates regions of gain and green 
indicates regions of loss. 
 
 
 
 
 
 
 
 
 
 
 
116 
 
5.5 Discussion 
High resolution aCGH analysis of pHGG samples has identified widespread 
chromosome arm gains and losses. This study includes the largest cohort of 
brainstem gliomas to date (13) plus 25 non-brainstem high grade gliomas. By 
comparing brainstem and non-brainstem HGG some site related differences in 
chromosome arm aberrations were found. Overall, 39% of chromosome arm 
aberrations were gains and 61% were losses. The higher frequency of chromosome 
arm losses suggests that the mechanism of oncogenesis in these tumours is most 
commonly loss of tumour suppressor genes. However, aCGH only shows copy 
number alterations, and recent studies have shown mutations and epigenetics 
alterations to be important in oncogenesis. Therefore, the mechanisms of 
oncogenesis in these tumours can not be completely determined from aCGH data.  
 
Gain of 1q has been previously reported as the most common whole chromosome 
arm abnormality in paediatric high grade glioma, as seen in this study. Gain of 1q is 
commonly seen in paediatric brain tumours including CNS PNETs, ependymoma 
and high grade glioma (Dyer, Prebble et al. 2002; Pfister, Remke et al. 2007; Paugh, 
Qu et al. 2010). In this study 22% of high grade gliomas demonstrated gain of 1q 
whilst only 9% of adult high grade gliomas have been reported to have gain 1q 
(TCGA 2008). A similar pattern of high frequency of 1q gain in children compared 
to adult tumours is seen in ependymoma (Dyer, Prebble et al. 2002). 23% of 
brainstem tumours in this study have gain of 1q which is comparable to the level of 
gain seen in other paediatric high grade glioma. Why 1q gain is seen so frequently in 
paediatric tumours is unknown although certain genes have been implicated as being 
the oncogenic culprits. The gene MUC1 (1q21) has been suggested as a potentially 
important oncogene in CNS PNETs, and gain of MUC1 was shown to be associated 
with poor prognosis in these tumours (Pomeroy, Tamayo et al. 2002). Gain of 1q has 
been associated with poorer outcome in other paediatric brain tumours (Dyer, 
Prebble et al. 2002; Mendrzyk, Korshunov et al. 2006). 
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Loss of 10q is seen in 18% of all high grade glioma samples in this study (5/25 
(20%) non-brainstem gliomas and 1/13 (8%) brainstem gliomas), which is notably 
lower than 35% loss of 10q previously reported in paediatric high grade glioma 
(Paugh, Qu et al. 2010). Loss of 10q is the most common whole arm aberration in 
adult GBM (80%) which includes loss of PTEN (10q23). The difference between the 
frequency of 10q loss in pHGG in this study (6/38) compared to adult HGG 
(152/189) is statistically significant (p = 0.0001). PTEN is a tumour suppressor 
which negatively regulates the Akt signalling pathway and PTEN loss or mutation is 
seen in many cancers (Maher, Furnari et al. 2001). The differential lack of 10q loss 
in this cohort, and particularly in the brainstem tumours, may indicate a different 
mechanism of loss or that different pathways are involved in these paediatric 
tumours and this has implications for therapy. However, aCGH does not allow for 
LOH analysis so it is possible that LOH of 10q is present in some samples. The 
quality of the FFPE DNA used in this study may also account for minor differences 
in the frequency of aberrations seen in this study compared to SNP array studies 
using DNA from frozen samples. 
 
17p loss was seen in 13% tumours overall. Loss of 17p is seen in many tumours and 
17p13.1 is the location of the well characterised tumour suppressor gene p53, which 
has been widely implicated in cancer. (King 2000) Mutation of p53 has been 
reported in adult high grade glioma but less so in paediatric high grade glioma, 
especially in children under three, indicating that there is another mechanism of loss 
of function of p53 in paediatric tumours (Pollack, Finkelstein et al. 2001; Paugh, Qu 
et al. 2010). Indeed, the high frequency of loss of 17p in the brainstem tumours 
indicates loss of the 17p arm is the mechanism for the loss of at least one copy of 
p53 in this subset of tumours. In medulloblastoma loss of 17p is seen in up to 50% of 
samples with focal loss often seen at 17p13.2 (De Smaele, Di Marcotullio et al. 
2004). The gene KCTD11, located at 17p13.2 has been recently identified as a 
suppressor of Hedgehog (HH) signalling which is mainly involved in embryonic 
patterning and tissue differentiation (De Smaele, Di Marcotullio et al. 2004). The 
expression of KCTD11 is normally restricted to embryonal development and 
neurogenesis and loss of KCTD11 may lead to deregulation of the HH pathway and 
therefore promote tumour proliferation (De Smaele, Di Marcotullio et al. 2004). 17p 
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loss was seen in 4/13 (31%) brainstem tumours and just 1/25 (4%) non-brainstem 
tumour and so appears to be associated with infratentorial tumours although sample 
numbers are not high enough for this to be significant. Interesting, 17p loss is 
associated with medulloblastoma but not with supratentorial CNS PNETs. 
14q loss was seen in 4/13 (31%) brainstem tumours but only 1/25 non-brainstem 
tumour (4%). Interestingly, the non-brainstem glioma with loss of 17p was the same 
non-brainstem sample with loss of 14q. This sample, HGG30, is a GBM located in 
the thalamus. A recent report by Zarghooni et al also saw 17p loss and 14q loss 
associated with paediatric brainstem tumours compared to non-brainstem high grade 
gliomas (Zarghooni, Bartels et al. 2010). 
 
Loss of 13q was seen in 11% of samples in this study which is notably lower than 
the loss of 13q in 35% samples as reported recently by Paugh et al, but is still 
amongst the most common arm aberrations (Paugh, Qu et al. 2010). 13q14.2 is the 
location of the RB1 gene, a well characterised tumour suppressor gene that has been 
implicated in paediatric brain tumours including gliomas. RB1 was the first tumour 
suppressor gene identified, and loss of RB1 function is the cause of  retinoblastoma 
(King 2000). The majority of adult HGG have disruption of the RB pathway, 
frequently due to loss of RB1 (see section 1.5.3). Disruption of the RB pathway is 
thought to be associated with the marked increase in cell proliferation seen in the 
transformation from low grade to high grade glioma in adults (Ohgaki 2005; Wong, 
Tsang et al. 2006).  
 
Loss of 16q was seen in 13% tumours and has also been reported lost in CNS PNETs 
and medulloblastoma (Lo, Rossi et al. 2007; Pfister, Remke et al. 2007). 16q is the 
location of a number of potential tumour suppressor genes including WWOX 
(16q23.3-24.1) which had been implicated in a variety of cancers (Ramos and Aldaz 
2006; Hezova, Ehrmann et al. 2007; Jenner, Leone et al. 2007). WWOX is involved 
in inducing apoptosis and is known to regulate the WNT pathway (Ramos and Aldaz 
2006). 
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 Loss of 22q is seen in 13% of tumours in this study and is the location of the tumour 
suppressor gene NF2 (22q12.2). NF2 mutations are associated with 
neurofibromatosis type 2, a syndrome characterised by tumours of the CNS. NF2 is 
highly expressed during embryonic development whilst in adults expression is 
localised to nerves, Schwann cells and the meninges (Evans 2009). 
Neurofibromatosis type 2 is associated with schwannomas, meningiomas and 
ependymomas but not HGG, whilst sufferers of neurofibromatosis type 1 can 
develop HGG and brainstem gliomas (see section 1.3.1). 
  
 
 
 
 
 
 
 
 
 
CHAPTER 6 
FOCAL GENOMIC CHANGES 
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6.1 Identifying aberrant regions 
 
2OLJR DUUD\ &*+ GDWD ZDV DQDO\VHG XVLQJ $JLOHQW¶V µ&*+ $QDO\WLFV¶ VRIWZDUH
version 3.5.14. (Agilent Technologies) The data was analysed in a variety of ways 
using CGH Analytics. The software allows for visual analysis down to the probe 
level and also generates gene lists for small aberrant regions, individual samples and 
for the most commonly gained and lost genes across the sample set. 
Although CGH Analytics is able to generate summary gene lists from the data, the 
poor quality DNA used on this study meant some areas of certain chromosomes were 
consistently noisy. Therefore, when gene lists were generated through the program 
the most commonly aberrant genes were those in persistently noisy areas, i.e. 
telomeric regions and chromosome 19.  Because of this a visual analysis of each 
chromosome of every sample was performed in CGH Analytics using the 
chromosome view and gene view display. This visual analysis allows for a closer 
look at the log2ratios of the probes in regions that KDYHEHHQFDOOHGµDEHUUDQW¶E\WKH
VRIWZDUHWRVHHLIWKHDEHUUDWLRQLVUHDO,IDQDEHUUDQWUHJLRQZDVGHHPHGWREHµUHDO¶
through visual analysis, a small gene list was generated for that region. All these 
small gene lists were collated to give a final gene list. This list, together with 
information on the function of the genes from Pubmed, was used to create a final 
gene list for further study.  
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Table 6.1: Regions of Gain/Loss identified in CGH Analytics. 
Chromosome Region Genes of Interest in Region Gain Loss 
1p36 CDC42, WNT4   2 
1q22 CLK2 1   
1q42 WNT3A, ARF1 2   
2p24.1 MYCN 2   
2p24-22 
MTA3, SIX2/3, MAP4K3, 
RAB10, CAD   1 
2q12 MAP4K4,AFF3, REV1 1  1 
3q25 NMD3   3 
4q11-13 PDGFRA, KIT, CLOCK 3   
4q13.2 UGT2B15, UGT2B17   2 
6p21 TAP1, TAP2 3 1 
6q26-27 QKI, PACRG 1   
7p15 HOXA1-13 1   
7q36 CDK55, MLL3 1   
8p11.23 ADAM3A   6 
8p23 MSRA, MFHAS1   1 
9p22 CDKN2A, CDKN2B, MTAP   4 
10q11.22 ANXA8 1   
11q13 CCND1, FGF3, FGF4 13 1 
11q13.4 RSF1, PAK1, WNT11 1   
12q13 CDK4 3   
13q22 KLF12, MYCBP2   1 
16p12.2 
ARHGAP17, PRKCB, 
PALB2   1 
17q21.2  No genes in region   1 
20p21.1 FLRT3   1 
Genes highlighted in red were used for validation studies. 
123 
 
6.1.1 Gene List 
The genes from the aberrant regions that will be target for further study are displayed 
in Table 6.2 below: 
Table 6.2: Gene list generated by analysis in CGH Analytics. 
Chromosome Gene Deletion (% samples) Gain (% samples) 
chr2 MYCN 0 5  
chr4 PDGFRA 0 8 
chr6 QKI 0 3  
chr8 ADAM3A 15 0 
chr9 CDKN2A 10 0 
chr9 CDKN2B 10 0 
chr11 CCND1 0 33 
chr11 FGF3 0 33 
chr12 CDK4 0 8 
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6.2 Visual Analysis in CGH Analytics 
 
6.2.1 Amplified regions 
Four different regions of high level amplifications were seen across the 38 samples; 
2p24.1 (MYCN), 4q12 (PDGFRA and KIT), 6q26-27(QKI) and 11q13 (CCND1 and 
FGF3). 
High level amplification of MYCN on 2p24.1 was seen in two samples, one 
brainstem glioma (HGG20) and one GBM (HGG15) (Figure 6.1).  
 
 
Whilst HGG20 has a moderately good DLR spread, HGG15 is very noisy with a 
DLR spread of 1.03 and yet the amplification of MYCN is still clear.  
 
Figure 6.1: Chromosome views 
showing amplification of MYCN in 
samples HGG20 (left) and HGG15 
(right). Gene view showing probes for 
amplified region to the far right of the 
zero line, indicating high level 
amplification. 
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Amplification of 4q was seen in 3 samples, although the size of the amplified region and 
therefore the genes involved varies between the samples (Figure 6.2). 
 
Figure 6.2: Amplification of PDGFRA in sample HGG20, HGG30 and HGG36 (left to right).  
 
In sample HGG20 the region of high level amplification covers genes including 
PDGFRA and KIT. In HGG30 PDGFRA is amplified whilst KIT is not. HGG36 has 
low level amplification of both PDGFRA and KIT. Interestingly, in HGG20 and 
HGG30 PDGFRA amplification is seen alongside loss of the majority of 4q. Samples 
HGG20 and HGG36 are brainstem gliomas and HGG30 is a GBM. 
 
Amplification at 6q26-27 is seen in just one sample, HGG20 (Figure 6.3). This high 
level amplification includes the gene QKI which is involved in RNA splicing and 
protein translation. QKI has also been implicated in oligodendrocyte formation and 
myelination in the CNS. 
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Figure 6.3: Chromosome view of chromosome 6 of HGG20 showing loss of 6q with amplification at 
6q26. The gene list shows three genes in the region including QKI. The gene view shows the probes 
in the amplified region to the far right of the zero line, indicating high level amplification.  
 
This discrete high level amplification is seen in conjunction with the loss of the 
majority of 6q. 
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6.2.2 Gained regions 
The most common small region of gain appears to be at 11q13. This region is shown 
as gained in 40% of samples (Figure 6.4).  
 
Figure 6.4: Chromosome 11 heatmap shows an apparent region of gain at 11q13 in 40% of samples. 
 
This region contains the well characterised cell cycle control gene CCND1 and 
various fibroblast growth factors (FGFs) including FGF3 which is frequently over 
expressed in tumours and thought to be involved in malignant transformation and 
tumour progression. This region is noisy with the log2ratios on adjacent probes often 
varying widely. Therefore it is important to validate this gain as it is seen in so many 
samples. 
 
One sample, HGG11, has an area of gain at 11q13 with a smaller focal region of 
amplification which includes CCND1 and FGF3 (Figure 6.5). This sample is a 
brainstem glioma. 
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Figure 6.5: Amplification at 11q13 in sample HGG11 including CCND1 and FGF3, 4 and 19. CGH 
Analytics can generate a gene list for a specific aberrant region. 
 
 
Three samples showed regions of gain on 12q (Figure 6.6). The gene showing the 
highest level of gain in this region was CDK4, a cyclin dependant kinase. All three 
aberration profiles are similar for chromosome 12, with the wavy moving aberration 
line often indicating areas of noise.  
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Figure 6.6: Samples HGG17, HGG18 and HGG25 all appear to have gain of CDK4, although the 
profiles are noisy. 
 
6.2.3 Regions of loss 
Loss of 9p21 is seen in four samples although the size of the deleted region is varied 
(Figure 6.7). 9p21 is the site of genes CDKN2A and B. CDKN2A is a well known 
tumour suppressor gene that is known to be deleted in a variety of tumour types. 
CDKN2B lies adjacent to CDKN2A on chromosome 9p, and is a cell growth 
regulator gene. CDKN2A and CDKN2B are frequently deleted together, as seen in 
these samples. 
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Figure 6.7: Chromosome view for HGG1, HGG4, HGG10 and HGG25 (left to right) with deletions 
of CDKN2A and CDKN2B. 
 
The deleted region varies from almost all of 9p and some of 9q in HGG4  to a much 
more specific deletion seen in HGG25  involving just a handful of genes, including 
CDKN2A and CDKN2B. 
 
The most discrete deletion in this data set is at 8p11.23. This deletion is seen in 6/38 
samples, and the minimal deleted region covers probes on just one gene, ADAM3A 
(Figure 6.8).  
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Figure 6.8: Deletion of ADAM3A represented by the green bands on the chromosome 8 summaries 
(left). The probes for the gene ADAM3A lie to the left of the centre line on the chromosome view 
(right), indicating loss. 
ADAM3A is a member of the ADAM family of genes which are involved in cell to 
cell communication and adhesion.  
There is one primary/recurrent pair in this study; HGG31 (primary) and HGG32 
(recurrence). Both these tumours had no chromosome arm aberrations and very few 
focal aberrations. HGG31 and HGG32 had homozygous deletion at 8p11.23 and a 
small region of loss on 22q. No differences between the primary and recurrent 
sample were seen in this study. 
 
6.2.4 Frozen DNA vs FFPE DNA 
 
Corresponding frozen DNA from four of the FFPE samples in this study was 
analysed by aCGH to determine whether aberrations seen in the high quality frozen 
samples were replicated in the profiles of the poorer quality FFPE samples. The four 
frozen samples were not included as part of the overall analysis in this study. On the 
whole, the frozen/FFPE pairs demonstrated the same gains and losses although there 
were certain noisy regions in the FFPE samples where CGH Analytics identified 
false regions of gain, e.g. chromosome 19. This makes validation of genes identified 
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by aCGH with FFPE samples vital. Selected chromosomes from the FFPE and 
frozen samples of HGG30 are displayed in Figure 6.9. 
 
Figure 6.9: Chromosome views for Frozen and FFPE samples of HGG30. Aberrations are preserved 
in the FFPE sample, e.g. loss of chromosome 4 (green) with amplification at 4q13 (red), gain of ~50% 
5p (red) with loss of the remainder of chromosome 5 (green), loss of chromosome 13 (green), and loss 
of 18p (green). 
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6.3 Discussion 
The high resolution analysis of 38 FFPE pHGG samples by aCGH has identified 
focal regions of gains and loss. Comparisons between the 13 brainstem tumours 
compared to the 25 non-brainstem tumours led to the discovery of anatomical site 
associated aberrations that warrant further study.  
 
Numerous gene and chromosome region aberrations were seen across the data set. 
There were four regions that showed amplification in one or more samples. Out of 
those four regions, amplification of 4q12 was the most frequent in 3/38 samples 
(8%). 4q12 contains the genes PDGFRA and KIT which have both been identified as 
aberrant in other cancers. Interestingly two out of the three samples with PDGFRA 
amplification are brainstem tumours and so 2/13 brainstem gliomas (15%) had 
amplification at 4q12.The PDGFRA protein is a growth factor receptor for the PDGF 
family. The PDGFs are mitogens that influence cells of mesenchymal origin by 
promoting the cell cycle and mitosis. Therefore, amplification of PDGFRA leading 
to high level expression of PDGFRA will promote high levels of cell proliferation 
consistent with high grade tumours. PDGFRA is a possible drug target in pHGG (see 
section 1.5.1). KIT is an oncogene which encodes a growth factor receptor protein. 
An increase in the number of growth factor receptors potentially means that more 
growth factors can be detected by the cell and so when KIT is amplified this may 
lead to increased cell proliferation. 
 
MYCN amplification was seen in 2/38 (5%) samples and appeared to be the most 
highly amplified gene in this study according to aCGH data analysis (see fig. 6.1). 
Both samples with MYCN amplification were anaplastic astrocytomas. MYCN is 
highly amplified in aggressive neuroblastoma but has also been reported amplified in 
CNS PNETs, medulloblastoma and paediatric high grade gliomas, as well as non-
brain tumours (Fruhwald, O'Dorisio et al. 2000; Pfister, Remke et al. 2009; Paugh, 
Qu et al. 2010).  MYCN, an oncogene, is a member of the MYC family of 
transcription factors and so amplification leading to aberrant expression of the 
MYCN protein causes increased transcription of growth factors and in turn leads to 
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increased cell proliferation (Maris and Matthay 1999). Amplification of the gene 
QKI at 6q26-27 was seen in just one sample, HGG20. QKI proteins belong to a 
family of proteins that are involved in RNA splicing, protein translation and 
transport of RNA from the nucleus. QKI is also thought to play a role in 
oligodendrocyte differentiation and myelination (Bockbrader and Feng 2008). 6q26 
has been identified as a fragile site. Fragile sites are specific regions that are 
susceptible to chromosome instability and are distributed throughout the genome 
(Durkin and Glover 2007). Fragile sites have been identified as the location of 
frequent chromosome rearrangements and deletions in cancer. Losses at 7q36 and 
10q11.2 were also identified in this study, and both these locations have been shown 
to be fragile sites.11q13 was amplified in one sample, and contains the gene CCND1 
and a number of FGF genes. CCND1 is a well characterised regulator of the cell 
cycle so amplification would promote the cell cycle and so cell proliferation. FGF3, 
FGF4 and FGF19 are all in this region. The FGFs are growth factors which promote 
cell cycle progression and so amplification of these genes could lead to increased 
cellular proliferation and tumour progression. (Schwertfeger 2009) 
 
The focal deletion at 9p21 includes the well known tumour suppressor genes 
CDKN2A and B which have previously been reported lost in other types of paediatric 
brain tumour including CNS PNETs. (Pfister, Remke et al. 2007) CDKN2A and B 
are cyclin dependant kinase inhibitors which inhibit the cell cycle. Therefore, loss of 
CDKN2A and B could lead to uncontrolled cell proliferation. Interestingly, CDKN2A 
and B loss was only seen in four GBMs that are all supratentorial tumours. None of 
the brainstem gliomas or other infratentorial tumours in the oligo aCGH study 
showed loss of CDKN2A and B. Our group has recently reported loss of CDKN2A 
and B is seen in supratentorial CNS PNETs but not in medulloblastoma, suggesting 
further studies are needed to determine whether this genetic abnormality is restricted 
to supratentorial tumours. 
 
The most common focal deletion seen in this study was a small region of loss at 
8p11 that was seen in 6/38 samples and has not been previously found in adult or 
paediatric high grade gliomas in high resolution studies using the Affymetrix SNP 
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platforms (Paugh, Qu et al. 2010; Qu, Jacob et al. 2010). This is likely due to the 
lack of probes for this particular gene on the Affymetrix 500K and 250K platforms. 
The minimal deleted region across these six samples is a discrete deletion of the gene 
ADAM3A. Very little is known about the function of this gene in humans, although 
ADAM3A has been shown to be vital to sperm binding and migration in mice 
(Yamaguchi, Muro et al. 2009).  ADAM3A is a member of the ADAM family of 
genes which are involved in cell to cell communication and adhesion (Wolfsberg, 
Straight et al. 1995). Certain ADAM family genes are thought to be involved in 
neurogenesis whilst others have been implicated in cancer (Mochizuki and Okada 
2009; Seniski, Camargo et al. 2009).   
The frequency and specificity of the deletion at 8p11 in this sample set makes this 
focal region, and specifically ADAM3A, an interesting target for possible future 
study. However, 8p11.23 has been identified as a copy number variable region 
(CNV) in the human genome. CNVs are widespread throughout the human genome 
in healthy individuals and are thought to include around 12% of the whole human 
genome (Kuiper, Ligtenberg et al. 2010).  Some CNVs are associated with diseases, 
including cancer, whilst many CNVs have unknown clinical significance. As 
matched constitutional blood was unavailable for the samples used in this study it is 
possible that the loss seen at 8p11.23 is a CNV that may be also present in healthy 
individuals. However, this deletion was seen at a higher frequency (16%) than may 
be expected for a non-pathogenic CNV. 
Three members of the Wnt family of genes were identified in the original gene list; 
Wnt3a, Wnt4 and Wnt11. Wnt3a lies within a CNV in the human genome. The Wnt 
gene family encodes a range of signalling proteins that are involved in embryonic 
patterning and other developmental processes. The Wnt pathway regulates many 
developmental processes including cell proliferation, cell migration and cell fate 
(Giunta 2009). As the Wnt pathway has such a diverse range of targets ands effects, 
loss of control of the pathway can have dire consequences.  
The Wnt signalling cascade has been widely implicated in oncogenesis in a variety 
of cancers. Wnt4 encodes a signalling protein involved in sex determination and has 
been implicated in abnormal proliferation of cells in breast carcinoma. Wnt3a has 
also been implicated in breast cancer studies. Wnt11 encodes a protein involved in 
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the development of bones, lungs and kidneys and has been implicated in prostate 
cancer. Aberrant Wnt pathway activation has previously been reported in 
medulloblastoma (Zurawel, Chiappa et al. 1998; Koch, Waha et al. 2001).  
A cluster of homeobox (HOX) genes (HOXA1-13) was seen gained at 7p15 in one 
sample. 7p15 has been identified as a CNV. HOX genes encode for a family of 
transcription factors involved in embryonic patterning at specific time points during 
development (Shah and Sukumar 2010). The genes HOXA1-13 encode for 
transcriptions factors involved in the regulation or morphogenesis and differentiation 
of cells. HOXA1-6 encode proteins that are involved in the development of the 
hindbrain along the anterior-posterior axis. A fusion between HOXA9 and the gene 
NUP98 has been identified in myeloid leukaemia. HOXA10 encodes a protein 
involved in haematopoietic differentiation, whilst both HOXA10 and HOXA11 play 
role in female fertility and uterine development.  
Deregulation of Hox gene expression has been widely implicated in oncogenesis 
(Shah and Sukumar 2010). Hox genes control organogenesis pathways that can 
become deregulated and lead to uncontrolled cell proliferation. Alterations on Hox 
gene expression can also maintain a more primitive cell phenotype by suppressing 
differentiation of cells and activating anti-apoptotic pathways.  
 
Transporter associated with antigen processing 1 (TAP1) and Transporter associated 
with antigen processing 2 (TAP2) (6p21) were seen gained in three samples. TAP1 
and TAP2 encode proteins of the ATP-binding cassette (ABC) transporter family 
involved in transport of molecules in and out of cells. The proteins encoded by these 
genes are involved in multidrug resistance. 
 
5/38 (13%) samples in this study did not have any whole arm or focal aberrations 
according to the aCGH analysis. This indicates that epigenetic changes and 
mutations are important in these tumours. Subsets of balanced tumours have also 
been seen in studies of ependymoma and CNS PNETs (Dyer, Prebble et al. 2002; 
Natrajan, Williams et al. 2006). 
  
 
 
 
 
CHAPTER 7 
VALIDATION OF aCGH 
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7.1 Quantitative Real Time PCR (qPCR) 
 
7.1.1 Primers 
qPCR is a techniques to measure copy number of a gene using specifically designed 
SULPHUVIRU WKHJHQHRI LQWHUHVW$FRQWUROJHQH LVDOVR UHTXLUHG WRJLYHD µQRUPDO¶
result that the gene of interest can be compared to. In this study, the gene PPIA was 
chosen as the normal control as it had in normal copy number in all samples 
according to the aCGH results. A further nine genes of interest that were identified 
as being most highly amplified or most commonly gained/lost were validated. 
Primers were designed using PrimerBlast (NCBI) and ordered from Operon 
(Eurofins MWG Operon, London, UK). 
Table 7.1: qPCR primers. 
Gene Primer Primer Sequence 
Primer 
Length 
(bp) 
Product 
Length 
(bp) 
CCND1 (exon 1) Forward CTGTGCTGCGAAGTGGAAAC 20   
CCND1 (exon 1) Reverse GGACCTCCTTCTGCACACAT 20 142 
PDGFRA (exon 4) Forward AGTCAGGGGAAACGATTGTG 20   
PDGFRA (exon 4) Reverse AGCCATTGCACGTTTTGAG 19 111 
CDK4 (exon 1) Forward CCCTTGATCTGAGAATGGCT 20   
CDK4 (exon 1) Reverse CCATTGGGGACTCTCACACT 20 139 
CDKN2A (exon 2) Forward TCAGGTAGCGCTTCGATTCT 20   
CDKN2A (exon 2) Reverse GGCTCCTCATTCCTCTTCCT 20 132 
CDKN2B (exon 2) Forward GCGGATTTCCAGGGATATTT 20   
CDKN2B (exon 2) Reverse CACCAGGTCCAGTCAAGGAT 20 105 
MYCN (exon 2) Forward CGCTACAGCCCTGCTTCTAC 20   
MYCN (exon 2) Reverse GGCAGCAGCTCAAACTTCTT 20 103 
QKI (exon 1) Forward  GGGAAATGGAAACGAAGGAG 20   
QKI (exon 1) Reverse TTGAAGATCCCGCAGAAGTT 20 109 
FGF3 Forward  AGATAACGGCAGTGGAGGTG 20   
FGF3 Reverse TGGACTCACCGAAGCATAGA 20 104 
ADAM3A Forward  AGCCTCATTGCCTTTCACAT 20   
ADAM3A Reverse TTTCTGTGGACCTTTTTGGC 20 125 
PPIA (exon 4) Forward  ATGCTGGACCCAACACAAAT 20   
PPIA (exon 4) Reverse TAGTGTTTGTTCCGTTCCCC 20 132 
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7.1.2 Optimisation of qPCR with FFPE DNA 
Ideally, high quality DNA is used for qPCR. FFPE DNA is often highly fragmented 
and degraded which can cause problems with primer binding and the production of 
the PCR product. 10ng of DNA from frozen tissue is used as a standard. A 
concentration gradient PCR experiment was set up to determine the optimal amount 
of FFPE DNA to use in qPCR. The DNA quantities used were 100 ng, 50 ng, 25 ng 
and 12.5 ng.  
 
 
Figure 7.1: Amplification curves from optimisation of FFPE DNA for qPCR. 
The x axis of the amplification graph displays the number of PCR cycles and the y 
axis displays the fluorescence. 25 ng and 12.5 ng of FFPE gave clean amplification 
curves, with 25 ng giving the most consistent result. Therefore, 25 ng of FFPE DNA 
was used for each qPCR reaction. 
 
Unfortunately, the DNA for some samples analysed by aCGH was depleted and so 
unavailable for validation studies. A number of samples were used for qPCR but 
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consistently failed to give any result so were also unusable for validation. 21 samples 
had DNA available and worked with qPCR. Many of these 21 samples only had 
small quantities of DNA available for validation and therefore only select samples 
were used to validate each gene. Each qPCR is performed in triplicate. 
 
7.1.3 Control Gene Primers 
PPIA was the control gene used for all the qPCR reactions. Temperature gradient 
PCR showed the optimal temperature for these primers is 58oC. The efficiency of the 
PPIA primers was calculated in the MxPRO software (Stratagene) from a 
concentration gradient using a control DNA. As these primers were used as a control 
for every target gene the efficiency of these primers was re-calculated after each set 
of experiments was completed to make sure the efficiency was accurate. 
 
The derived copy number was calculated E\PXOWLSO\LQJWKHµ)ROGFKDQJH¶IURPWKH
3IDIIO HTXDWLRQ E\ WZR 7KH µD&*+ &RS\ 1XPEHU¶ LV GHULYHG IURP WKH ORJUDWLR
values given to each probe on the array. The log2ratios from all the probes in the 
gene of interest were averaged and converted into a copy number. 
 
 
7.2 Results of qPCR 
CCND1 
CCND1 was seen gained in ~40% of samples in the aCGH results, however the area 
of chromosome 11 where CCND1 is located was prone to noise and therefore 
validation of this gain is important. The temperature gradient PCR had shown that 
the CCND1 primers work optimally at 58oC. 
 
An efficiency of 91.5% was calculated from the concentration gradient standard 
curve. The Pfaffl equation was used to calculate fold change. 
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Table 7.2:  qPCR results for CCND1. 
Sample Gene aCGH Copy Number Fold change Derived Copy Number 
HGG11 CCND1 21.2 5.3 10.6 
HGG17 CCND1 5.2 1.3 2.6 
HGG22 CCND1 3.8 1.1 2.2 
HGG28 CCND1 2.8 1.5 3.0 
HGG10 CCND1 3.4 1.3 2.6 
HGG7 CCND1 3.6 0.9 1.9 
HGG32 CCND1 3.0 0.7 1.5 
HGG36 CCND1 1.0 0.4 0.7 
Whilst qPCR has confirmed the amplification in sample HGG11 and the deletion in 
samples HGG36 it has failed to validate gain of CCND1 in HGG17 and HGG22 
which had been suggested by aCGH. All samples which had copy number 2 for 
CCND1 in the aCGH data have normal copy numbers by qPCR. 
 
FGF3 
FGF3 is located at 11q13, the same region as CCND1. Gain of FGF3 was seen in 
around 40% samples. 
Table 7.3: qPCR results for FGF3. 
Sample Gene aCGH Copy Number Fold change Derived Copy Number 
HGG17 FGF3 9.8 1.5 3.0 
HGG18 FGF3 12.2 1.7 3.4 
HGG11 FGF3 13.0 8.9 17.8 
HGG7 FGF3 2.2 1.0 2.0 
HGG31 FGF3 1.6 1.0 2.0 
HGG25 FGF3 2.2 1.4 2.8 
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The gains of FGF3 in HGG17 and HGG18 were confirmed by qPCR as was the 
amplification of FGF3 in HGG11. The three samples with normal copy number of 
FGF3 according to aCGH also have normal copy number according to qPCR. 
 
PDGFRA 
Amplification of PDGFRA was seen in three samples in the aCGH results; HGG20, 
HGG30 and HGG36.  HGG20 and HGG30 showed high level amplification whilst 
HGG36 showed low level amplification. The efficiency of the PDGFRA primers was 
shown to be 92.4%. 
Table 7.4: qPCR results for PDGFRA. 
Sample Gene aCGH Copy Number Fold change Derived Copy Number 
HGG30 PDGFRA 6.4 6.9 13.8 
HGG20 PDGFRA 17.2 13.9 27.8 
HGG36 PDGFRA 3.8 2.7 5.4 
HGG3 PDGFRA 2.2 0.9 1.9 
HGG24 PDGFRA 2.2 1.4 2.7 
HGG32 PDGFRA 2.0 1.1 2.2 
HGG7 PDGFRA 2.0 0.8 1.6 
HGG10 PDGFRA 2.0 1.0 2.0 
 
The amplification of PDGFRA in HGG20 and HGG30 has been validated.  Sample 
HGG36 has a derived copy number of 5.4 which is a gain rather than an 
amplification ( > copy number 6). The five samples which showed a normal copy 
number of PDGFRA by aCGH all show a normal copy number by qPCR. 
 
 
 
143 
 
CDK4 
The aCGH results showed three samples, HGG17, 18 and 30, having gain of CDK4, 
although all three samples had a noisy chromosome 12 with a wavy moving average 
line. The efficiency of the CDK4 primers was calculated as 103% and the 
temperature gradient showed the optimal temperature to be 58oC. 
Table 7.5: qPCR results for CDK4. 
Sample Gene aCGH Copy Number Fold change 
Derived Copy 
Number 
HGG17 CDK4 6.4 0.8 1.6 
HGG18 CDK4 9.2 0.9 1.8 
HGG30 CDK4 5.0 1.6 3.2 
HGG4 CDK4 1.8 1.4 2.8 
 
qPCR validated gain in just 1/3 samples with the other two samples showing a 
normal copy number by qPCR. It was concluded that these two gains were not real 
and were due to noise on chromosome 12.  
 
CDKN2A and CDKN2B 
These two genes are often seen deleted together in a range of tumour types although 
they have separate functions. Both genes will be analysed by qPCR to show the 
correlation between the copy numbers of these genes.  
 
Four samples, HGG1, HGG4, HGG10 and HGG25 showed deletions of CDKN2A 
and CDKN2B. CDKN2A primers were shown to have an optimal annealing 
temperature of 58oC and an efficiency of 94.5%. 
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Table 7.6: qPCR results for CDKN2A. 
Sample Gene aCGH Copy Number Fold change 
Derived Copy 
Number 
HGG25 CDKN2A 0.7 0.2 0.4 
HGG4 CDKN2A 0.4 0.2 0.3 
HGG10 CDKN2A 1.1 0.7 1.4 
HGG1 CDKN2A 0.5 0.3 0.5 
HGG32 CDKN2A 2.2 0.9 1.7 
HGG26 CDKN2A 2.2 0.8 1.7 
HGG31 CDKN2A 2.0 1.1 2.2 
HGG3 CDKN2A 2.0 1.1 2.2 
 
Samples HGG1, HGG4 and HGG25 showed homozygous deletions by qPCR, whilst 
HGG10 showed a heterozygous deletion. All four samples with a normal copy 
number in the aCGH data have a normal copy number by qPCR. 
 
CDKN2B primers were shown to have an optimal annealing temperature of 58oC and 
an efficiency of 92.9%. 
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Table 7.7: qPCR results for CDKN2B. 
Sample Gene aCGH Copy Number Fold change 
Derived Copy 
Number 
HGG25 CDKN2B 0.9 0.2 0.4 
HGG4 CDKN2B 0.4 0.2 0.3 
HGG10 CDKN2B 1.1 0.7 1.5 
HGG1 CDKN2B 0.9 0.4 0.8 
HGG3 CDKN2B 2.4 1.1 2.2 
HGG31 CDKN2B 2.4 1.2 2.4 
HGG7 CDKN2B 2.4 1.0 1.9 
 
Sample HGG25 and HGG4 show homozygous deletions whilst HGG10 show a 
heterozygous deletion. HGG1 has a derived copy number of 0.78 which also 
indicates a homozygous deletion as the value is less than 1. All three samples which 
had normal copy number according to aCGH also have a normal copy number by 
qPCR. 
 
CDKN2A and B are often lost together, as is seen in these four samples. 
Table 7.8: Correlation of CDKN2A and CDKN2B loss. 
Sample CDKN2A Derived Copy Number CDKN2B Derived Copy Number 
HGG25 0.36 0.4 
HGG4 0.34 0.32 
HGG10 1.38 1.48 
HGG1 0.5 0.78 
HGG31 2.2 2.4 
HGG3 2.2 2.2 
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10% of samples demonstrated loss of CDKN2A and B although interestingly none of 
the 13 brainstem gliomas in the study had loss of CDKN2A or B.  
 
 
MYCN 
High level amplification of MYCN was seen in two samples in the aCGH results, and 
one sample showed gain. MYCN primers showed an optimal annealing temperature 
of 58oC and an efficiency of 90.2%. 
Table 7.9: qPCR results for MYCN. 
Sample Gene 
aCGH Copy 
Number Fold change Derived Copy Number 
HGG20 MYCN 27.8 36.2 72.4 
HGG15 MYCN 14.0 7.8 15.6 
HGG26 MYCN 3.5 3.0 6.0 
HGG17 MYCN 2.0 1.3 2.6 
HGG3 MYCN 2.2 1.4 2.8 
HGG7 MYCN 2.0 1.4 2.8 
 
MYCN amplification is confirmed in HGG20 and HGG15 and gain of MYCN is 
confirmed in HGG26. The three samples which showed normal copy number of 
MYCN by aCGH have all shown normal copy number by qPCR. 
 
QKI 
Amplification of the gene QKI was seen in just one sample, HGG20. Temperature 
gradient PCR showed that the optimal temperature for the QKI primers was 58oC 
and the efficiency of the primers was calculated as 95.8%. 
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Table 7.10: qPCR results for QKI. 
Sample Gene aCGH Copy Number Fold change 
Derived Copy 
Number 
HGG20 QKI 15.0 9.6 19.2 
HGG3 QKI 2.2 1.3 2.6 
HGG37 QKI 2.0 1.6 3.2 
HGG11 QKI 1.8 1.3 2.6 
The amplification of QKI in HGG20 was validated by qPCR.  Two of the normal 
samples from aCGH analysis showed normal copy number for QKI by qPCR, but 
one sample that had a normal copy number in aCGH analysis showed gain by qPCR. 
 
ADAM3A 
Deletion of ADAM3A was the most common focal deletion seen in the aCGH data 
with 15% of samples showing deletion of ADAM3A. Optimal annealing temperature 
for the ADAM3A primers was shown to be 58oC and the efficiency of the primers 
was calculated as 90%. 
Table 7.11: qPCR results for ADAM3A. 
Sample Gene aCGH Copy Number Fold change 
Derived Copy 
Number 
HGG4 ADAM3A 0.5 0.1 0.3 
HGG32 ADAM3A 0.3 0.0 0.0 
HGG28 ADAM3A 0.5 0.0 0.0 
HGG22 ADAM3A 0.2 0.0 0.0 
HGG7 ADAM3A 2.0 0.9 1.8 
HGG8 ADAM3A 2.0 0.9 1.7 
HGG3 ADAM3A 3.6 2.2 4.4 
HGG10 ADAM3A 2.0 1.2 2.4 
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Four samples which showed loss of ADAM3A by aCGH were validated by qPCR. 
All four samples showed homozygous loss with samples HGG28 and HGG22 not 
even registering a Ct value showing a complete loss of ADAM3A. Four samples that 
had normal copy number for ADAM3A in the aCGH data were validated by qPCR. 
Three of these samples showed normal copy number by qPCR, however one sample 
showed a low level gain. 
 
7.3 FISH 
Fluorescence in situ hybridisation (FISH) is a technique used to measure copy 
number of chromosomal regions, ranging from whole arms to single genes. 10 high 
grade glioma tissue microarrays (TMAs) were available for this study with ~150 
high grade glioma samples across the TMAs in triplicate. There are 26 brainstem 
gliomas on the TMAs, including 10 of the 13 brainstem tumours analysed by aCGH. 
7KH DPRXQW RI µVFRUDEOH¶ samples on the TMA varies in each experiment due to 
differences in core loss, auto-fluorescence, and how successfully the FISH has 
worked with a particular probe set. 
 
7.3.1 Gain of 1q 
Gain 1q was the most common aberration seen in this study in the aCGH analysis 
(40% samples).  1q FISH was performed on all high grade glioma TMAs using 1q25 
SpectrumGreen probe (green) and a 1p36 SpectrumOrange control probe (red) 
(Vysis LSI 1p36/LSI 1q25 Dual colour probe, Abbott Technologies).  
41 samples were scorable for 1q FISH. 12 of the 41 scorable samples were analysed 
by aCGH and only two of the 41 samples were brainstem gliomas. 11/41 (27%) 
samples had gain of 1q. Of those 11 samples seven were GBM, two AA and two 
GBM of the brainstem. Sample HGG35 had gain of 1q and loss of 1p, as seen in the 
aCGH analysis (Figure 7.2).  
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Figure 7.2: 1q FISH on sample HGG35. Three copies of 1q are visible (green probe) but 
only one copy of 1p (red probe). 
 
7.3.2 Amplification of MYCN 
 
MYCN amplification was seen in 5% samples in the aCGH analysis, and was the 
highest level amplification seen. A MYCN (2p24) specific PlatinumBright550 probe 
(red) plus a LAF (2q11) PlatinumBright495 control probe (green) was used to FISH 
all TMAs. (Poseidon Repeat Free MYCN & LAF Control Probe, Kreatech).  
80 samples on the TMAs were scorable for MYCN FISH. Of those 80 samples, four 
samples had amplification of MYCN (figure 7.3) including the two samples with 
MYCN amplification that were analysed by aCGH (HGG20 and HGG15). 
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Figure 7.3: TMA37, TMA60, HGG20 and HGG15 all displayed amplification of MYCN by FISH. 
FISH has validated the amplification of MYCN in samples HGG20 and HGG15 seen in the aCGH 
data (red probe is MYCN, green probe is control). 
 
It is impossible to count copy number for MYCN in any of these four samples as the 
high copy number makes it very difficult to distinguish between each separate probe 
signal (Figure 7.3).  
 
Sample HGG20 is a brainstem glioma whilst sample HGG15, TMA37 and TMA60 
are all anaplastic astrocytomas. No GBMs demonstrated amplification of MYCN. 
)LVKHU¶V H[DFW WHVW ZDV XVHG WR VKRZ WKDW MYCN amplification was significantly 
associated with anaplastic astrocytomas in this dataset (p=0.03). 
 
151 
 
One sample, HGG2, demonstrated amplification of LAF4, the control probe target on 
2q. High level gain of LAF4 in HGG2 was seen in the aCGH data (Figure 7.4). 
 
Figure 7.4: Chromosome view of chromosome 2 from sample HGG2 showing gain at 2q12. LAF4 
FISH confirms amplification of LAF4 (green probe) in sample HGG2. 
Sample HGG2 is a GBM but the patient had previously had radiation treatment for 
acute lymphoblastic leukaemia (ALL). The LAF4 gene is associated with ALL. 
 
7.3.3 Loss of p16 
Loss of CDKN2A and CDKN2B (9p21) was seen in 10% samples by aCGH. FISH 
was performed across all TMAs using p16 (9p21) PlatinumBright550 probe (red) 
and 9q21 PlatinumBright495 (green) control probe (Figure 7.5).  
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There were 61 scorable samples across the TMAs. 21/61 samples were infratentorial 
tumours including five brainstem gliomas, 28/61 were supratentorial tumours, 3/61 
were spinal tumours and for nine tumours the location was unknown. 39 of the 
scorable samples were GBM, 11 AA, five brainstem gliomas, four AO, one APX and 
one CNS PNET that had been originally diagnosed as a high grade glioma.  
 
Out of the 61 samples, three had heterozygous loss of p16 and five had homozygous 
loss of p16, although two of the samples with homozygous loss were from two 
surgeries on the same tumour. Interestingly, all the tumours with loss of p16 were 
supratentorial GBMs, occurring in the cerebral lobes.  None of the 21 scorable 
infratentorial samples on the TMAs showed loss of p16, the same result seen in the 
aCGH data.  
 
 
 
 
Figure 7.5: p16 FISH. A. Heterozygous loss of 
p16 in sample TMA18 (red signal is p16, green 
signal is control probe). B. Homozygous loss of 
p16 in HGG1. C. Normal copy number of p16 in 
TMA70. 
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7.3.4 Amplification of PDGFRA 
PDGFRA FISH was performed on five of the high grade glioma TMAs as part of a 
separate study. There were 45 scorable samples (27 GBM, 7 AA, 3 AO and 8 
brainstem tumours) across the five TMAs with six samples showing amplification of 
PDGFRA. Of the six samples with PDGFRA amplification, two were brainstem 
gliomas, two were GBMs and two AAs.  13% (6/45) of samples demonstrated 
amplification of PDGFRA by FISH whilst only 8% (3/38) samples showed 
amplification of PDGFRA by aCGH. 
 
7.4 Immunohistochemistry 
Immunohistochemistry (IHC) was performed on the high grade glioma TMAs to 
look at the expression of the MYCN, CDKN2B and PDGFRA proteins.  
 
7.4.1 MYCN IHC 
MYCN IHC was carried out to determine whether the level of MYCN expression in 
those samples that showed amplification of MYCN by aCGH or FISH was higher 
than those samples without MYCN amplification. MYCN IHC was performed on all 
HGG TMAs and 81 samples were scorable across the TMAs. Of those 81 samples, 
67 were negative for MYCN expression and 14 samples were positive for MYCN 
expression. Five of the 14 samples had previously shown normal copy number of 
MYCN indicating a different mechanism of overexpression in these samples. No 
MYCN copy number data was available for the remaining five samples with 
overexpression of MYCN, and so the mechanism of overexpression is undefined. All 
four samples which demonstrated amplification of MYCN were positive for MYCN 
expression (Figure 7.6). 
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Figure 7.6: a. MYCN IHC with high level expression in sample TMA37 b. FISH showing 
amplification of MYCN in sample TMA37 c. MYCN IHC with high level expression in sample 
TMA60 d. FISH showing amplification of MYCN in sample TMA60 e. MYCN IHC with high level 
expression in sample HGG20 f. FISH showing amplification of MYCN in sample HGG20 g. MYCN 
IHC with high level expression in sample HGG15 h. FISH showing amplification of MYCN in sample 
HGG15. 
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7.4.2 CDKN2B IHC 
CDKN2B IHC was performed to investigate levels of expression of CDKN2B in 
samples with normal CDKN2B copy number compared to those samples with loss of 
one or both copies of CDKN2B, as shown in previous experiments. CDKN2B IHC 
was performed on all HGG TMAs and 93 samples were scorable. 38/93 samples 
were negative for CDKN2B expression, 35 samples showed low level expression of 
CDKN2B and 20 samples showed high level expression of CDKN2B (Figure 7.7). 
Out of the 93 samples scorable for IHC, four samples had shown homozygous loss 
of CDKN2B in previous experiments. All four samples were negative for expression 
of CDKN2B. 2/93 samples had previously shown heterozygous loss of CDKN2B. 
One of these samples was negative for CDKN2B expression and the other sample 
showed low level expression of CDKN2B. 
 
 
 
Of the 38 samples negative for CDKN2B expression, five were infratentorial 
tumours and 33 were supratentorial tumours. Of the 55 samples positive for 
Figure 7.7: a. Sample TMA71 negative for 
CDKN2B expression. b. Sample TMA76 
with low level nuclear expression of 
CDKN2B. c. Sample TMA42 with high 
level nuclear expression of CDKN2B. 
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CDKN2B expression, 46 had location data available. 30/46 were supratentorial and 
16/46 infratentorial. Therefore, around half the supratentorial tumours were negative 
and around half were positive, whilst a quarter of infratentorial tumours were 
negative and ¾ were positive. This comparison between CDKN2B expression in 
supratentorial and infratentorial tumours is statistically significant (p = 0.03). 
 
7.4.3 PDGFRA IHC 
PDGFRA IHC was performed across all HGG TMAs (Figure 7.8). 101 samples were 
scorable for PDGFRA expression. Of those 101 samples, 75 samples were negative 
for PDGFRA expression, 12 samples showed weak expression of PDGFRA and 14 
samples showed strong expression of PDGFRA. 
 
 
 
Four of the scorable samples on the TMA had previously demonstrated amplification 
or high level gain either by aCGH or by FISH as part of a separate study. Of these 
Figure 7.8: a. Sample TMA76 negative for 
PDGFRA expression. b. Sample TMA63 
with low level membranous expression of 
PDGFRA. c. Sample TMA113 with high 
level membranous expression of PDGFRA. 
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four samples, three showed high expression of PDGFRA whilst the other sample 
appeared to be negative for expression of PDGFRA.  
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7.5 Discussion 
 
In a study where the starting DNA material was degraded DNA isolated from FFPE 
samples, validation is especially important.  The optimal quantity of FFPE DNA was 
shown to be 25 ng for qPCR, which is higher than that of frozen DNA. This is as 
expected due to the fragmentation of the FFPE DNA. Several tumour samples 
repeatedly failed to work in a qPCR reaction probably due to the degraded nature of 
the DNA. This, in addition to the DNA for many samples having been depleted by 
aCGH, made it important to carefully select which of the available samples to use for 
validation, and how many samples to use for each gene. 
 
Despite concerns regarding the quality of the DNA the majority of the genes selected 
for further study were validated, with the qPCR results confirming those seen in the 
aCGH data. However, the gains of CCND1 and CDK4 seen in the aCGH data failed 
to validate. Both these genes were in noisy regions on chromosome 11 and 12 
respectively. The gain of 11q13 was seen in around 40% samples and the size of the 
apparent region of gain was similar in all samples. The two samples that were used 
for CCND1 qPCR were the two samples which appeared to have the highest level of 
CCND1 gain in the aCGH data, excluding the sample with amplification. These two 
samples both gave a normal derivative copy number by qPCR. However, FGF3 
which is in the same region and was also seen gained in the aCGH data did validate 
by qPCR. Unfortunately, the DNA for samples with gain at 11q13 was limited and 
only two samples that showed gain by aCGH could be validated. The fact FGF3 
validated and CCND1 did not may indicate that the gain of FGF3 is real and because 
the region is noisy CGH Analytics has called a larger region as gained than is 
actually gained. Another explanation could be that only part of the CCND1 gene is 
gained and that the primers were desiJQHGWRWDUJHWDUHJLRQRIWKHJHQHWKDWZDVQ¶W
gained. Because of the lack of DNA available for these samples it is not possible to 
do further qPCR experiments on this sample set.  
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Gain of 1q was the most common whole chromosome arm aberration seen in the 
aCGH study (22%). The 1q FISH showed a very similar level of 1q gain with 11/41 
(27%) samples having gain of 1q. Gain of 1q has been previously reported as 
commonly gained in paediatric high grade glioma, as well as other paediatric brain 
tumours. It is not known why 1q is gained at such high frequencies in these tumours 
or the effect on the behaviour of the tumour as a result. It was shown in the aCGH 
data that the whole of 1q was gained as opposed to just regions of 1q as sometimes 
seen in other tumours, e.g. paediatric ependymoma (Dyer, Prebble et al. 2002). 
 
High level MYCN amplification was seen in 5% tumours in the aCGH study. 4/80 
samples showed amplification of MYCN by FISH with two of those samples being 
the two samples identified as having MYCN amplification by aCGH. Interestingly, 
three out of the four tumours with MYCN amplification were anaplastic astrocytomas 
with the other sample being a brainstem glioma. Amplification of this oncogene has 
been associated with poor prognosis in other tumour types including neuroblastoma 
(Tonini, Boni et al. 1997). However none of the grade IV GBMs in this study 
showed amplification of MYCN.  MYCN amplification was shown to be significantly 
associated with anaplastic astrocytomas (p=0.03). More cases need to be studied to 
further explore the relationship between MYCN amplification and anaplastic 
astrocytoma. 
 
Loss of p16 (CDKN2A and B) was seen in 10% samples by aCGH, and all of those 
samples were supratentorial GBMs. In the FISH experiment 8/61 samples showed 
loss of either one or two copies of p16. As seen in the aCGH data, all eight samples 
showing loss at p16 were supratentorial GBMS. No infratentorial tumours, including 
brainstem tumours, showed loss at p16. This would indicate different mechanisms or 
different pathways being disrupted in supratentorial and infratentorial tumours. The 
association of CDKN2A/B with supratentorial high grade gliomas has not been 
previously reported. Unfortunately the numbers in this study were insufficient for the 
association of CDKN2A/B loss with supratentorial GBMs to be significant. However, 
the differential expression of CDKN2B between supratentorial and infratentorial 
tumours, shown using IHC, is statistically significant (p = 0.03). 
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The FISH for PDGFRA was performed as part of a separate study. 3/39 samples 
analysed by aCGH showed amplification of PDGFRA. In the FISH study 6/45 
showed amplification of PDGFRA, which is always twice the frequency seen in the 
aCGH study. However, the frequency of PDGFRA amplification in the FISH data is 
closer to the frequency previously reported in other studies. It may be that the probes 
on the aCGH arrays are not correctly designed to detect some of the PDGFRA 
amplifications.  
 
IHC across TMAs allows efficient screening of a large sample set for expression of a 
target protein. IHC for expression of MYCN, CDKN2B and PDGFRA was 
performed for this study. MYCN IHC showed expression in those samples with 
MYCN amplification and low level or negative MYCN expression in all other 
samples. Whilst MYCN IHC was as expected, CDKN2B IHC proved harder to 
interpret. However, all samples that had homozygous loss of CDKN2B and had 
expression data available from IHC showed negative expression of CDKN2B.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 8 
FINAL DISCUSSION 
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8.0 Final discussion 
Original hypotheses; 
 Paediatric and adult high grade glioma have different genetic causes. 
 High grade glioma occurring in the brainstem are genetically distinct from 
high grade glioma in the cerebrum. 
 High grade glioma occurring in children over 3 years old are genetically 
distinct from those tumours occurring in children under 3 years old. 
 
The aim of this study was to use DNA isolated from formalin fixed brain tumour 
samples to facilitate the identification of aberrant regions and genes that would lead 
to diagnostic and prognostic markers for paediatric high grade glioma. Formalin 
fixed tumour samples is a resource which is only now starting to be exploited in 
cancer research. A large number of FFPE blocks are available for many types of 
cancer and so high throughput genomic techniques which can allow for the degraded 
nature of FFPE DNA will open up a whole new sample set. This is vitally important 
for tumours that are rare or that only small samples can be taken from, such as 
brainstem tumours. 
 
In this study, only around half the FFPE blocks from which DNA isolation was 
attempted provided DNA of sufficient quality and quantity for oligo aCGH. 
However, new DNA isolation techniques are being developed all the time and so this 
number can only improve. The quality of the isolated DNA varied widely and 
although multiplex PCR gave an indication of how degraded the DNA was, the 
results of the PCR were often not as clear as hoped. A handful of samples failed to 
label in the preparation for aCGH probably due to the poor quality of the DNA. 
Since this study was completed, Agilent Technologies have released a new labelling 
kit specifically for use with FFPE DNA which uses non-enzymatic labelling to 
overcome the problems of DNA fragmentation. The new labelling method is based 
RQ .UHDWHFK¶V Universal Linkage System (Stretton Scientific, Stretton, UK) and 
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involves the binding of a platinum complex, labelled with either Cy-3 or Cy-5, 
directly to the N7 position of guanine bases in the DNA (De Witte 2007). This direct 
method labels independently of fragment length which makes it ideal for poor 
quality FFPE DNA. If this new kit had been available to be used in this study may be 
even less samples would have failed the labelling step. 
 
38 FFPE samples were run on Agilent 244K oligo arrays with mixed results ranging 
from very clean, precise genomic profiles to messy, difficult to interpret profiles. 
The Agilent guidelines for array quality are stringent and not designed for this type 
of research. The majority of arrays in this study failed most of the QC thresholds that 
Agilent has set and yet aberrations in the majority of these samples, both whole arm 
aberrations and regions, were clearly visible. This illustrates that a change in attitude 
may be required towards using low quality samples, and that although the data 
maybe noisy and take more time to analyse useful data can be produced from even 
the poorest samples.  
 
The oligo aCGH results described a heterogeneous sample set with widespread 
chromosome arm gains and losses, and many other regional aberrations. Gain of 1q 
was the most common arm aberration, and is also seen in other paediatric brain 
tumours. Why gain of 1q is such a frequent event in these tumours, and indeed other 
paediatric cancers, is as yet unknown. Loss of 10q was also frequent with 10q being 
the location of the tumour suppressor PTEN which is lost in up to 80% adult high 
grade gliomas (Paugh, Qu et al. 2010). Overall, more regions of gain were seen than 
regions of loss across all the samples. Amplification of genes PDGFRA, KIT, 
MYCN, QKI and CCN D1 was seen at varying frequencies, with amplification of 
PDGFRA being the most common amplification. There were several focal regions of 
loss including loss of CDKN2A and B and loss at 8p11. 
 
Homozygous loss at 8p11.23 was seen in 16% of high grade gliomas and has not 
been previously reported in adult or paediatric high grade gliomas. The minimal 
deleted region is of the gene ADAM3A. The ADAM  (A Disintegrin And 
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Metalloproteinase) family of genes are widely expressed and have many potential 
functions relating to cell to cell communication and adhesion. Little is known about 
ADAM3A and it is listed on PubMed as a pseudogene and has been reported as non-
functional in humans (Grzmil, Kim et al. 2001). However, a number of other papers 
have described a role for ADAM3A in spermatogenesis and fertilisation. 
(McLaughlin, Frayne et al. 2001) The ADAM family of genes have functions relating 
to cell to cell communication and adhesion and several other members of the ADAM 
gene family have been implicated in cancer. Notable examples include 
overexpression of ADAM28 in lung and breast carcinomas (Mochizuki and Okada 
2009) and loss of expression of ADAM23 in breast tumours correlating with 
increasing grade (Seniski, Camargo et al. 2009) (Costa, Verbisck et al. 2004). 
ADAM17 has been shown to be involved in EGFR regulation, and overexpression of 
ADAM17 in astrocytes promotes an increase in cell proliferation and invasion 
(Katakowski, Jiang et al. 2009). This novel homozygous deletion of ADAM3A merits 
further study. 8p11.23 has been identified as a CNV and as matched somatic DNA 
was not available for the samples in this study it is important to note that this 
deletion could be a somatic CNV. It would be interesting to look at the expression of 
ADAM3A, possibly by IHC on HGG TMAs, to see if ADAM3A is being expressed in 
samples without deletion of ADAM3A. 
 
Using FISH on FFPE tissue microarrays is a fast, efficient way of screening a high 
number of samples at once for a specific aberration, and as shown in this study can 
be very successful. Constructing TMAs allows FFPE samples, including those that 
maybe do not have enough tissue available for DNA isolation, to be analysed by 
methods such as FISH and IHC. FISH was used in this study to confirm the 
frequency of 1q gain, MYCN amplification and CDKN2A and B loss in paediatric 
gliomas, and indeed the frequency of these aberrations was almost identical in the 
aCGH data and the FISH data.  
 
In addition to confirming the frequencies of the aberrations, FISH also allowed some 
further conclusions to be made. Loss of CDKN2A and B occurred in 10% samples in 
the aCGH analysis, and the size of the deleted region varied between these samples 
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from a small discrete deletion to loss of over half the 9p chromosome arm.  
CDKN2A and CDKN2B are well characterised tumour suppressors that are known to 
be deleted in other types of paediatric brain tumours and other cancers, including 
adult high grade gliomas. CDKN2A and CDKN2B loss was only seen in 
supratentorial GBMs in the aCGH data and the p16 FISH across a larger sample set 
showed the same result; there was no loss of CDKN2A and CDKN2B in any 
infratentorial tumours including brainstem tumours, only in supratentorial GBMs. 
This may point to a cell of origin effect as seen in ependymoma (Taylor, Poppleton 
et al. 2005). Deletion of CDKN2A/B in 24% of paediatric high grade glioma has been 
previously reported (Paugh, Qu et al. 2010). In this study deletion of CDKN2A/B 
was seen in 10% samples by aCGH and 13% samples by FISH. Unfortunately, the 
number of samples in this study was insufficient for the relationship between 
CDKN2A/B loss and supratentorial GBMs to be significant. However, differential 
expression of CDKN2B in infratentorial and supratentorial tumours was shown to be 
significant by IHC (p = 0.03). The results of methylation analysis of CDKN2A and 
CDKN2B in these tumours would be interesting and mutation analysis could also be 
performed to further investigate this site-associated aberration. 
 
MYCN amplification was seen in one anaplastic astrocytoma and one brainstem 
tumour in the aCGH data. The FISH results confirmed both these amplifications and 
showed a further two samples with MYCN amplification, both of which were 
anaplastic astrocytomas. MYCN amplification was shown to be significantly 
associated with anaplastic astrocytomas (p=0.03). MYCN is highly amplified in 
neuroblastoma but has also been reported amplified in CNS PNETs, 
medulloblastoma and paediatric high grade gliomas, as well as non-brain tumours. 
MYCN is a proto-oncogene and part of the MYC transcription factor family and 
amplification is often associated with poor outcome in other tumour types, (Tonini, 
Boni et al. 1997) so it is interesting that MYCN amplification is seen in AAs and not 
the more aggressive grade IV GBMs. A larger cohort of samples, particularly larger 
numbers of AAs, would need to be analysed either by FISH or by microarray 
analysis to further establish this relationship. 
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The lack of p16 loss in infratentorial tumours and the absence of MYCN 
amplification in any of the GBMs analysed are both interesting results that could be 
further investigated in future projects. 
  
A small sub-group of tumours (13%) appeared to have balanced genomes by aCGH 
analysis. This has also been seen in other paediatric tumours including ependymoma, 
&1631(7VDQG:LOPV¶7XPRXUV (Dyer, Prebble et al. 2002; Natrajan, Williams et 
al. 2006). The lack of copy number changes indicates that these tumours may be 
driven purely by mutations or by epigenetic mechanisms. Methylation and 
expression studies may provide further insight into this subset of tumours. 
Methylation analysis is currently being carried out on a cohort of pHGG tumours 
including some tumours with balanced genomes. This methylation data combined 
with expression data will expand our understanding of balanced tumours and allow 
further insight into pHGG as a whole. 
 
The quantity and quality of the DNA isolated from the FFPE samples was the 
limiting factor in this study. Some samples were completely used for aCGH, whilst 
others were depleted or of insufficient quality for qPCR. This meant that validation 
studies had to be carefully planned and were not as extensive as they might have 
been if more DNA had been available. Real time quantitative PCR (qPCR) proved to 
work successfully with the majority of remaining FFPE DNA samples once the 
technique had been optimised for FFPE DNA. Samples that repeatedly failed to 
work with qPCR were those that had given the noisiest aCGH profiles and so the 
failure was most likely due to the poor quality of these samples. On the whole, those 
genes that were chosen for validation validated well. However, the high frequency of 
CCND1 gain failed to validate although the results for FGF3 which is adjacent to 
CCND1 were more encouraging. This region on 11q13 was a noisy region across the 
whole sample set and this shows the importance of validation when using degraded 
DNA. 
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8.1 Original Hypotheses 
Paediatric and adult high grade glioma have different genetic causes. 
The findings in this study have shown that paediatric and adult high grade gliomas 
represent two different genetic entities that are distinguished by differences in copy 
number changes. The most obvious difference is the increased frequency gain of 1q 
in paediatric high grade glioma compared to adult tumours. Gain of 1q is commonly 
seen in paediatric brain tumours including CNS PNETs, ependymoma and high 
grade glioma. In this study 21% of high grade gliomas demonstrated gain of 1q by 
aCGH whilst only 9% of adult high grade gliomas have been reported to have gain 
1q (TCGA 2008). A recent study by Bax et al found gain of 1q in 12/63 (19%) of 
paediatric high grade glioma samples. Combining data from this study with that of 
Bax et al reveals 20/101 (20%) paediatric high grade gliomas have gain of 1q 
compared to 17/189 (9%) of adult tumours. This is statistically significant (p = 0.03). 
23% of brainstem tumours have gain of 1q which is comparable to the level of gain 
seen in other paediatric high grade glioma. Gain of 1q has been associated with 
poorer outcome in other paediatric brain tumours (Mendrzyk, Korshunov et al. 
2006). 
 
PARP-1 has been highlighted as a gene of interest on 1q in a recent brainstem glioma 
study by Zarghooni et al, although no focal gain of PARP-1 was seen in this study 
(Zarghooni, Bartels et al. 2010). Zarghooni et al carried out IHC on a limited number 
of samples and saw a correlation between gain of PARP-1 (as part of 1q gain) and 
increased PARP-1 expression (Zarghooni, Bartels et al. 2010). PARP-1 is a possible 
drug target and so further investigation of this PARP-1 expression should be carried 
out. PARP-1 IHC could be performed across HGG TMAs to look for a correlation 
between 1q gain and increased PARP-1 expression. 
 
Loss of 10q is seen in 16% of all high grade glioma samples and only 1/13 brainstem 
gliomas in this study, which is notably lower than 35% loss of 10q previously 
reported in paediatric high grade glioma (Paugh, Qu et al. 2010). Loss of 10q is the 
most common whole arm aberration in adult GBM (80%) which includes loss of 
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PTEN (10q23). PTEN is a tumour suppressor which negatively regulates the Akt 
signalling pathway and PTEN loss or mutation is seen in many cancers (Maher, 
Furnari et al. 2001). The lack of 10q loss in this cohort may indicate a different 
mechanism of loss or that different pathways are involved in these paediatric 
tumours. 
 
Amplification of PDGFRA is seen more frequently in paediatric high grade gliomas 
compared with adults, and has recently been reported as occurring at a frequency of 
~15% in adults and ~25% in paediatric high grade gliomas (Paugh, Qu et al. 2010). 
This study has shown amplification of PDGFRA in just 2/38 (5%) high grade 
gliomas with an additional sample showing high level gain of PDGFRA. PDGFRA is 
a possible target for therapy in the subset of paediatric high grade glioma with 
PDGFRA amplification. 
 
Expression of PDGFRA has been shown to correlate with malignant grade in pHGG, 
with high expression being associated with malignant histology (WHO grades III 
and IV) (Thorarinsdottir, Santi et al. 2008). Amplification of PDGFRA has recently 
been reported in 12% of Grade III and 17% of grade IV pHGG tumours in a large 
recent series based on high resolution copy number and expression profiling (Paugh, 
Qu et al. 2010). Similar levels of focal amplification are reported in this study based 
on the aCGH and IHC data. In the study by Paugh et al amplification of PDGFRA 
was found at a significantly higher frequency (50%) in irradiation induced childhood 
and adolescent HGG (Paugh, Qu et al. 2010). This later finding might explain the 
relatively high frequency of PDGFRA expression reported in a brainstem glioma 
study by Zarghooni et al, as 82% of their cohort was analysed post treatment 
(Zarghooni, Bartels et al. 2010).  
 
Consistent with this possibility is that amplification of PDGFRA in adult tumours is 
associated with a secondary GBM (Toepoel, Joosten et al. 2008), although the time 
course for the latter is likely longer. Further studies of the role of PDGFRA in 
childhood and adolescent HGG are needed to understand the influence of treatment 
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on PDGFRA amplification and to determine whether this TRK receptor is a 
conditional target for therapy in the subset of pHGG with PDGFRA amplification. 
 
No amplification of EGFR was seen in the 38 paediatric high grade glioma samples, 
where as EGFR amplification is the most common focal amplification in adult high 
grade gliomas (Maher, Furnari et al. 2001). 
 
Four focal regions of amplification were seen across this data set compared to 27 
different sites of amplification identified in a dataset of 97 adult high grade glioma 
samples by metaphase CGH (Mohapatra, Bollen et al. 1998).  Moreover, a sub-group 
of pHGG tumours (13%) have balanced genomes by aCGH analysis. This has also 
been seen in other paediatric brain tumours including ependymoma and CNS PNETs 
(Dyer, Prebble et al. 2002; Natrajan, Williams et al. 2006). In our series of pHGG  
this was not defined by young age at diagnosis as for ependymoma (Dyer, Prebble et 
al. 2002). This important difference in the number of genomic imbalances and 
regions of amplification in adults and children may reflect the development of the 
tumour in a narrower time frame / developmental window. It might also be that other 
mechanisms are important in the pathogenesis of these tumours and suggests that 
relatively fewer mutations may be required to initiate the disease if these arise within 
a specific developmental period.   
 
High grade glioma occurring in the brainstem are genetically distinct from 
other high grade gliomas. 
 
The brainstem gliomas in this study demonstrated many of the same aberrations as 
the other high grade tumours in the study e.g. PDGFRA amplification, MYCN 
amplification, 1q gain. As a group the brainstem gliomas were as heterogeneous as 
the other high grade gliomas and displayed many of the same aberrations. One 
difference between the brainstem tumours and the other high grade tumours was the 
lack of CDKN2A and B loss in the brainstem tumours. Similar findings were recently 
170 
 
reported in a study by Zarghooni et al (Zarghooni, Bartels et al. 2010). However, 
since CDKN2A and B loss was seen only in supratentorial GBMs it may be that high 
grade gliomas should be grouped into supratentorial and infratentorial rather than 
brainstem and non-brainstem. Interestingly, loss of CDKN2A and B has been 
reported in supratentorial CNS PNETs but not in infratentorial medulloblastoma 
(Pfister, Remke et al. 2007). The differential loss of CDKN2A/CDKN2B depending 
on tumour location  may point to a cell of origin effect as seen in ependymoma 
(Taylor, Poppleton et al. 2005). This finding merits further study. 
 
Loss of 14q was seen in 4/13 (31%) brainstem tumours and only 1/25 non-brainstem 
tumours (4%). In a recent study, Zarghooni et al also identified 14q loss as being 
more common in DIPG (Zarghooni, Bartels et al. 2010).  Loss of 17p was seen in 
4/13 (31%) brainstem tumours and only 1/25 non-brainstem tumours. Zarghooni et 
al also reported 17p loss associated with paediatric DIPG compared to non-brainstem 
high grade gliomas (Zarghooni, Bartels et al. 2010). Combining data from this study 
and that of Zarghooni et al reveals 11/24 (46%) DIPG had loss of 17p whilst only 
3/36 (8%) of non-brainstem tumours had loss of 17p, which is statistically significant 
(p = 0.02). Interestingly, loss of 17p is seen in up to 50% of infratentorial 
medulloblastoma but is rarely seen in supratentorial CNS PNETs (De Smaele, Di 
Marcotullio et al. 2004). This site related difference in the frequency of 17p loss and 
14q loss deserves further study. 17p and 14q FISH could be performed across HGG 
TMAs to further investigate the relationship between loss of these chromosome arms 
and brainstem gliomas. 
 
Loss of 10q was seen in only 8% of brainstem tumours compared to 18% of high 
grade gliomas overall in this study. Loss of 10q is the location of a number of 
tumour suppressors, most notably PTEN which is implicated in adult high grade 
glioma. The lack of 10q loss in brainstem gliomas may indication a different 
mechanism of tumour suppressor loss in these tumours, or that different pathways 
are involved.  
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Zarghooni et al identified a number of genes involved in DNA repair pathways as 
being lost in brainstem gliomas compared to supratentorial high grade gliomas  
(Zarghooni, Bartels et al. 2010). Loss of some of these DNA repair pathway genes 
was seen in this study as part of whole arm deletions, e.g. 17p (RPA1 and MYH1, 
14q (MNAT1 and RAD51L1) and 1p (MSH4). However, losses of other DNA repair 
pathway genes identified by Zarghooni were not seen in this study (GTF2H3, LIG4, 
XRCC4, XRCC5, MLH1, BRCA1, BRCA2, RAD50, DUT, PMS1) (Zarghooni, Bartels 
et al. 2010). Importantly their cohort included just two pre-treatment samples 
compared to ten pre-treatment brainstem samples in this study suggesting that 
treatment with DNA damaging agents such as radiotherapy and temozolomide may 
be responsible for the loss of DNA repair pathway genes and possibly other genetic 
aberrations.  
 
It has previously been shown that diagnostic biopsy of diffuse brainstem glioma is 
relatively safe (Cartmill and Punt 1999) and this study demonstrates that pre 
treatment tumour tissue, even small samples from biopsy, can generate high quality 
biological information on which to base future strategies. Therefore, it is important 
that brainstem gliomas are biopsied to allow further studies into these devastating 
tumours. 
 
High grade glioma occurring in children over three years old are genetically 
distinct from those tumours occurring in children under three years old. 
 
At the start of this study one aim was to look at the genetic differences between 
children diagnosed with a high grade glioma under the age of three and those 
diagnosed over the age of three. Unfortunately, the majority of the samples in this 
study were from children over three although some samples were missing clinical 
information and so age at diagnosis was unknown. This group of samples is very 
important as the underlying biology is thought to be different to that of tumours 
occurring in children over three.  
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The oligo aCGH on FFPE high grade samples was part of a larger study to 
comprehensively map the genetic profiles of these tumours. By performing aCGH on 
DNA isolated from FFPE high grade glioma samples many aberrations were 
discovered across the sample set. The results of this study, combined with SNP data, 
methylation data and expression data and will hopefully lead to a wider 
understanding of the genetic profiles of paediatric high grade glioma. If complete 
clinical information can be gathered for these samples and all the data pulled 
together then hopefully diagnostic or prognostic targets can be teased out for these 
complex, heterogeneous tumours.  
 
This study involved the high-throughput analysis of the largest ever cohort of 
brainstem gliomas (13) plus 25 non-brainstem pHGG. Although the tissue used in 
this study was FFPE tissue which presents problems with DNA quality, and 
therefore quality of array data produced, the results of this study have still provided 
interesting and novel data on these rare tumours. When the DNA isolation and aCGH 
was performed for this study there were very few protocols and kits being produced 
by companies specifically for FFPE tissue. Over the past few years the interest in 
using FFPE tissue for high-throughput techniques has led to the development of 
DNA isolation methods and array protocols specifically for FFPE DNA. If these had 
been available for this study then results may have been less noisy and less complex 
to analyse. However, the data from this study is still useful and has shown novel 
aberrations as well as confirming aberrations and frequencies of aberrations seen in 
the few other studies of pHGG. 
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Sample: HGG1  CCLG Centre:  Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.61) 
 
181 
 
Sample:  HGG2   CCLG Centre: Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.56) 
 
182 
 
Sample: HGG3    CCLG Centre: Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.37) 
 
183 
 
Sample: HGG4   CCLG Centre: Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.30) 
 
184 
 
Sample: HGG5   CCLG Centre: Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.82) 
 
185 
 
Sample: HGG6   CCLG Centre: Nottingham 
Diagnosis:  GBM 
Genomic Overview of Aberrations (DLR Spread: 0.63) 
 
 
186 
 
Sample: HGG7    CCLG Centre: Nottingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.32) 
 
187 
 
Sample: HGG8   CCLG Centre: Nottingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.39) 
 
188 
 
Sample: HGG9   CCLG Centre: Nottingham 
Diagnosis: DIPG (LGA) 
Genomic Overview of Aberrations (DLR Spread: 0.50) 
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Sample: HGG10   CCLG Centre: Nottingham 
Diagnosis:  GBM 
Genomic Overview of Aberrations (DLR Spread: 0.36) 
 
190 
 
Sample: HGG11   CCLG Centre: Nottingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.70) 
 
191 
 
Sample HGG11: FROZEN 
Genomic Overview of Aberrations (DLR Spread: 0.31) 
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Sample: HGG12   CCLG Centre: Nottingham 
Diagnosis: AA 
Genomic Overview of Aberrations (DLR Spread: 0.57) 
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Sample: HGG13  CCLG Centre: Nottingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.90) 
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Sample: HGG14  CCLG Centre: Nottingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.91) 
 
195 
 
Sample: HGG15   CCLG Centre: Nottingham 
Diagnosis: AA 
Genomic Overview of Aberrations (DLR Spread: 1.03) 
 
196 
 
Sample: HGG16   CCLG Centre: Nottingham 
Diagnosis: AO 
Genomic Overview of Aberrations (DLR Spread: 0.54) 
 
197 
 
Sample HGG16: FROZEN 
Genomic Overview of Aberrations (DLR Spread: 0.40) 
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Sample: HGG17  CCLG Centre: Newcastle 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.47) 
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Sample: HGG18   CCLG Centre: Newcastle 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.70) 
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Sample: HGG19   CCLG Centre: Newcastle 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.61) 
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Sample: HGG20   CCLG Centre: Newcastle 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.51) 
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Sample: HGG21   CCLG Centre: Newcastle 
Diagnosis:  DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.43) 
 
203 
 
Sample: HGG22  CCLG Centre: Liverpool 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.39) 
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Sample: HGG23   CCLG Centre: Liverpool 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.35) 
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Sample: HGG24   CCLG Centre: Liverpool 
Diagnosis: AA 
Genomic Overview of Aberrations (DLR Spread: 0.33) 
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Sample: HGG25   CCLG Centre: Liverpool 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.41) 
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Sample: HGG26   CCLG Centre: Liverpool 
Diagnosis: AO 
Genomic Overview of Aberrations (DLR Spread: 0.43) 
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Sample: HGG27   CCLG Centre: Cardiff 
Diagnosis: AO 
Genomic Overview of Aberrations (DLR Spread: 0.62) 
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Sample: HGG28   CCLG Centre: Birmingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.34) 
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Sample: HGG29   CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.71) 
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Sample: HGG30   CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.46) 
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Sample HGG30: FROZEN 
Genomic Overview of Aberrations (DLR Spread: 0.17) 
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Sample: HGG31   CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.47) 
 
214 
 
Sample: HGG32   CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.38) 
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Sample: HGG33   CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.63) 
 
216 
 
Sample HGG33: FROZEN 
Genomic Overview of Aberrations (DLR Spread: 0.38) 
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Sample: HGG34  CCLG Centre: Birmingham 
Diagnosis: GBM 
Genomic Overview of Aberrations (DLR Spread: 0.40) 
 
218 
 
Sample: HGG35   CCLG Centre: Birmingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.61) 
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Sample: HGG36   CCLG Centre: Birmingham 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 1.02) 
 
220 
 
Sample: HGG37   CCLG Centre: Edinburgh 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.54) 
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Sample: HGG38   CCLG Centre: Edinburgh 
Diagnosis: DIPG (GBM) 
Genomic Overview of Aberrations (DLR Spread: 0.80) 
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